Title
stringlengths 1
395
⌀ | abstractText
stringlengths 57
5.98k
| meshMajor
stringlengths 14
1.03k
| pmid
int64 22
33.2M
| meshid
stringlengths 2
3.14k
| meshroot
stringlengths 2
421
| A
int64 0
1
| B
int64 0
1
| C
int64 0
1
| D
int64 0
1
| E
int64 0
1
| F
int64 0
1
| G
int64 0
1
| H
int64 0
1
| I
int64 0
1
| J
int64 0
1
| L
int64 0
1
| M
int64 0
1
| N
int64 0
1
| Z
int64 0
1
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
O6-methylguanine as a modulator of antitumor activity of N-alkyl-N-nitrosoureas in vivo.
|
The effect of O6-methylguanine (O6-MeG) on the therapeutic efficiency of 1-methyl-1-nitrosourea (MNU) and 1,3-bis-(2-chloroethyl)-1-nitrosourea (BCNU) against the murine L1210 leukemia and B16 melanoma was studied in vivo. Although the level of O6-alkylguanine-DNA alkyltransferase (AGT) in L1210/BCNU leukemia cells was three times higher than in L1210 leukemia cells, no enhancement of the antitumor activity of MNU and BCNU in L1210 leukemia or B16 melanoma with O6-MeG or MNU potentiated markedly the cytotoxic effects of MNU and BCNU. Administration of O6-MeG to mice bearing L1210 leukemia led to delayed inhibition of DNA synthesis and appearance of long-term single-strand breaks in DNA of tumor cells.
|
['Animals', 'Antineoplastic Combined Chemotherapy Protocols', 'Carmustine', 'DNA Damage', 'DNA, Neoplasm', 'Drug Interactions', 'Drug Resistance', 'Guanine', 'Leukemia L1210', 'Methylnitrosourea', 'Mice', 'Mice, Inbred C57BL', 'Mice, Inbred DBA', 'Neoplasm Transplantation', 'Nucleic Acid Conformation', 'Time Factors']
| 1,958,863
|
[['B01.050'], ['E02.183.750.500', 'E02.319.077.500', 'E02.319.310.037'], ['D02.065.950.594.247', 'D02.654.692.247'], ['G05.200'], ['D13.444.308.425'], ['G07.690.773.968'], ['G07.690.773.984'], ['D03.633.100.759.758.399.454'], ['C04.557.337.372.594', 'C04.619.531.594'], ['D02.065.950.594.490', 'D02.654.692.480'], ['B01.050.150.900.649.313.992.635.505.500'], ['B01.050.050.199.520.520.420', 'B01.050.150.900.649.313.992.635.505.500.400.420'], ['B01.050.050.199.520.520.500', 'B01.050.150.900.649.313.992.635.505.500.400.500'], ['E05.624'], ['G02.111.570.820.486', 'G05.360.580'], ['G01.910.857']]
|
['Organisms [B]', 'Analytical, Diagnostic and Therapeutic Techniques, and Equipment [E]', 'Chemicals and Drugs [D]', 'Phenomena and Processes [G]', 'Diseases [C]']
| 0
| 1
| 1
| 1
| 1
| 0
| 1
| 0
| 0
| 0
| 0
| 0
| 0
| 0
|
Initial state perturbations as a validation method for data-driven fuzzy models of cellular networks.
|
BACKGROUND: Data-driven methods that automatically learn relations between attributes from given data are a popular tool for building mathematical models in computational biology. Since measurements are prone to errors, approaches dealing with uncertain data are especially suitable for this task. Fuzzy models are one such approach, but they contain a large amount of parameters and are thus susceptible to over-fitting. Validation methods that help detect over-fitting are therefore needed to eliminate inaccurate models.RESULTS: We propose a method to enlarge the validation datasets on which a fuzzy dynamic model of a cellular network can be tested. We apply our method to two data-driven dynamic models of the MAPK signalling pathway and two models of the mammalian circadian clock. We show that random initial state perturbations can drastically increase the mean error of predictions of an inaccurate computational model, while keeping errors of predictions of accurate models small.CONCLUSIONS: With the improvement of validation methods, fuzzy models are becoming more accurate and are thus likely to gain new applications. This field of research is promising not only because fuzzy models can cope with uncertainty, but also because their run time is short compared to conventional modelling methods that are nowadays used in systems biology.
|
['Computational Biology', 'Computer Simulation', 'Fuzzy Logic', 'Gene Regulatory Networks', 'Humans', 'Systems Biology']
| 30,241,464
|
[['H01.158.273.180', 'L01.313.124'], ['L01.224.160'], ['E05.599.250', 'K01.752.448.250', 'L01.224.050.375.250'], ['G05.360.080.689.360'], ['B01.050.150.900.649.313.988.400.112.400.400'], ['H01.158.273.180.800']]
|
['Disciplines and Occupations [H]', 'Information Science [L]', 'Analytical, Diagnostic and Therapeutic Techniques, and Equipment [E]', 'Humanities [K]', 'Phenomena and Processes [G]', 'Organisms [B]']
| 0
| 1
| 0
| 0
| 1
| 0
| 1
| 1
| 0
| 0
| 1
| 0
| 0
| 0
|
The differential protein expression profiles and immunogenicity of tachyzoites and bradyzoites of in vitro cultured Neospora caninum.
|
We report a study on the variations in the protein expression profiles of tachyzoites and bradyzoites of Neospora caninum. The in vitro stage conversion of N. caninum-infected Vero cells was induced by continuous treatment of infected cultures with 70 muM sodium nitroprusside (SNP) for up to 9 days. The stage conversion indicated by the expression of the bradyzoite-specific antigen BAG1 was analyzed by immunofluoresence assay. Morphological changes between tachyzoites and bradyzoites and localization of nuclei were demonstrated by transmission electron microscopy. Notably, we showed the differential protein expression profiles of tachyzoites and bradyzoites of N. caninum upon treatment with SNP. Sodium dodecyl sulfate-polyacrylamide gel electrophoresis analysis indicated different protein patterns between tachyzoites and bradyzoites. Furthermore, Western blotting using rabbit polyclonal antibodies directed against tachyzoites revealed several reactive bands, one of which represented a tachyzoite-specific antigen of approximately 40 kDa remarkably expressed in the tachyzoite stage, but was absent from bradyzoites. Moreover, rabbit polyclonal serum raised against bradyzoites recognized a significant increased expression of an antigen with a MW of approximately 25 kDa in bradyzoites by Western blotting, suggesting that this protein is specifically expressed at the bradyzoite stage. Taken together, our data showed that differential protein expression profiling is a useful tool for discriminating between the two stages during tachyzoite-bradyzoite interconversion in N. caninum infections.
|
['Animals', 'Blotting, Western', 'Chlorocebus aethiops', 'Electrophoresis, Polyacrylamide Gel', 'Fluorescent Antibody Technique', 'Fungal Proteins', 'Microscopy, Electron, Transmission', 'Molecular Weight', 'Neospora', 'Nitroprusside', 'Proteome', 'Vero Cells']
| 18,597,117
|
[['B01.050'], ['E05.196.401.143', 'E05.301.300.096', 'E05.478.566.320.200', 'E05.601.262', 'E05.601.470.320.200'], ['B01.050.150.900.649.313.988.400.112.199.120.126.110'], ['E05.196.401.402', 'E05.301.300.319'], ['E01.370.225.500.607.512.240', 'E01.370.225.750.551.512.240', 'E05.200.500.607.512.240', 'E05.200.750.551.512.240', 'E05.478.583.375'], ['D12.776.354'], ['E01.370.350.515.402.580', 'E05.595.402.580'], ['G02.494'], ['B01.043.075.189.250.750.550'], ['D01.248.497.158.291.350.550', 'D01.490.100.300.550', 'D01.625.400.100.325.550'], ['D12.776.817'], ['A11.251.210.955', 'A11.436.955']]
|
['Organisms [B]', 'Analytical, Diagnostic and Therapeutic Techniques, and Equipment [E]', 'Chemicals and Drugs [D]', 'Phenomena and Processes [G]', 'Anatomy [A]']
| 1
| 1
| 0
| 1
| 1
| 0
| 1
| 0
| 0
| 0
| 0
| 0
| 0
| 0
|
Wrist actigraphy in insomnia.
|
To assess the use of actigraphy in evaluating insomnia, 36 patients with a serious complaint of insomnia slept 3 nights each in the laboratory, where the usual polysomnograms (PSGs) were obtained as well as actigraphic assessments of their sleep. Patients also wore actigraphs for 7 days at home, were extensively interviewed and filled out psychometric tests. Based on all this information, the patients were then diagnosed according to the International Classification of Sleep Disorders. Averaged over the 3 nights for each insomniac, the mean discrepancy between actigram and PSG was 49 minutes per night. In three-fourths of the cases, actigram and PSG agreed to within 1 hour on the total amount of sleep per night. Discrepancies, however, were not random: In patients with psychophysiologic insomnia and in insomnia associated with psychiatric disease, the actigram typically overestimated sleep when compared with the PSG. In patients with sleep-state misperception, the actigram was either quite accurate or it underestimated sleep when compared with the PSG. Comparing laboratory with home sleep, one-third of all insomniacs slept better in the laboratory and two-thirds slept better at home. In addition, night-by-night variability was higher at home than in the laboratory. Based on our study, we now recommend actigraphy as an additional tool in the clinical evaluation of insomnia, but we believe that in complex cases it should be combined with 1 PSG night in the sleep disorders center.
|
['Adult', 'Aged', 'Analysis of Variance', 'Clinical Laboratory Techniques', 'Female', 'Humans', 'Male', 'Middle Aged', 'Monitoring, Physiologic', 'Sleep', 'Sleep Initiation and Maintenance Disorders', 'Wrist']
| 1,519,002
|
[['M01.060.116'], ['M01.060.116.100'], ['E05.318.740.150', 'N05.715.360.750.125', 'N06.850.520.830.150'], ['E01.370.225', 'E05.200'], ['B01.050.150.900.649.313.988.400.112.400.400'], ['M01.060.116.630'], ['E01.370.520'], ['F02.830.855', 'G11.561.803'], ['C10.886.425.800.800', 'F03.870.400.800.800'], ['A01.378.800.875']]
|
['Named Groups [M]', 'Analytical, Diagnostic and Therapeutic Techniques, and Equipment [E]', 'Health Care [N]', 'Organisms [B]', 'Psychiatry and Psychology [F]', 'Phenomena and Processes [G]', 'Diseases [C]', 'Anatomy [A]']
| 1
| 1
| 1
| 0
| 1
| 1
| 1
| 0
| 0
| 0
| 0
| 1
| 1
| 0
|
Guinea-pig lung adenylyl and guanylyl cyclase and PDE activities associated with airway hyper- and hypo-reactivity following LPS inhalation.
|
The relationships between changes in in vivo airway reactivity and levels cyclicAMP and cyclicGMP were determined in guinea-pig lungs after exposure to inhaled lipopolysaccharide (LPS). After LPS (30 microg.ml(-1), 1 h), guinea-pigs displayed in vivo airway hyperreactivity (AHR) at 1 h and hyporeactivity (AHOR) at 48 h, to inhaled (20 s) histamine (1 or 3 mM, respectively). Isoprenaline-stimulated cAMP or SNAP-stimulated cGMP were determined in the lungs isolated from guinea-pigs exposed to LPS inhalation to determine whether there was a relationship between AHR or AHOR and adenylyl/guanylyl cyclase and phosphodiesterase (PDE) activities. Assays were performed in the absence and presence of the non-selective PDE inhibitor, 3-isobutyl-1-methylxanthine (IBMX). Levels of cAMP and cGMP in its presence indicated adenylyl and guanylyl cyclase activities, respectively. The difference between cAMP and cGMP levels, in the absence and presence of IBMX, reflected relevant PDE activity. In vivo AHR was associated with increased PDE activity towards cAMP and cGMP (67 and 278%, respectively) and also increased adenylyl (47%) and guanylyl (210%) cyclase activities. In vivo AHOR at 48 h after LPS inhalation was also associated with raised cyclase activity (p < 0.05), whereas relevant PDE activity declined by 79 and 68%, compared with 48 h after vehicle. Although net stimulated cGMP levels increased during AHR and AHOR and net stimulated cAMP increased during AHOR, our index of PDE activity increased during AHR and decreased during AHOR. These results therefore support the rationale for the use of PDE-inhibitors in the treatment of respiratory diseases associated with AHR.
|
['1-Methyl-3-isobutylxanthine', 'Adenylyl Cyclases', 'Administration, Inhalation', 'Animals', 'Bronchi', 'Bronchial Hyperreactivity', 'Bronchoconstriction', 'Cyclic AMP', 'Cyclic GMP', 'Guanylate Cyclase', 'Guinea Pigs', 'Histamine', 'Lipopolysaccharides', 'Lung', 'Male', 'Phosphoric Diester Hydrolases']
| 15,607,329
|
[['D03.633.100.759.758.824.751.500'], ['D08.811.520.650.200', 'D12.644.360.050', 'D12.776.476.050'], ['E02.319.267.050'], ['B01.050'], ['A04.411.125'], ['C08.127.210'], ['G09.772.705.700.080'], ['D03.633.100.759.646.138.395', 'D13.695.462.200', 'D13.695.667.138.395', 'D13.695.827.068.395'], ['D03.633.100.759.646.454.160', 'D13.695.462.275', 'D13.695.667.454.160', 'D13.695.827.426.160'], ['D08.811.520.650.600', 'D12.644.360.350', 'D12.776.476.350'], ['B01.050.150.900.649.313.992.550'], ['D02.092.211.215.501', 'D02.092.471.440', 'D03.383.129.308.373', 'D23.469.050.300'], ['D09.400.500', 'D09.698.718.450', 'D10.494', 'D23.050.161.616.525', 'D23.946.123.329.500'], ['A04.411'], ['D08.811.277.352.640']]
|
['Chemicals and Drugs [D]', 'Analytical, Diagnostic and Therapeutic Techniques, and Equipment [E]', 'Organisms [B]', 'Anatomy [A]', 'Diseases [C]', 'Phenomena and Processes [G]']
| 1
| 1
| 1
| 1
| 1
| 0
| 1
| 0
| 0
| 0
| 0
| 0
| 0
| 0
|
Impact of extent of resection on survival in high-risk neuroblastoma: A systematic review and meta-analysis.
|
BACKGROUND: Despite the development of new treatment options, the prognosis of high-risk neuroblastoma patients is still poor. Many studies designed to elaborate the association between the extent of resection (EOR) and outcome have reported conflicting results. We performed a meta-analysis to assess whether greater EOR is associated with improved overall survival (OS) and event-free survival (EFS) in patients with high-risk neuroblastoma.METHODS: Embase, PubMed, Cochrane library, and conference proceedings were searched between March 10 and October 1, 2017. Studies of pediatric patients with newly diagnosed high-risk neuroblastoma comparing various EOR and presenting objective overall or event-free survival data were included. Primary outcomes were relative risk (RR) for mortality at 3 and 5 years. Secondary outcomes were 3-year and 5-year EFS rates.RESULTS: 19 retrospective studies including a total of 2358 cases were identified. Compared with subtotal resection (STR), patients who underwent gross total resection (GTR) had significantly decreased mortality at 3 years (RR, 0.69; 95% CI, 0.58-0.82; P < 0.001; I2 = 27%) and 5 years (RR, 0.70; 95% CI, 0.60-0.82; P < 0.001; I2 = 38%). A similar decrease was revealed in the 3-year risk for mortality for STR compared with biopsy (RR, 0.71; 95% CI, 0.53-0.95; P = 0.02; I2 = 0%). When comparing any resection with biopsy, resection group also showed a decreased risk for mortality at 3 years (RR, 0.66; 95% CI, 0.53-0.83; P < 0.001; I2 = 8%) and 5 years (RR, 0.67; 95% CI, 0.50-0.91; P = 0.009; I2 = 61%). With respect to the risk ratio for EFS, there were no significant differences in any comparisons.CONCLUSION: This literature highlights the importance of "extent of resection" in treating high-risk neuroblastoma, and when feasible, the currently available evidences in favor of the use of GTR for high-risk neuroblastoma for reducing 3- and 5-year mortality.LEVEL OF EVIDENCE: 3A.
|
['Biopsy', 'Humans', 'Neoplasm, Residual', 'Neuroblastoma', 'Prognosis', 'Progression-Free Survival', 'Risk Factors', 'Survival Rate']
| 30,262,202
|
[['E01.370.225.500.384.100', 'E01.370.225.998.054', 'E01.370.388.100', 'E04.074', 'E05.200.500.384.100', 'E05.200.998.054', 'E05.242.384.100'], ['B01.050.150.900.649.313.988.400.112.400.400'], ['C04.697.700', 'C23.550.727.700'], ['C04.557.465.625.600.590.650.550', 'C04.557.470.670.590.650.550', 'C04.557.580.625.600.590.650.550'], ['E01.789'], ['E01.789.800.285', 'E05.318.740.998.738', 'N04.761.559.590.800.474', 'N05.715.360.575.575.800.474', 'N05.715.360.750.795.738', 'N06.850.520.830.998.825'], ['E05.318.740.600.800.725', 'N05.715.350.200.700', 'N05.715.360.750.625.700.700', 'N06.850.490.625.750', 'N06.850.520.830.600.800.725'], ['E05.318.308.985.550.900', 'N01.224.935.698.826', 'N06.850.505.400.975.550.900', 'N06.850.520.308.985.550.900']]
|
['Analytical, Diagnostic and Therapeutic Techniques, and Equipment [E]', 'Organisms [B]', 'Diseases [C]', 'Health Care [N]']
| 0
| 1
| 1
| 0
| 1
| 0
| 0
| 0
| 0
| 0
| 0
| 0
| 1
| 0
|
Isolation and translation in vitro of poly(A)+RNA from the free-living nematode Panagrellus silusiae.
|
Polysomal RNA was isolated from the free-living nematode Panagrellus silusiae. Passage of this RNA through a cellulose column resulted in the fractionation of the input RNA into poly(A)-RNA (ca. 97.5% of the total) and poly(A)+ RNA (ca. 2.5% of the total). RNase digestion, followed by polyacrylamide gel electrophoresis, revealed that the poly(A)+ RNA contained poly(A) tracts that ranged from 75 to 104 nucleotides in length with a mean value of about 90 residues. There was no evidence of poly(A) sequences in the poly(A)- RNA fraction. Poly(A)+ RNA gave a 25- to 50-fold stimulation (over background) of amino acid incorporation in the wheat germ cell-free protein-synthesizing system. At least 26 proteins were evident after electrophoresis in cylindrical sodium dodecyl sulfate-polyacrylamide gels. Poly(A)-RNA was capable of stimulating protein synthesis in vitro with about five discrete proteins being produced. In summary, the properties of mRNA from a simple organism such as P. silusiae are very similar to those of more complex eukaryotes.
|
['Animals', 'Kinetics', 'Nematoda', 'Plants', 'Poly A', 'Polyribosomes', 'Protein Biosynthesis', 'RNA, Ribosomal', 'Triticum']
| 445,222
|
[]
|
[]
| 0
| 0
| 0
| 0
| 0
| 0
| 0
| 0
| 0
| 0
| 0
| 0
| 0
| 0
|
[A phase II pharmacological study of leuprolide acetate 6-month depot, TAP-144-SR (6M), in treatment-Nazve patients with prostatic cancer who received a single subcutaneous or intramuscular injection].
|
The aim of this phase II study was to evaluate the pharmacokinetics, pharmacodynamics, efficacy, and safety of a 6- month depot formulation of a luteinizing hormone-releasing hormone (LH-RH) agonist, TAP-144-SR (6M), in Japanese treatment-na?ve patients with prostatic cancer. Each subject received a single subcutaneous or intramuscular injection of TAP- 144-SR (6M) and was monitored for 24 weeks. The primary endpoint was the change in serum testosterone levels. The serum testosterone level in six subjects who received 22.5 mg of TAP-144 (SR) subcutaneously decreased below the castrate level after 4 weeks and remained suppressed during the 24 weeks of follow-up. With regard to safety, TAP-144-SR (6M)was not associated with any additional concerns compared to those reported for the approved 1-month and 3-month depot formulations of TAP-144-SR. In addition, 30 mg of TAP-144-SR (6M) was administered subcutaneously to six subjects, and, on the basis of the results, the optimal clinical dosage of TAP-144-SR (6M) in Japan was considered to be 22.5 mg. Outcomes with 22.5mg TAP-144-SR (6M) administered intramuscularly were similar to those with TAP-144-SR (6M) administered subcutaneously.
|
['Aged', 'Humans', 'Injections, Intramuscular', 'Injections, Subcutaneous', 'Leuprolide', 'Male', 'Prostate-Specific Antigen', 'Prostatic Neoplasms', 'Testosterone']
| 24,917,003
|
[['M01.060.116.100'], ['B01.050.150.900.649.313.988.400.112.400.400'], ['E02.319.267.530.460'], ['E02.319.267.530.620'], ['D06.472.699.327.740.320.400', 'D12.644.400.400.740.320.400', 'D12.644.456.460.480', 'D12.644.548.365.740.320.400', 'D12.776.631.650.405.740.320.400'], ['D08.811.277.656.300.760.442.750', 'D08.811.277.656.959.350.442.750', 'D12.776.866.249.500', 'D23.050.285.625', 'D23.101.140.625'], ['C04.588.945.440.770', 'C12.294.260.750', 'C12.294.565.625', 'C12.758.409.750'], ['D04.210.500.054.079.429.824', 'D06.472.334.851.968.984']]
|
['Named Groups [M]', 'Organisms [B]', 'Analytical, Diagnostic and Therapeutic Techniques, and Equipment [E]', 'Chemicals and Drugs [D]', 'Diseases [C]']
| 0
| 1
| 1
| 1
| 1
| 0
| 0
| 0
| 0
| 0
| 0
| 1
| 0
| 0
|
High expression of microRNA-130b correlates with poor prognosis of patients with hepatocellular carcinoma.
|
BACKGROUND: Whether microRNA-130b(miR-130b) can serve as a prognostic biomarker of hepatocellular carcinoma (HCC) has not been investigated. In the present study, we investigated the feasibility of miR-130b as a novel prognostic biomarker for HCC.METHODS: We retrospectively investigated 97 patients diagnosed with HCC who underwent routine curative surgery between May 2007 and July 2012. miR-130b expression in HCC tissues and paired normal adjacent liver tissues was measured by reverse transcription and real-time PCR (RT-PCR). Survival curves were plotted using the Kaplan-Meier method and differences in survival rates were analyzed using the log-rank test.RESULTS: miR-130b expression level was significantly higher in HCC tissues compared with normal adjacent liver tissues (P<0.0001). The 5-year overall survival (OS) of high miR-130b expression group was significantly shorter than that of low miR-130b expression group (43.6% vs. 71.5%; P=0.022). Moreover, the 5-year disease-free survival (DFS) of high miR-130b expression group was also significantly shorter than that of low miR-130b expression group (25.9% vs. 63.9%; P=0.012). In a multivariate Cox model, we found that miR-130b expression was an independent prognostic factor for both 5-year OS (hazards ratio [HR] =2.523, 95% confidence interval [CI] =1.024-7.901, P=0.011) and 5-year DFS (HR=4.003, CI=1.578-7.899, P=0.005) in HCC.CONCLUSION: The results indicated that high expression of microRNA-130b was correlated with significant characteristics of patients with HCC, and it might be useful as a novel prognostic biomarker for HCC.VIRTUAL SLIDES: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/13000_2014_160.
|
['Biomarkers, Tumor', 'Carcinoma, Hepatocellular', 'Disease Progression', 'Disease-Free Survival', 'Female', 'Gene Expression Regulation, Neoplastic', 'Humans', 'Kaplan-Meier Estimate', 'Liver Neoplasms', 'Male', 'MicroRNAs', 'Middle Aged', 'Prognosis', 'Proportional Hazards Models', 'Retrospective Studies', 'Survival Rate', 'Up-Regulation']
| 25,123,453
|
[['D23.101.140'], ['C04.557.470.200.025.255', 'C04.588.274.623.160', 'C06.301.623.160', 'C06.552.697.160'], ['C23.550.291.656'], ['E01.789.800.190', 'E05.318.740.998.300', 'N04.761.559.590.800.190', 'N05.715.360.575.575.800.190', 'N05.715.360.750.795.300', 'N06.850.520.830.998.300'], ['G05.308.370'], ['B01.050.150.900.649.313.988.400.112.400.400'], ['E05.318.740.998.650', 'N05.715.360.750.795.650', 'N06.850.520.830.998.650'], ['C04.588.274.623', 'C06.301.623', 'C06.552.697'], ['D13.150.650.319', 'D13.444.735.150.319', 'D13.444.735.790.552.500'], ['M01.060.116.630'], ['E01.789'], ['E05.318.740.500.700', 'E05.318.740.600.700', 'E05.318.740.750.725', 'E05.318.740.998.825', 'E05.599.835.900', 'N05.715.360.750.530.650', 'N05.715.360.750.625.650', 'N05.715.360.750.695.650', 'N05.715.360.750.795.825', 'N06.850.520.830.500.700', 'N06.850.520.830.600.700', 'N06.850.520.830.750.725', 'N06.850.520.830.998.912'], ['E05.318.372.500.500.500', 'E05.318.372.500.750.750', 'N05.715.360.330.500.500.500', 'N05.715.360.330.500.750.825', 'N06.850.520.450.500.500.500', 'N06.850.520.450.500.750.825'], ['E05.318.308.985.550.900', 'N01.224.935.698.826', 'N06.850.505.400.975.550.900', 'N06.850.520.308.985.550.900'], ['G02.111.905', 'G05.308.850', 'G07.690.773.998']]
|
['Chemicals and Drugs [D]', 'Diseases [C]', 'Analytical, Diagnostic and Therapeutic Techniques, and Equipment [E]', 'Health Care [N]', 'Phenomena and Processes [G]', 'Organisms [B]', 'Named Groups [M]']
| 0
| 1
| 1
| 1
| 1
| 0
| 1
| 0
| 0
| 0
| 0
| 1
| 1
| 0
|
[Toxicity study of cefmatilen hydrochloride hydrate (S-1090) (2)--Single oral dose toxicity study in dogs].
|
Cefmatilen hydrochloride hydrate (S-1090) was administered at 500 and 1000 mg potency/kg once orally to beagle dogs. No deaths occurred. Vomiting, diarrhea or mucous feces occurred on the dosing day, and reddish-brown feces (due to chelated products of S-1090 and its decomposition products with Fe3+ in the diet) were also observed on the dosing and next day. Increases of plasma urea nitrogen and iron were observed on the next day after dosing. No remarkable changes were noted in other examination items. The animals in both groups were considered to be exposed to a similar level of S-1090 based on the toxicokinetic data. The oral lethal dose of S-1090 in dogs was estimated to be more than 1000 mg potency/kg.
|
['Administration, Oral', 'Animals', 'Blood Chemical Analysis', 'Body Weight', 'Cephalosporins', 'Dogs', 'Eating', 'Male', 'Occult Blood', 'Urinalysis']
| 11,400,318
|
[['E02.319.267.100'], ['B01.050'], ['E01.370.225.124.100', 'E05.200.124.100'], ['C23.888.144', 'E01.370.600.115.100.160.120', 'E05.041.124.160.750', 'G07.100.100.160.120', 'G07.345.249.314.120'], ['D02.065.589.099.249', 'D02.886.665.074', 'D03.633.100.300.249'], ['B01.050.150.900.649.313.750.250.216.200'], ['G07.203.650.283', 'G10.261.330'], ['E01.370.225.925', 'E05.200.925'], ['E01.370.225.124.810', 'E01.370.390.810', 'E05.200.124.810']]
|
['Analytical, Diagnostic and Therapeutic Techniques, and Equipment [E]', 'Organisms [B]', 'Diseases [C]', 'Phenomena and Processes [G]', 'Chemicals and Drugs [D]']
| 0
| 1
| 1
| 1
| 1
| 0
| 1
| 0
| 0
| 0
| 0
| 0
| 0
| 0
|
Aim44p regulates phosphorylation of Hof1p to promote contractile ring closure during cytokinesis in budding yeast.
|
Whereas actomyosin and septin ring organization and function in cytokinesis are thoroughly described, little is known regarding the mechanisms by which the actomyosin ring interacts with septins and associated proteins to coordinate cell division. Here we show that the protein product of YPL158C, Aim44p, undergoes septin-dependent recruitment to the site of cell division. Aim44p colocalizes with Myo1p, the type II myosin of the contractile ring, throughout most of the cell cycle. The Aim44p ring does not contract when the actomyosin ring closes. Instead, it forms a double ring that associates with septin rings on mother and daughter cells after cell separation. Deletion of AIM44 results in defects in contractile ring closure. Aim44p coimmunoprecipitates with Hof1p, a conserved F-BAR protein that binds both septins and type II myosins and promotes contractile ring closure. Deletion of AIM44 results in a delay in Hof1p phosphorylation and altered Hof1p localization. Finally, overexpression of Dbf2p, a kinase that phosphorylates Hof1p and is required for relocalization of Hof1p from septin rings to the contractile ring and for Hof1p-triggered contractile ring closure, rescues the cytokinesis defect observed in aim44 cells. Our studies reveal a novel role for Aim44p in regulating contractile ring closure through effects on Hof1p.
|
['Cell Cycle Proteins', 'Cytokinesis', 'Gene Deletion', 'Gene Expression Regulation, Fungal', 'Intracellular Signaling Peptides and Proteins', 'Microtubule-Associated Proteins', 'Myosin Heavy Chains', 'Phosphorylation', 'Protein Binding', 'Protein Transport', 'Protein-Serine-Threonine Kinases', 'Saccharomyces cerevisiae', 'Saccharomyces cerevisiae Proteins', 'Septins', 'Signal Transduction']
| 24,451,263
|
[['D12.776.167'], ['G04.144.220.250'], ['G05.365.590.762.320', 'G05.558.800.320'], ['G05.308.330'], ['D12.644.360', 'D12.776.476'], ['D12.776.220.600.450', 'D12.776.631.560'], ['D05.750.078.730.475.100', 'D08.811.277.040.025.193.750.249', 'D12.776.210.500.600.100', 'D12.776.220.525.475.100'], ['G02.111.665', 'G02.607.780', 'G03.796'], ['G02.111.679', 'G03.808'], ['G03.143.700'], ['D08.811.913.696.620.682.700'], ['B01.300.107.795.785.800', 'B01.300.930.705.655'], ['D12.776.354.750'], ['D08.811.277.040.330.300.700', 'D12.776.157.325.757', 'D12.776.220.932'], ['G02.111.820', 'G04.835']]
|
['Chemicals and Drugs [D]', 'Phenomena and Processes [G]', 'Organisms [B]']
| 0
| 1
| 0
| 1
| 0
| 0
| 1
| 0
| 0
| 0
| 0
| 0
| 0
| 0
|
Optical coherence tomography (OCT) features of cystoid spaces in choroideremia (CHM).
|
PURPOSE: To investigate the prevalence and features of cystoid spaces (CS) in patients with confirmed genetic diagnosis of choroideremia (CHM) using swept source optical coherence tomography (OCT).METHODS: We retrospectively reviewed CHM patients examined at the Regional Reference Center for Hereditary Retinal Degenerations at the Eye Clinic in Florence. We took into consideration genetically confirmed CHM patients with ophthalmological and swept source optical coherence tomography (OCT) examinations. The presence/absence and location of cystoid spaces in the retina of each eye were reported.RESULTS: A total of 42 eyes of 21 CHM patients were included in our series. The average age of the patients was 36.5 ± 20.1 (range, 13-73 years). The average best-corrected visual acuity (BCVA) for all patients was 0.63 ± 1.00 logMar (range, 0-2,80). CS were present in 15 eyes of eight patients (8/21, 38%). In all cases, CS were located in inner nuclear layer (INL); in five eyes of three patients, CS were detected also in ganglion cell layer (GCL). CS appeared as microcistoyd abnormalities and were detected in retinal areas characterized by retinal pigment epithelium (RPE) and outer retinal layers atrophy at the transition zone.CONCLUSIONS: Cystoid spaces in choroideremia showed peculiar features; they are clusters of small-size extrafoveal degenerative cysts mainly located in inner nuclear layer at the transition zone where outer retinal layers and RPE are severely damaged.
|
['Adolescent', 'Adult', 'Aged', 'Child', 'Choroid', 'Choroideremia', 'Female', 'Follow-Up Studies', 'Humans', 'Male', 'Middle Aged', 'Retinal Pigment Epithelium', 'Retrospective Studies', 'Tomography, Optical Coherence', 'Visual Acuity', 'Visual Fields', 'Young Adult']
| 31,654,189
|
[['M01.060.057'], ['M01.060.116'], ['M01.060.116.100'], ['M01.060.406'], ['A09.371.894.223'], ['C11.270.142', 'C11.941.160.300', 'C16.320.290.142', 'C16.320.322.092'], ['E05.318.372.500.750.249', 'N05.715.360.330.500.750.350', 'N06.850.520.450.500.750.350'], ['B01.050.150.900.649.313.988.400.112.400.400'], ['M01.060.116.630'], ['A09.371.670.500', 'A09.371.729.887'], ['E05.318.372.500.500.500', 'E05.318.372.500.750.750', 'N05.715.360.330.500.500.500', 'N05.715.360.330.500.750.825', 'N06.850.520.450.500.500.500', 'N06.850.520.450.500.750.825'], ['E01.370.350.589.249.500', 'E01.370.350.825.805.500', 'E05.642.249.500'], ['E01.370.380.850.950', 'F02.463.593.932.901', 'G14.940'], ['F02.463.593.932.934', 'G14.950'], ['M01.060.116.815']]
|
['Named Groups [M]', 'Anatomy [A]', 'Diseases [C]', 'Analytical, Diagnostic and Therapeutic Techniques, and Equipment [E]', 'Health Care [N]', 'Organisms [B]', 'Psychiatry and Psychology [F]', 'Phenomena and Processes [G]']
| 1
| 1
| 1
| 0
| 1
| 1
| 1
| 0
| 0
| 0
| 0
| 1
| 1
| 0
|
NMDA and AMPA receptors mediate intracellular calcium increase in rat cortical astrocytes.
|
AIM: To study the effect of glutamate on the intracellular calcium signal of pure cultured rat astrocytes and the role of N-methyl-D-aspartate (NMDA) and alpha-amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid (AMPA) receptors in the procedure.METHODS: The fluorescence of calcium was measured by Fura-2/AM (F(345)/F(380)).RESULTS: L-Glutamate induced [Ca(2+)](i) increase in most of the cells in concentration- and time-dependent manner. NMDA 50 mmol/L induced the fluorescence increase by almost three to four times, while the effect of AMPA 50 mmol/L was just half of that of D-(-)-2-amino-5-phosphonopentanoic acid (D-AP-5; a selective antagonist of the NMDA receptor). 6-Cyano-7-nitroquinoxaline-2,3-dione (CNQX, a selective antagonist of the AMPA receptor) abolished the effects of NMDA and AMPA, respectively. D-AP-5 and CNQX simultaneously or respectively attenuated the effect of L-glutamate at different degrees, but could not abolish it entirely.CONCLUSION: Glutamate modulated intracellular Ca(2+) of pure cultured rat astrocytes through different pathways. The activation of NMDA and AMPA receptors took part in the complex mechanisms.
|
['2-Amino-5-phosphonovalerate', '6-Cyano-7-nitroquinoxaline-2,3-dione', 'Animals', 'Animals, Newborn', 'Astrocytes', 'Calcium', 'Cells, Cultured', 'Cerebral Cortex', 'Glutamic Acid', 'N-Methylaspartate', 'Rats', 'Rats, Sprague-Dawley', 'Receptors, AMPA', 'Receptors, N-Methyl-D-Aspartate', 'alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid']
| 15,169,621
|
[['D12.125.070.950.100', 'D12.125.740.025'], ['D03.633.100.857.160'], ['B01.050'], ['B01.050.050.282'], ['A08.637.200', 'A11.650.200'], ['D01.268.552.100', 'D01.552.539.288', 'D23.119.100'], ['A11.251'], ['A08.186.211.200.885.287.500'], ['D12.125.067.625.349', 'D12.125.119.409.349', 'D12.125.427.300'], ['D12.125.067.500.400', 'D12.125.119.170.400'], ['B01.050.150.900.649.313.992.635.505.700'], ['B01.050.150.900.649.313.992.635.505.700.750'], ['D12.776.157.530.400.400.500.100', 'D12.776.543.550.450.500.200.100', 'D12.776.543.585.400.500.200.100', 'D12.776.543.750.720.200.450.400.100'], ['D12.776.157.530.400.400.500.500', 'D12.776.543.550.450.500.200.500', 'D12.776.543.585.400.500.200.500', 'D12.776.543.750.720.200.450.400.500'], ['D03.383.129.385.025']]
|
['Chemicals and Drugs [D]', 'Organisms [B]', 'Anatomy [A]']
| 1
| 1
| 0
| 1
| 0
| 0
| 0
| 0
| 0
| 0
| 0
| 0
| 0
| 0
|
Variants of NOS1, NOS2, and NOS3 genes in asthmatics.
|
Nitric oxide (NO) gas concentrations are higher in expired air in asthmatics. NO is synthesized by three isoforms of NO synthase (NOS) encoded by three distinct genes, NOS1, NOS2, and NOS3. Genome-wide searches have identified linkages to asthma on chromosomes 7, 12, and 17 where these three genes are localized. No association study, however, has been reported to date. To test whether variants of NOS1, NOS2, and NOS3 relate to asthma, a genetic association study was conducted in a British population (n = 300). Intragenic microsatellite variants of NOS1 were significantly associated with asthma [odds ratio (OR) = 2.08, 95% CI: 1.20-3.57 (95% CI), P = 0.008 (Pc = 0.048)], but not with IgE levels. Neither NOS2 nor NOS3 variants showed any association with asthma nor IgE levels. These findings suggest that NOS1 variants may be a significant contributor to asthma in a British population.
|
['Alleles', 'Asthma', 'Chromosome Mapping', 'Chromosomes, Human, Pair 12', 'Chromosomes, Human, Pair 17', 'Chromosomes, Human, Pair 7', 'Genetic Variation', 'Humans', 'Immunoglobulin E', 'Introns', 'Microsatellite Repeats', 'Minisatellite Repeats', 'Nerve Tissue Proteins', 'Nitric Oxide Synthase', 'Nitric Oxide Synthase Type I', 'Nitric Oxide Synthase Type II', 'Nitric Oxide Synthase Type III', 'Promoter Regions, Genetic', 'Reference Values', 'United Kingdom']
| 10,673,365
|
[['G05.360.340.024.340.030'], ['C08.127.108', 'C08.381.495.108', 'C08.674.095', 'C20.543.480.680.095'], ['E05.393.183'], ['A11.284.187.520.300.325.360', 'G05.360.162.520.300.325.360'], ['A11.284.187.520.300.415.425', 'G05.360.162.520.300.415.425'], ['A11.284.187.520.300.325.335', 'G05.360.162.520.300.325.335'], ['G05.365'], ['B01.050.150.900.649.313.988.400.112.400.400'], ['D12.776.124.486.485.114.619.312', 'D12.776.124.790.651.114.619.312', 'D12.776.377.715.548.114.619.312'], ['G05.360.340.024.220.400', 'G05.360.340.024.340.137.515'], ['G02.111.570.080.708.800.500', 'G05.360.080.708.800.500', 'G05.360.340.024.850.500'], ['G02.111.570.080.708.800.550', 'G05.360.080.708.800.550', 'G05.360.340.024.850.550'], ['D12.776.631'], ['D08.811.682.664.500.772'], ['D08.811.682.664.500.772.249'], ['D08.811.682.664.500.772.500', 'D12.776.157.687.575', 'D12.776.660.720.575'], ['D08.811.682.664.500.772.750'], ['G02.111.570.080.689.675', 'G05.360.080.689.675', 'G05.360.340.024.340.137.750.680'], ['E05.978.810'], ['Z01.542.363']]
|
['Phenomena and Processes [G]', 'Diseases [C]', 'Analytical, Diagnostic and Therapeutic Techniques, and Equipment [E]', 'Anatomy [A]', 'Organisms [B]', 'Chemicals and Drugs [D]', 'Geographicals [Z]']
| 1
| 1
| 1
| 1
| 1
| 0
| 1
| 0
| 0
| 0
| 0
| 0
| 0
| 1
|
Chromosomal aberrations in adenomatoid hyperplasia of palatal minor salivary gland.
|
Adenomatoid hyperplasia of minor salivary glands is rare, idiopathic, and benign, and typically presents as a tumour-like mass in the hard or soft palate. Its exact nature is not clear and histological examination usually shows an excess of normal-appearing minor salivary glands. To our knowledge, cytogenetic analysis of it in a minor salivary gland of the palate has not previously been reported. We present the cytogenetic analysis of adenomatoid hyperplasia in the hard palate of a 52-year-old woman.
|
['Chromosome Aberrations', 'Chromosome Breakage', 'Chromosomes, Human, Pair 14', 'Chromosomes, Human, Pair 2', 'Chromosomes, Human, Pair 21', 'Chromosomes, Human, Pair 22', 'Epithelium', 'Female', 'Follow-Up Studies', 'Humans', 'Hyperplasia', 'Middle Aged', 'Palate, Hard', 'Salivary Ducts', 'Salivary Gland Neoplasms', 'Salivary Glands, Minor', 'Translocation, Genetic']
| 22,571,812
|
[['C23.550.210', 'G05.365.590.175'], ['C23.550.210.170', 'G05.200.210.170', 'G05.365.590.175.175'], ['A11.284.187.520.300.370.380', 'G05.360.162.520.300.370.380'], ['A11.284.187.520.300.235.245', 'G05.360.162.520.300.235.245'], ['A11.284.187.520.300.505.510', 'G05.360.162.520.300.505.510'], ['A11.284.187.520.300.505.515', 'G05.360.162.520.300.505.515'], ['A10.272'], ['E05.318.372.500.750.249', 'N05.715.360.330.500.750.350', 'N06.850.520.450.500.750.350'], ['B01.050.150.900.649.313.988.400.112.400.400'], ['C23.550.444'], ['M01.060.116.630'], ['A02.835.232.781.324.502.660', 'A14.521.658.660', 'A14.549.617.660'], ['A03.556.500.760.640', 'A10.336.779.640', 'A14.549.760.640'], ['C04.588.443.591.824', 'C07.465.530.824', 'C07.465.815.718'], ['A03.556.500.760.650', 'A10.336.779.650', 'A14.549.760.650'], ['C23.550.210.870', 'G05.365.590.175.870', 'G05.558.860']]
|
['Diseases [C]', 'Phenomena and Processes [G]', 'Anatomy [A]', 'Analytical, Diagnostic and Therapeutic Techniques, and Equipment [E]', 'Health Care [N]', 'Organisms [B]', 'Named Groups [M]']
| 1
| 1
| 1
| 0
| 1
| 0
| 1
| 0
| 0
| 0
| 0
| 1
| 1
| 0
|
Cysteine and crocin oxidation catalyzed by horseradish peroxidase.
|
The amino acid cysteine is oxidized by horseradish peroxidase, and the water-soluble carotenoid crocin is bleached by cooxidation. The monophenol p-hydroxyacetophenone stimulates oxygen uptake, cysteine oxidation and crocin bleaching, whereas its concentration does not change. Superoxide dismutase significantly enhances all these oxidative reactions. Addition of H2O2 is not required for these peroxidase-catalyzed oxidations.
|
['Carotenoids', 'Cysteine', 'Horseradish Peroxidase', 'Kinetics', 'Oxidation-Reduction', 'Peroxidases', 'Substrate Specificity']
| 2,707,627
|
[['D02.455.326.271.665.202', 'D02.455.426.392.368.367.379.249', 'D02.455.849.131', 'D23.767.261'], ['D02.886.030.230', 'D02.886.489.155', 'D12.125.154.299', 'D12.125.166.230'], ['D08.811.682.732.512'], ['G01.374.661', 'G02.111.490'], ['G02.700', 'G03.295.531'], ['D08.811.682.732'], ['G02.111.835']]
|
['Chemicals and Drugs [D]', 'Phenomena and Processes [G]']
| 0
| 0
| 0
| 1
| 0
| 0
| 1
| 0
| 0
| 0
| 0
| 0
| 0
| 0
|
[Treatment of beta-thalassemia with Bushen Yisui therapy: a randomized controlled trial].
|
OBJECTIVE: To investigate the efficacy and safety of Yisui Shengxue Granule (YSSXG), a compound traditional Chinese herbal medicine, in treating beta-thalassemia.METHODS: A randomized single-blinded trial was designed. Sixty patients with beta-thalassemia were divided into two groups: 30 patients in YSSXG-treated group and 30 in placebo parallel-control group. The patients in the two groups were assigned to receive either YSSXG or placebo for three months. The patients' symptoms and their blood indexes such as hemoglobin (Hb), red blood cell (RBC), reticulocytes (Ret) and fetal hemoglobin (HBF) were examined before and after the treatment. Meanwhile, the liver and spleen were examined with B-mode ultrasound.RESULTS: In the YSSXG-treated group, the blood indexes (Hb, RBC, Ret and HBF) and the symptoms of the patients were improved after three-month treatment, with statistical significance compared to those before treatment (P<0.01); hepatauxe and splenomegaly were also relieved (P<0.05) and no adverse reactions were monitored. In the placebo parallel-control group, no significant improvement of the blood indexes and symptoms, as well as the hepatauxe and splenomegaly had been found (P>0.05).CONCLUSION: YSSXG demonstrates obvious clinical efficacy and no adverse reactions in treating beta-thalassemia.
|
['Adolescent', 'Child', 'Child, Preschool', 'Drugs, Chinese Herbal', 'Female', 'Humans', 'Male', 'Phytotherapy', 'Single-Blind Method', 'Treatment Outcome', 'beta-Thalassemia']
| 17,352,867
|
[['M01.060.057'], ['M01.060.406'], ['M01.060.406.448'], ['D20.215.784.500.350', 'D26.335'], ['B01.050.150.900.649.313.988.400.112.400.400'], ['E02.190.755'], ['E05.318.370.850', 'N05.715.360.325.730', 'N06.850.520.445.850'], ['E01.789.800', 'N04.761.559.590.800', 'N05.715.360.575.575.800'], ['C15.378.071.141.150.875.150', 'C15.378.420.826.150', 'C16.320.070.875.150', 'C16.320.365.826.150']]
|
['Named Groups [M]', 'Chemicals and Drugs [D]', 'Organisms [B]', 'Analytical, Diagnostic and Therapeutic Techniques, and Equipment [E]', 'Health Care [N]', 'Diseases [C]']
| 0
| 1
| 1
| 1
| 1
| 0
| 0
| 0
| 0
| 0
| 0
| 1
| 1
| 0
|
Chronic pancreatitis: a complication of systemic lupus erythematosus.
|
Systemic lupus erythematosus (SLE), an autoimmune disease with multisystem involvement, has been reported to be associated with a number of gastrointestinal complications. Acute pancreatitis is an unusual manifestation of this disorder. This report presents two cases of patients with SLE who developed chronic pancreatitis with no other identifiable etiology.
|
['Adult', 'Chronic Disease', 'Female', 'Humans', 'Lupus Erythematosus, Systemic', 'Pancreatitis']
| 8,425,705
|
[['M01.060.116'], ['C23.550.291.500'], ['B01.050.150.900.649.313.988.400.112.400.400'], ['C17.300.480', 'C20.111.590'], ['C06.689.750']]
|
['Named Groups [M]', 'Diseases [C]', 'Organisms [B]']
| 0
| 1
| 1
| 0
| 0
| 0
| 0
| 0
| 0
| 0
| 0
| 1
| 0
| 0
|
Synthesis of colour tunable lanthanide-ion doped NaYF4 upconversion nanoparticles by controlling temperature.
|
A simple and general method is reported to tune the multicolour output of lanthanide-ion doped NaYF(4) upconversion nanoparticles within a given composition by controlling the reaction temperature in the thermolysis procedure.
|
['Color', 'Fluorides', 'Lanthanoid Series Elements', 'Nanoparticles', 'Temperature', 'X-Ray Diffraction', 'Yttrium']
| 20,414,492
|
[['G01.590.540.199'], ['D01.248.497.158.380', 'D01.303.350.300'], ['D01.268.558.362', 'D01.552.550.399'], ['J01.637.512.600'], ['G01.906.595', 'G16.500.275.063.725.710', 'G16.500.750.775.710', 'N06.230.150.450', 'N06.230.300.100.725.710'], ['E05.196.309.742', 'E05.196.822.950', 'G01.867.950', 'G02.965'], ['D01.268.558.975', 'D01.268.956.890', 'D01.552.550.975']]
|
['Phenomena and Processes [G]', 'Chemicals and Drugs [D]', 'Technology, Industry, and Agriculture [J]', 'Health Care [N]', 'Analytical, Diagnostic and Therapeutic Techniques, and Equipment [E]']
| 0
| 0
| 0
| 1
| 1
| 0
| 1
| 0
| 0
| 1
| 0
| 0
| 1
| 0
|
Calcium is a key constituent for maintaining the in vitro properties of platelets suspended in the bicarbonate-containing additive solution M-sol with low plasma levels.
|
BACKGROUND: Commercially available additive solutions (ASs) require 30% to 35% plasma for optimal storage of platelets (PLTs). PLTs suspended in M-sol, a bicarbonate-based experimental platelet additive solution (PAS), maintain in vitro PLT properties during storage with low levels of plasma (< or =5%).STUDY DESIGN AND METHODS: Four different formulations of M-sol were prepared at the optimal pH (6.1): M-sol, M-sol without calcium, M-sol without citric acid, and M-sol without calcium and citric acid. Apheresis PLT units (100% plasma) were equally divided into five 50-mL aliquots in PL732 containers, centrifuged, and resuspended to prepare units suspended in the four different PASs (95%) with 5% plasma and 1 unit in 100% plasma. Units (n = 10) were stored under standard conditions and assayed for in vitro properties on Days 1, 5, and 7. The data were analyzed by analysis of variance for repeated measures (n = 10, p < 0.001).RESULTS: On Day 5 of storage, PLTs suspended in the M-sol formulation containing calcium but lacking citric acid had similar pH, extent of shape change (ESC) values, and percentage of CD62-positive PLTs and greater hypotonic shock response (HSR) and percentage of discoid PLTs compared to those of PLTs suspended in 100% plasma. In contrast, PLTs suspended in the M-sol formulation lacking calcium had lesser ESC values, greater percentage of CD62-positive PLTs, and similar HSR values and percentage of discoid PLTs compared to those of PLTs suspended in 100% plasma on Day 5 (p < 0.001).CONCLUSIONS: Calcium plays an important role in maintaining CD62-negative PLTs and relatively high ESC in 5% plasma. The removal of citric acid from M-sol may improve PLT storage properties with low plasma levels.
|
['Blood Platelets', 'Blood Preservation', 'Calcium', 'Humans', 'Sodium Bicarbonate', 'Suspensions']
| 20,030,790
|
[['A11.118.188', 'A15.145.229.188'], ['E02.792.833.230', 'E05.760.833.230'], ['D01.268.552.100', 'D01.552.539.288', 'D23.119.100'], ['B01.050.150.900.649.313.988.400.112.400.400'], ['D01.200.275.150.100.800', 'D01.857.625'], ['D20.280.810', 'D26.255.165.810']]
|
['Anatomy [A]', 'Analytical, Diagnostic and Therapeutic Techniques, and Equipment [E]', 'Chemicals and Drugs [D]', 'Organisms [B]']
| 1
| 1
| 0
| 1
| 1
| 0
| 0
| 0
| 0
| 0
| 0
| 0
| 0
| 0
|
Intraductal collagenase delivery into the human pancreas using syringe loading or controlled perfusion.
|
Effective intraductal delivery of the enzyme collagenase into the pancreas is crucial to the subsequent ability to isolate viable islets. Most clinical islet transplant centers load the enzyme into the pancreas by retrograde injection using a syringe following cannulation of the pancreatic duct. An alternative approach is to perfuse the pancreas via the pancreatic duct with collagenase solution using a recirculating perfusion device system. This provides control over perfusion pressures and collagenase temperature. This study reports on our evaluation of the delivery of Liberase-HI into the pancreas of 14 consecutive adult multiorgan cadaveric donors. Alternate glands were procured and processed using an identical protocol with the exception of collagenase delivery. The first group of pancreases was loaded using the perfusion technique where cold (4 degrees C) Liberase-HI was perfused at 80 mmHg for 5 min after which the pressure was increased to 180 mmHg. The collagenase solution was then slowly warmed to 35 degrees C, transferred to the dissociation chamber and mechanically dissociated, and then purified using discontinuous gradients of Ficoll. Pancreases in the second group were loaded with collagenase (28-32 degrees C) using the syringe technique before mechanical dissociation and purification. There were no significant differences in pancreas cold ischemia, donor age, body mass index, maximum blood glucose, or serum amylase of the donors between the two groups. Mean collagenase digestion time in the digestion chamber was not different between the two groups; however, the amount of undigested tissue remaining after dissociation was significantly higher in the syringe-loaded group (15.3 +/- 2.6 g vs. 4.6 +/- 2.1 g, mean +/- SEM, p < 0.05). Postdigestion recovery of islets was 471 +/- 83 x 10(3) IE in the perfusion group compared with 391 +/- 57 x 10(3) IE for the syringe-loaded group. Postpurification recovery was higher in the perfused group (379 +/- 45 vs. 251 +/- 28 x 10(3) IE, p < 0.05, two-tailed paired t-test). No difference in in vitro islet viability was observed between the two groups following glucose perifusion with the calculated stimulation index of 4.6 +/- 0.6 for the perfusion group and 4.2 +/- 0.7 for the syringe-loaded group. Controlled perfusion via the pancreatic duct allows the effective delivery of the enzyme achieving maximal distension to all regions of the pancreas leading to an increased recovery of the islets with no detrimental effect on subsequent in vitro islet function.
|
['Adenosine', 'Adult', 'Allopurinol', 'Brain Death', 'Cadaver', 'Cell Separation', 'Collagenases', 'Glutathione', 'Humans', 'Insulin', 'Islets of Langerhans', 'Organ Preservation Solutions', 'Pancreatic Ducts', 'Perfusion', 'Raffinose', 'Thermolysin', 'Tissue Donors', 'Tissue Preservation']
| 10,442,741
|
[['D03.633.100.759.590.138', 'D13.570.583.138', 'D13.570.800.096'], ['M01.060.116'], ['D03.633.100.759.160'], ['C10.228.140.151', 'C10.597.606.358.800.200.100', 'C23.550.260.159'], ['C23.550.260.224'], ['E01.370.225.500.363', 'E05.200.500.363', 'E05.242.363'], ['D08.811.277.656.300.480.205', 'D08.811.277.656.675.374.205'], ['D12.644.456.448'], ['B01.050.150.900.649.313.988.400.112.400.400'], ['D06.472.699.587.200.500.625', 'D12.644.548.586.200.500.625'], ['A03.734.414', 'A06.300.414'], ['D26.776.675'], ['A03.734.667'], ['E05.680'], ['D09.698.629.802.700'], ['D08.811.277.656.300.480.827', 'D08.811.277.656.675.374.827'], ['M01.898'], ['E01.370.225.500.620.760', 'E01.370.225.750.600.760', 'E02.792.833', 'E05.200.500.620.760', 'E05.200.750.600.760', 'E05.760.833']]
|
['Chemicals and Drugs [D]', 'Named Groups [M]', 'Diseases [C]', 'Analytical, Diagnostic and Therapeutic Techniques, and Equipment [E]', 'Organisms [B]', 'Anatomy [A]']
| 1
| 1
| 1
| 1
| 1
| 0
| 0
| 0
| 0
| 0
| 0
| 1
| 0
| 0
|
Effects of Melanocortin 3 and 4 Receptor Deficiency on Energy Homeostasis in Rats.
|
Melanocortin-3 and 4 receptors (MC3R and MC4R) can regulate energy homeostasis, but their respective roles especially the functions of MC3R need more exploration. Here Mc3r and Mc4r single and double knockout (DKO) rats were generated using CRISPR-Cas9 system. Metabolic phenotypes were examined and data were compared systematically. Mc3r KO rats displayed hypophagia and decreased body weight, while Mc4r KO and DKO exhibited hyperphagia and increased body weight. All three mutants showed increased white adipose tissue mass and adipocyte size. Interestingly, although Mc3r KO did not show a significant elevation in lipids as seen in Mc4r KO, DKO displayed even higher lipid levels than Mc4r KO. DKO also showed more severe glucose intolerance and hyperglycaemia than Mc4r KO. These data demonstrated MC3R deficiency caused a reduction of food intake and body weight, whereas at the same time exhibited additive effects on top of MC4R deficiency on lipid and glucose metabolism. This is the first phenotypic analysis and systematic comparison of Mc3r KO, Mc4r KO and DKO rats on a homogenous genetic background. These mutant rats will be important in defining the complicated signalling pathways of MC3R and MC4R. Both Mc4r KO and DKO are good models for obesity and diabetes research.
|
['Adipose Tissue, White', 'Animals', 'Animals, Genetically Modified', 'Body Weight', 'Drinking', 'Eating', 'Energy Metabolism', 'Female', 'Gene Knockout Techniques', 'Glucose', 'Homeostasis', 'Kidney', 'Lipids', 'Liver', 'Male', 'Rats', 'Rats, Mutant Strains', 'Rats, Sprague-Dawley', 'Receptor, Melanocortin, Type 3', 'Receptor, Melanocortin, Type 4']
| 27,713,523
|
[['A10.165.114.830'], ['B01.050'], ['B01.050.050.136', 'B05.620.136'], ['C23.888.144', 'E01.370.600.115.100.160.120', 'E05.041.124.160.750', 'G07.100.100.160.120', 'G07.345.249.314.120'], ['G07.203.650.283.249', 'G10.261.330.249'], ['G07.203.650.283', 'G10.261.330'], ['G03.295'], ['E05.393.335.750'], ['D09.947.875.359.448'], ['G07.410'], ['A05.810.453'], ['D10'], ['A03.620'], ['B01.050.150.900.649.313.992.635.505.700'], ['B01.050.150.900.649.313.992.635.505.700.550'], ['B01.050.150.900.649.313.992.635.505.700.750'], ['D12.776.543.750.695.430.875', 'D12.776.543.750.720.600.285.500.875', 'D12.776.543.750.750.555.285.500.875', 'D12.776.543.750.750.660.285.500.875'], ['D12.776.543.750.695.430.937', 'D12.776.543.750.720.600.285.500.937', 'D12.776.543.750.750.555.285.500.937', 'D12.776.543.750.750.660.285.500.937']]
|
['Anatomy [A]', 'Organisms [B]', 'Diseases [C]', 'Analytical, Diagnostic and Therapeutic Techniques, and Equipment [E]', 'Phenomena and Processes [G]', 'Chemicals and Drugs [D]']
| 1
| 1
| 1
| 1
| 1
| 0
| 1
| 0
| 0
| 0
| 0
| 0
| 0
| 0
|
Air pollution and daily clinic visits for migraine in a subtropical city: Taipei, Taiwan.
|
This study was undertaken to determine whether there was an association between air pollutant levels and daily clinic visits for migraine in Taipei, Taiwan. Daily clinic visits for migraine and ambient air pollution data for Taipei were obtained for the period 2006-2011. The relative risk of clinic visits for migraine was estimated using a case-crossover approach, controlling for weather variables, day of the week, seasonality, and long-term time trends. In the single-pollutant models, on warm days (>23°C) statistically significant positive associations were found for increased rate of migraine occurrence and levels of particulate matter (PM10), sulfur dioxide (SO2), nitrogen dioxide (NO2), carbon monoxide (CO), and ozone (O3). On cool days (<23°C), all pollutants were significantly associated with increased migraine visits except CO and SO2. For the two-pollutant models, O3 and NO2 were significant for higher rate of migraine visits in combination with each of the other four pollutants on cool days. On warm days, CO remained statistically significant in all two-pollutant models. This study provides evidence that higher levels of ambient air pollutants enhance the risk of clinic visits for migraine.
|
['Air Pollutants', 'Ambulatory Care', 'Cities', 'Cross-Over Studies', 'Environmental Exposure', 'Environmental Monitoring', 'Female', 'Humans', 'Male', 'Migraine Disorders', 'Seasons', 'Taiwan']
| 25,965,190
|
[['D27.888.284.101'], ['E02.760.106', 'N02.421.585.106'], ['G16.500.275.069', 'N06.230.069', 'Z01.433'], ['E05.318.370.150', 'N05.715.360.325.150', 'N06.850.520.445.150'], ['N06.850.460.350'], ['N06.850.460.350.080', 'N06.850.780.375'], ['B01.050.150.900.649.313.988.400.112.400.400'], ['C10.228.140.546.399.750'], ['G01.910.645.661', 'G16.500.275.071.590', 'N06.230.300.100.250.525'], ['Z01.252.474.872', 'Z01.639.850']]
|
['Chemicals and Drugs [D]', 'Analytical, Diagnostic and Therapeutic Techniques, and Equipment [E]', 'Health Care [N]', 'Phenomena and Processes [G]', 'Geographicals [Z]', 'Organisms [B]', 'Diseases [C]']
| 0
| 1
| 1
| 1
| 1
| 0
| 1
| 0
| 0
| 0
| 0
| 0
| 1
| 1
|
Optimization of experimental conditions for RNA-based sequencing of MLH1 and MSH2 genes.
|
The most sensitive technique for the detection of germline mutations is exon by exon sequencing of the gene under investigation using genomic DNA as a template for analysis. This approach, however, has cost and sensitivity limitations that can, at least in part, be overcome by RNA-based analysis. Germline mutations of MLH1 and MSH2 are the most frequent cause of the inherited susceptibility to colorectal and other epithelial cancers known as hereditary non-polyposis colorectal cancer (HNPCC). We compared the analysis of the MLH1 and MSH2 genes using mRNA and genomic DNA as starting material from 21 HNPCC patients. All samples were investigated by RT-PCR, sequencing of cDNA and simultaneous sequencing of genomic DNA. The cDNA was generated using specific primers complementary to the ends of MLH1 and MSH2 genes, respectively. Mutations in MLH1 and MSH2 were detected in 11 out of 21 unrelated patients. In 10 out of 11 cases, mutations were detected independently of the type of primers used for reverse transcription (RT). One novel missense mutation (K751R) in MLH1 was detected using this method. One nonsense mutation (E205X) in MSH2 was only detectable when RT was performed using MSH2 gene-specific primers. Shorter PCR products indicative of alternatively spliced transcripts were not observed when MLH1 or MSH2 specific cDNA RT primers were employed to generate template, except in one case where exon skipping was observed for exons 9 and 10. In this report we demonstrate that primers specific for RT of MLH1 and MSH2 are crucial for increasing the sensitivity of cDNA analysis. DNA sequencing using RNA as a basis for template construction may be a valuable and economical alternative to genomic DNA sequencing.
|
['Adaptor Proteins, Signal Transducing', 'Alternative Splicing', 'Amino Acid Substitution', 'Arginine', 'Base Pair Mismatch', 'Carrier Proteins', 'Colorectal Neoplasms, Hereditary Nonpolyposis', 'DNA Repair', 'DNA-Binding Proteins', 'Germ-Line Mutation', 'Humans', 'Lysine', 'MutL Protein Homolog 1', 'MutS Homolog 2 Protein', 'Mutation, Missense', 'Neoplasm Proteins', 'Nuclear Proteins', 'Proto-Oncogene Proteins', 'Reverse Transcriptase Polymerase Chain Reaction', 'Sequence Analysis, RNA']
| 11,139,242
|
[['D12.644.360.024', 'D12.776.157.057', 'D12.776.476.024'], ['G02.111.760.700.100', 'G03.839.700.100', 'G05.308.700.700.100'], ['E05.393.420.601.035', 'G05.558.109'], ['D12.125.068.050', 'D12.125.095.104', 'D12.125.142.087'], ['G05.365.590.060'], ['D12.776.157'], ['C04.588.274.476.411.307.190', 'C04.700.250', 'C06.301.371.411.307.190', 'C06.405.249.411.307.190', 'C06.405.469.158.356.190', 'C06.405.469.491.307.190', 'C16.320.700.250', 'C18.452.284.255'], ['G02.111.222', 'G05.219'], ['D12.776.260'], ['G05.365.590.350'], ['B01.050.150.900.649.313.988.400.112.400.400'], ['D12.125.068.555', 'D12.125.095.647', 'D12.125.142.497'], ['D08.811.074.766.500', 'D08.811.277.040.025.215.500', 'D12.776.260.540.500'], ['D08.811.074.844.750', 'D08.811.277.040.025.292.750', 'D12.776.260.556.750', 'D12.776.624.664.700.130'], ['G05.365.590.650'], ['D12.776.624'], ['D12.776.660'], ['D12.776.624.664.700'], ['E05.393.620.500.725'], ['E05.393.760.710']]
|
['Chemicals and Drugs [D]', 'Phenomena and Processes [G]', 'Analytical, Diagnostic and Therapeutic Techniques, and Equipment [E]', 'Diseases [C]', 'Organisms [B]']
| 0
| 1
| 1
| 1
| 1
| 0
| 1
| 0
| 0
| 0
| 0
| 0
| 0
| 0
|
Women with adenomyosis are at higher risks of endometrial and thyroid cancers: A population-based historical cohort study.
|
OBJECTIVE: Both adenomyosis and endometriosis are characterized by the presence of ectopic endometrial glands and stroma and have been suggested to share some characteristics with malignant tumors. Although accumulating evidence indicates that endometriosis is associated with some cancer types, the cancer risks in patients with adenomyosis have been rarely examined. In this study, we investigated the relationship between adenomyosis and risks of common cancers.METHODS: This study included a cohort of 12,447 women with adenomyosis but not endometriosis, born in 1951-1984, and a cohort of 124,470 adenomyosis-free women matched by birth year. Their medical records (collected between 1996 and 2011) were obtained from the National Health Insurance Research Database of Taiwan. We first compared the distribution of cancer-free survival (CFS) between cohorts with and without adenomyosis. Subsequently, within the adenomyosis cohort, we examined whether time-to-onset of the identified cancer type was correlated with time-to-onset of adenomyosis. The Cox proportional hazards model was used to compare the distribution of CFS between the adenomyosis and adenomyosis-free cohorts and between the early- and late-diagnosed adenomyosis groups. For comparison, we further evaluated the cancer risks for a cohort of 10,962 women with endometriosis but not adenomyosis and a birth-year matched cohort of 109,620 endometriosis-free women.RESULTS: Compared with adenomyosis-free women, patients with adenomyosis had higher risks of endometrial and thyroid cancers, with estimated hazard ratios (HRs) (95% confidence interval) of 2.19 (1.51-3.16) and 1.70 (1.29-2.24), respectively. For both cancers, distributions of CFS were not significantly different between the early- and late-diagnosed adenomyosis groups. Furthermore, compared with endometriosis-free women, patients with endometriosis had higher risks of endometrial and ovarian cancers, with HRs of 1.89 (1.07-3.35) and 2.01 (1.27-3.16), respectively.CONCLUSIONS: Women with adenomyosis are at higher risks of endometrial and thyroid cancers, while women with endometriosis are at higher risks of endometrial and ovarian cancers.
|
['Adenomyosis', 'Adult', 'Age Distribution', 'Aged', 'Cohort Studies', 'Comorbidity', 'Disease Susceptibility', 'Endometrial Neoplasms', 'Endometriosis', 'Female', 'Historically Controlled Study', 'Humans', 'Middle Aged', 'Neoplasms', 'Ovarian Neoplasms', 'Risk Factors', 'Taiwan', 'Thyroid Neoplasms']
| 29,522,577
|
[['C13.351.500.852.113'], ['M01.060.116'], ['I01.240.050', 'N01.224.033', 'N06.850.505.400.050'], ['M01.060.116.100'], ['E05.318.372.500.750', 'N05.715.360.330.500.750', 'N06.850.520.450.500.750'], ['N05.715.350.225', 'N06.850.490.687'], ['C23.550.291.687', 'G07.100.250'], ['C04.588.945.418.948.585', 'C13.351.500.852.762.200', 'C13.351.937.418.875.200'], ['C13.351.500.163'], ['E05.318.372.500.912'], ['B01.050.150.900.649.313.988.400.112.400.400'], ['M01.060.116.630'], ['C04'], ['C04.588.322.455', 'C13.351.500.056.630.705', 'C13.351.937.418.685', 'C19.344.410', 'C19.391.630.705'], ['E05.318.740.600.800.725', 'N05.715.350.200.700', 'N05.715.360.750.625.700.700', 'N06.850.490.625.750', 'N06.850.520.830.600.800.725'], ['Z01.252.474.872', 'Z01.639.850'], ['C04.588.322.894', 'C04.588.443.915', 'C19.344.894', 'C19.874.788']]
|
['Diseases [C]', 'Named Groups [M]', 'Anthropology, Education, Sociology, and Social Phenomena [I]', 'Health Care [N]', 'Analytical, Diagnostic and Therapeutic Techniques, and Equipment [E]', 'Phenomena and Processes [G]', 'Organisms [B]', 'Geographicals [Z]']
| 0
| 1
| 1
| 0
| 1
| 0
| 1
| 0
| 1
| 0
| 0
| 1
| 1
| 1
|
Effect of the alpha-1 adrenoceptor blocker on tissue norepinephrine contents in human benign prostatic hyperplasia.
|
To see the effect of the alpha-adrenergic blocking agent on tissue norepinephrine contents of the prostate, norepinephrine (NE) levels were investigated in patients with symptomatic benign prostatic hyperplasia (BPH). Morphometrical analyses were also performed to detect the differences in tissue composition. Nineteen patients were subdivided into two groups. Patients in Group 1 were given tamsulosin hydrochloride (0.2 mg/day) for at least 4 weeks before transurethral resection of the prostate (TURP), while patients in the control group (Group 2) underwent no previous treatment for BPH before TURP. Tissue NE contents were investigated by high performance liquid chromatography on a chip of the prostate obtained by TURP. These two groups were closely similar in age distribution, prostatic size, results of preoperative symptom scoring and relative proportion of smooth muscle component within the evaluated specimen. In the present series, tissue NE contents in these groups were not statistically different (p = 0.64). Chronic and acute administration of the alpha-1 antagonist did not apparently influence the tissue NE level in patients with BPH.
|
['Adrenergic alpha-1 Receptor Antagonists', 'Adrenergic alpha-Agonists', 'Adrenergic alpha-Antagonists', 'Aged', 'Chromatography, High Pressure Liquid', 'Humans', 'Male', 'Muscle, Smooth', 'Norepinephrine', 'Prostate', 'Prostatic Hyperplasia', 'Sulfonamides', 'Tamsulosin']
| 9,241,547
|
[['D27.505.519.625.050.200.100.100', 'D27.505.696.577.050.200.100.100'], ['D27.505.519.625.050.100.100', 'D27.505.696.577.050.100.100'], ['D27.505.519.625.050.200.100', 'D27.505.696.577.050.200.100'], ['M01.060.116.100'], ['E05.196.181.400.300'], ['B01.050.150.900.649.313.988.400.112.400.400'], ['A02.633.570', 'A10.690.467'], ['D02.033.100.291.502', 'D02.092.063.480', 'D02.092.211.215.746', 'D02.092.311.830', 'D02.455.426.559.389.657.166.175.830'], ['A05.360.444.575', 'A10.336.707'], ['C12.294.565.500'], ['D02.065.884', 'D02.886.590.700'], ['D02.065.884.863', 'D02.886.590.700.863']]
|
['Chemicals and Drugs [D]', 'Named Groups [M]', 'Analytical, Diagnostic and Therapeutic Techniques, and Equipment [E]', 'Organisms [B]', 'Anatomy [A]', 'Diseases [C]']
| 1
| 1
| 1
| 1
| 1
| 0
| 0
| 0
| 0
| 0
| 0
| 1
| 0
| 0
|
Vesicles in haptotaxis with hydrodynamical dissipation.
|
We analyze the problem of vesicle migration in haptotaxis (a motion directed by an adhesion gradient), though most of the reasoning applies to chemotaxis as well as to a variety of driving forces. A brief account has been published on this topic. We present an extensive analysis of this problem and provide a basic discussion of most of the relevant processes of migration. The problem allows for an arbitrary shape evolution which is compatible with the full hydrodynamical flow in the Stokes limit. The problem is solved within the boundary integral formulation based on the Oseen tensor. For the sake of simplicity we confine ourselves to 2D flows in the numerical analysis. There are basically two regimes (i) the tense regime where the vesicle behaves as a "droplet" with an effective contact angle. In that case the migration velocity is given by the Stokes law. (ii) The flask regime where the vesicle has a significant (on the scale of the vesicle size) contact curvature. In that case we obtain a new migration law which substantially differs from the Stokes law. We develop general arguments in order to extract analytical laws of migration. These are in good agreement with the full numerical analysis. Finally we mention several important future issues and open questions.
|
['Adsorption', 'Chemotaxis', 'Computer Simulation', 'Elasticity', 'Energy Transfer', 'Liposomes', 'Membrane Fluidity', 'Membranes, Artificial', 'Models, Chemical', 'Molecular Conformation', 'Motion', 'Particle Size', 'Rheology', 'Shear Strength']
| 15,011,072
|
[['G01.030', 'G02.020'], ['F01.145.113.780.500', 'F01.145.875.439.500.500', 'G04.198.424', 'G07.568.500.590.500', 'G11.427.410.568.850.500'], ['L01.224.160'], ['G01.374.590'], ['G01.154.240', 'G02.111.255', 'G02.216'], ['D25.479.517', 'D26.255.260.517', 'J01.637.051.479.517', 'J01.637.087.500.517'], ['G01.154.500', 'G02.111.550', 'G04.570'], ['D25.479', 'J01.637.051.479', 'J01.637.087.500'], ['E05.599.495'], ['G02.111.570.820'], ['G01.482'], ['G02.712'], ['E05.830', 'H01.671.808'], ['G01.374.820']]
|
['Phenomena and Processes [G]', 'Psychiatry and Psychology [F]', 'Information Science [L]', 'Chemicals and Drugs [D]', 'Technology, Industry, and Agriculture [J]', 'Analytical, Diagnostic and Therapeutic Techniques, and Equipment [E]', 'Disciplines and Occupations [H]']
| 0
| 0
| 0
| 1
| 1
| 1
| 1
| 1
| 0
| 1
| 1
| 0
| 0
| 0
|
Functional reconstruction with an extended supraclavicular fasciocutaneous island flap following ablation of advanced oropharyngeal cancer.
|
The aim of the present study was to evaluate the functional outcome of an extended supraclavicular fasciocutaneous island flap for reconstructing oropharyngeal defects.The 15 patients with oropharyngeal cancers ranged in age from 54 to 73 years. Primary tumor excisions via a transmandibular approach and neck dissection were performed in all patients. An extended supraclavicular fasciocutaneous island flap with a flap skin paddle ranging in size between 4 ? 10 and 6 ? 12 cm was used to reconstruct the defects.All of the flaps survived. Minor flap failure occurred in 2 cases, and 1 of these developed a minor orocutaneous fistula. All patients could eat soft foods and had normal speech. The extended supraclavicular fasciocutaneous island flap is a simple, reliable flap that can be used for functional reconstruction of oropharyngeal defects.
|
['Aged', 'Fascia', 'Female', 'Humans', 'Male', 'Middle Aged', 'Neck Dissection', 'Neoplasm Staging', 'Oropharyngeal Neoplasms', 'Reconstructive Surgical Procedures', 'Recovery of Function', 'Skin Transplantation', 'Surgical Flaps', 'Treatment Outcome']
| 23,147,314
|
[['M01.060.116.100'], ['A02.340', 'A10.165.425'], ['B01.050.150.900.649.313.988.400.112.400.400'], ['M01.060.116.630'], ['E04.446.318', 'E04.580.411'], ['E01.789.625'], ['C04.588.443.665.710.684', 'C07.550.745.671', 'C09.647.710.685', 'C09.775.549.685'], ['E04.680'], ['G16.757'], ['E02.095.147.725.700', 'E04.680.275.850', 'E04.936.580.700'], ['A10.850.710', 'E07.862.710'], ['E01.789.800', 'N04.761.559.590.800', 'N05.715.360.575.575.800']]
|
['Named Groups [M]', 'Anatomy [A]', 'Organisms [B]', 'Analytical, Diagnostic and Therapeutic Techniques, and Equipment [E]', 'Diseases [C]', 'Phenomena and Processes [G]', 'Health Care [N]']
| 1
| 1
| 1
| 0
| 1
| 0
| 1
| 0
| 0
| 0
| 0
| 1
| 1
| 0
|
Total laparoscopic hysterectomy with earlier uterine artery ligation.
|
We compared the feasibility, blood loss, duration of surgery, and complications between patients in whom both uterine arteries were sutured at the beginning of total laparoscopic hysterectomy (TLH) and patients in whom suturing was done after cornual pedicles. Using a prospective study (Canadian Task Force classification II-2) at a dedicated high-volume gynecologic laparoscopy center, a total of 350 women who underwent TLH from January 2005 through January 2007 were assigned into 2 groups. The indications for TLH were predominantly myomas and menorrhagia. In group A, TLH was done by suturing both uterine arteries at the beginning of the procedure. In group B, the uterine arteries were sutured after the cornual pedicles as done conventionally. All the other pedicles were desiccated and cut either with harmonic ultracision or bipolar diathermy. The uterus with cervix was removed either vaginally or by morcellation. The median age of patients in group A was 46 years and in group B was 44 years. Mean uterine size, weight, estimated blood loss, total operating time, need for blood transfusion, and complications were analyzed. In group A the total duration of surgery was 60 minutes (range 20-210). In group B, the total duration of surgery was 70 minutes (range 30-190). In group A, the median total blood loss was 50 mL (range 10-2000). In group B the total blood loss was 60 mL (range 10-2500). The comparison between the 2 groups revealed a statistically significant difference (p <.05, Mann-Whitney test). Need for blood transfusion was less in group A. One patient in group A had secondary hemorrhage 3 weeks later and the vaginal vault was resutured. In group B, 2 patients had blood loss more than 1500 mL (uterus weight > 1000 g) and required 4 units of packed cell transfusion in each. One patient in group B with previous cesarean section had a bladder wall rent and this was sutured laparoscopically using 3-0 delayed absorbable sutures. Uterine artery ligation at the beginning of TLH as done in group A is a technically feasible procedure. It reduces the total blood loss and decreases the time taken for the procedure.
|
['Adult', 'Aged', 'Arteries', 'Blood Loss, Surgical', 'Female', 'Humans', 'Hysterectomy', 'Laparoscopy', 'Ligation', 'Middle Aged', 'Uterus']
| 18,439,511
|
[['M01.060.116'], ['M01.060.116.100'], ['A07.015.114'], ['C23.550.414.300', 'C23.550.505.300'], ['B01.050.150.900.649.313.988.400.112.400.400'], ['E04.950.300.399'], ['E01.370.388.250.520', 'E04.502.250.520'], ['E04.426'], ['M01.060.116.630'], ['A05.360.319.679']]
|
['Named Groups [M]', 'Anatomy [A]', 'Diseases [C]', 'Organisms [B]', 'Analytical, Diagnostic and Therapeutic Techniques, and Equipment [E]']
| 1
| 1
| 1
| 0
| 1
| 0
| 0
| 0
| 0
| 0
| 0
| 1
| 0
| 0
|
Lactoperoxidase activity in milk is correlated with somatic cell count in dairy cows.
|
Lactoperoxidase (LPO) is a milk protein with antimicrobial function. The present study was undertaken to examine the correlation between LPO activity and somatic cell count (SCC) in milk to use LPO activity as an indicator of mastitis. Composite milk of 36 cows and quarter milk of 3 cows were collected once per week from 0 to 300 d postpartum and twice per day for 1 wk, respectively. For the measurement of LPO activity, milk was mixed with tetramethylbenzidine solution and incubated at 37°C for 30 min, followed by the measurement of optical density. When only milk with low SCC (132±12?10(3) cells/mL) was used, a significant decrease in LPO activity was detected in primiparous cows from 0 to 4 mo postpartum. Lactoperoxidase activities of primiparous cows in mo 1, 2, and 3 postpartum were significantly higher than those in multiparous cows. When composite milk was divided based on LPO activity, the SCC was significantly higher in the groups with LPO activity >5 and from 3 to 3.9 U/mL in the second- and fourth-parity cows, respectively, compared with the group with LPO activity <2U/mL. Extremely high SCC were found in the ?fifth-parity cows, even in low-LPO activity groups. In the case of quarter milk, higher LPO activity was associated with increased SCC in all 3 cows. The percentage of quarter milk samples with high SCC (4,062±415?10(3) cells/mL) increased with an increase in the LPO activity. The percentage of quarter milk samples with high SCC was 50.0 to 100% in the milk with LPO activity ?5 U/mL. These results indicate that the correlation of LPO activity to the SCC in bovine milk may point to the potential use of the former as an indicator of SCC.
|
['Animals', 'Cattle', 'Cell Count', 'Female', 'Lactoperoxidase', 'Milk', 'Parity']
| 21,787,923
|
[['B01.050'], ['B01.050.150.900.649.313.500.380.271'], ['E01.370.225.500.195', 'E05.200.500.195', 'E05.242.195', 'G04.140'], ['D08.811.682.732.550'], ['A12.200.455', 'A12.790', 'G07.203.100.700', 'G07.203.300.350.525', 'J02.200.700', 'J02.500.350.525'], ['G08.686.677', 'G08.686.784.769.472', 'N06.850.490.812.600']]
|
['Organisms [B]', 'Analytical, Diagnostic and Therapeutic Techniques, and Equipment [E]', 'Phenomena and Processes [G]', 'Chemicals and Drugs [D]', 'Anatomy [A]', 'Technology, Industry, and Agriculture [J]', 'Health Care [N]']
| 1
| 1
| 0
| 1
| 1
| 0
| 1
| 0
| 0
| 1
| 0
| 0
| 1
| 0
|
A novel beta1,3-N-acetylglucosaminyltransferase involved in invasion of cancer cells as assayed in vitro.
|
Using a two-step screening system for genes involved in tissue invasion [Kataoka et al., Cancer Lett. 163(2) (2001) 213], we identified a cDNA whose expression level was higher in mouse placenta at later stages of gestation and in sublines of cancer cells with low degrees of invasiveness. The deduced amino acid sequence showed relatively high similarity with beta1,3-N-acetylglucosaminyltransferase2 approximately 5 (beta3GnT2 approximately 5), and the protein was therefore named beta3GnT7. A possible human ortholog was identified and its chromosomal locus was determined to be 2q37.1. In the mouse, beta3GnT7 was most strongly expressed in the placenta and colon. Moderate amounts of mRNA were detected in the lung, stomach, small intestine, and kidney. The expression of beta3GnT7 was very weak in the cerebrum, cerebellum, heart, and testis. Transfection of the antisense oligonucleotide significantly enhanced the motility of a lung cancer cell line (KLN205-MUC1) in a monolayer compared to the controls. Furthermore, the antisense oligonucleotide increased the number of cells that invaded the matrix-coated membrane in an in vitro invasion model. These results indicate that beta3GnT7 may play a role in preventing cells from migrating out of the original tissues and invading surrounding tissues.
|
['Amino Acid Sequence', 'Animals', 'Base Sequence', 'Blotting, Northern', 'Cell Movement', 'DNA, Complementary', 'Gastric Mucosa', 'Intestine, Small', 'Kidney', 'Lung', 'Mice', 'Molecular Sequence Data', 'N-Acetylglucosaminyltransferases', 'Neoplasm Invasiveness', 'Neoplasms', 'Phylogeny', 'RNA, Messenger', 'Sequence Homology, Amino Acid', 'Time Factors', 'Tissue Distribution', 'Tumor Cells, Cultured']
| 12,061,784
|
[['G02.111.570.060', 'L01.453.245.667.060'], ['B01.050'], ['G02.111.570.080', 'G05.360.080', 'L01.453.245.667.080'], ['E05.196.401.095', 'E05.301.300.074', 'E05.601.100'], ['G04.198', 'G07.568.500.180'], ['D13.444.308.497.220', 'D13.444.600.223.500', 'D27.720.470.530.600.223.260'], ['A03.556.875.875.440', 'A10.615.550.291'], ['A03.556.124.684'], ['A05.810.453'], ['A04.411'], ['B01.050.150.900.649.313.992.635.505.500'], ['L01.453.245.667'], ['D08.811.913.400.100.250'], ['C04.697.645', 'C23.550.727.645'], ['C04'], ['G05.697', 'G16.075.605', 'L01.100.697'], ['D13.444.735.544'], ['G02.111.810.200', 'G05.810.200'], ['G01.910.857'], ['G03.787.917', 'G07.690.725.949'], ['A11.251.860']]
|
['Phenomena and Processes [G]', 'Information Science [L]', 'Organisms [B]', 'Analytical, Diagnostic and Therapeutic Techniques, and Equipment [E]', 'Chemicals and Drugs [D]', 'Anatomy [A]', 'Diseases [C]']
| 1
| 1
| 1
| 1
| 1
| 0
| 1
| 0
| 0
| 0
| 1
| 0
| 0
| 0
|
[Zika virus : a review].
|
Since early 2015, the Zika virus epidemic has spread rapidly through South America and the Caribbean and the first cases of local transmission have just been reported in Florida. Maternal infection during pregnancy can cause serious birth defects. Pregnant women and their partners should avoid travelling to areas of Zika epidemic.
|
['Congenital Abnormalities', 'Female', 'Humans', 'Pregnancy', 'Pregnancy Complications, Infectious', 'Travel', 'Zika Virus Infection']
| 28,692,228
|
[['C16.131'], ['B01.050.150.900.649.313.988.400.112.400.400'], ['G08.686.784.769'], ['C01.674', 'C13.703.700'], ['I03.883'], ['C01.920.500.990', 'C01.925.081.990', 'C01.925.782.350.250.990']]
|
['Diseases [C]', 'Organisms [B]', 'Phenomena and Processes [G]', 'Anthropology, Education, Sociology, and Social Phenomena [I]']
| 0
| 1
| 1
| 0
| 0
| 0
| 1
| 0
| 1
| 0
| 0
| 0
| 0
| 0
|
Newborn care practices in Pemba Island (Tanzania) and their implications for newborn health and survival.
|
Newborn mortality accounts for about one-third of deaths in children under five. Neglecting this problem may undermine the fourth Millennium Development Goal of reducing child mortality by two-thirds by 2015. This study was conducted in Tanzania, where an estimated 32/1000 infants die within the first 28 days. Our objective was to describe newborn care practices and their potential impact on newborn health. We interviewed two purposive samples of mothers from Pemba Island, a predominantly Muslim community of Arab-African ethnicity, and one of Tanzania's poorest. The first sample of mothers (n = 12) provided descriptive data; the second (n = 26) reported actual practice. We identified cultural beliefs and practices that promote early initiation of breastfeeding and bonding, including 'post-partum seclusion'. We also identified practices which are potentially harmful for newborn health, such as bathing newborns immediately after delivery, a practice motivated by concerns about 'ritual pollution', which may lead to newborn hypothermia and premature breast milk supplementation (e.g. with water and other fluids) which may expose newborns to pathogens. Some traditional practices to treat illness, such as exposing sick newborns to medicinal smoke from burning herbs, are also of concern. It is unclear whether the practice of massaging newborns with coconut oil is harmful or beneficial. Interventions to reduce neonatal mortality need to identify and address the cultural rationales that underlie negative practices, as well as reinforce and protect the beliefs that support positive practices. The results suggest the need to improve use of health services through improving health worker communication skills and social management of patients, as well as by lowering healthcare costs.
|
['Adolescent', 'Adult', 'Attitude to Health', 'Breast Feeding', 'Cultural Characteristics', 'Female', 'Health Knowledge, Attitudes, Practice', 'Humans', 'Infant Care', 'Infant Mortality', 'Infant, Newborn', 'Male', 'Mothers', 'Tanzania']
| 18,582,353
|
[['M01.060.057'], ['M01.060.116'], ['F01.100.150', 'N05.300.150'], ['F01.145.407.199', 'G07.203.650.195', 'G07.203.650.220.500.500', 'G07.203.650.353.199'], ['I01.076.201.450.324', 'I01.880.853.100.329'], ['F01.100.150.500', 'N05.300.150.410'], ['B01.050.150.900.649.313.988.400.112.400.400'], ['N02.421.088.120'], ['E05.318.308.985.550.475', 'N01.224.935.698.489', 'N06.850.505.400.975.550.475', 'N06.850.520.308.985.550.475'], ['M01.060.703.520'], ['F01.829.263.500.320.200', 'I01.880.853.150.500.340.270', 'M01.620.630'], ['Z01.058.290.120.840']]
|
['Named Groups [M]', 'Psychiatry and Psychology [F]', 'Health Care [N]', 'Phenomena and Processes [G]', 'Anthropology, Education, Sociology, and Social Phenomena [I]', 'Organisms [B]', 'Analytical, Diagnostic and Therapeutic Techniques, and Equipment [E]', 'Geographicals [Z]']
| 0
| 1
| 0
| 0
| 1
| 1
| 1
| 0
| 1
| 0
| 0
| 1
| 1
| 1
|
Only for "purely scientific" institutions: the Medical Library Association's Exchange, 1898-1950s.
|
OBJECTIVE: Centralized exchanges of scientific materials existed by the late nineteenth century, but they did not include medical publications. North American medical leaders therefore formed an association of institutions to run their own exchange: the Medical Library Association (MLA). After providing background to the exchange concept and the importance of institutional members for MLA, this article examines archival MLA correspondence to consider the role of its Exchange in the association's professional development before the 1950s.RESULTS: MLA's membership policy admitted only libraries open to the medical profession with a large number of volumes. But the correspondence of the MLA Executive Committee reveals that the committee constantly adjusted the definition of library membership: personal, public, sectarian, commercial, allied science, and the then-termed "colored" medical school libraries all were denied membership.CONCLUSION: Study of these decisions, using commercial and sectarian libraries as a focus, uncovers the primary justification for membership exclusions: a goal of operating a scientific exchange. Also, it shows that in this way, MLA shadowed policies and actions of the American Medical Association. Finally, the study suggests that the medical profession enforced its policies of exclusion through MLA, despite a proclaimed altruistic sharing of medical literature.
|
['American Medical Association', 'Drug Industry', 'History, 19th Century', 'History, 20th Century', 'Libraries, Medical', 'Societies', 'United States']
| 21,464,849
|
[['N03.540.828.589.274'], ['J01.576.655.750'], ['K01.400.504.937'], ['K01.400.504.968'], ['J03.400.596.831.937', 'L01.346.596.719.875'], ['N03.540.828'], ['Z01.107.567.875']]
|
['Health Care [N]', 'Technology, Industry, and Agriculture [J]', 'Humanities [K]', 'Information Science [L]', 'Geographicals [Z]']
| 0
| 0
| 0
| 0
| 0
| 0
| 0
| 0
| 0
| 1
| 1
| 0
| 1
| 1
|
Effect of finish line on marginal fit of sintered gold copings.
|
The aim of this study was to evaluate the vertical marginal gap of sintered gold copings and metal-ceramic crowns with different finish line preparations: a beveled round shoulder (BRS) and a beveled long chamfer (BLC), testing the null hypotheses that there are no differences in marginal gap regardless of finish line and phase of restoration (coping or crown). Stainless steel master models were fabricated to simulate tooth preparation for metal-ceramic crowns with different finish lines (BRS and BLC). Ten dies were obtained from each model. Preparations were coated with 2 layers of spacer to 1 mm from the margin. Sintercast gold copings were prepared, sintered and adjusted to the dies. The copings (n=10) were placed onto the master model and the marginal gap was measured in 24 equidistant points using optical microscopy (X230). An opaque and two body ceramic layers were subsequently applied to the copings and the same measuring procedure was performed for the crowns. The data were analyzed statistically using paired and unpaired Student's t-test (á=0.05). Mean marginal gap values (µm) for the copings and crowns were, respectively: 113.6 and 117.1 for the BRS; and 58.2 and 74.3 for the BLC preparation. Significantly greater marginal gaps (p=0.0307) were found for restorations with BRS than with BLC finish line, which also showed statistically significant differences in the gap size between coping and crown (p=0.001). In conclusion, marginal gap is influenced by ceramic application on copings fabricated on BLC preparation, and greater marginal gaps were found for restorations with BRS finish line, rejecting the experimental null hypotheses.
|
['Crowns', 'Dental Materials', 'Dental Prosthesis Design', 'Gold']
| 24,173,248
|
[['E06.780.346.250', 'E07.695.190.088'], ['D25.339', 'D27.720.102.339', 'J01.637.051.339'], ['E06.780.346.625', 'E06.912.145'], ['D01.268.556.322', 'D01.268.956.186', 'D01.552.544.322']]
|
['Analytical, Diagnostic and Therapeutic Techniques, and Equipment [E]', 'Chemicals and Drugs [D]', 'Technology, Industry, and Agriculture [J]']
| 0
| 0
| 0
| 1
| 1
| 0
| 0
| 0
| 0
| 1
| 0
| 0
| 0
| 0
|
[Detection of viruses in water of the Baltic Sea (author's transl)].
|
Virological examination of water of the Baltic Sea in the neighbourhood of a sewage outfall was done. By means of an apparatus for concentrating viruses in water, it was possible to detect enteroviruses in four of eleven samples, and in general in those moments, when conditions were fulfilled by a certain windway. The amount of viruses varied from 5 to 126 pfu in 10 liters, the ratio of virus to E. coli titer from 1:11 111 to 1:100 000. Factors influencing the decrease of virus titer in seawater were briefly discussed.
|
['Enterovirus', 'Escherichia coli', 'Germany, West', 'Seawater', 'Sewage', 'Water Microbiology', 'Water Pollution']
| 199,000
|
[['B04.820.578.750.284'], ['B03.440.450.425.325.300', 'B03.660.250.150.180.100'], ['Z01.586.350'], ['G16.500.275.725.500'], ['D20.944.932.500'], ['H01.158.273.540.274.777', 'N06.850.425.450'], ['N06.850.460.790']]
|
['Organisms [B]', 'Geographicals [Z]', 'Phenomena and Processes [G]', 'Chemicals and Drugs [D]', 'Disciplines and Occupations [H]', 'Health Care [N]']
| 0
| 1
| 0
| 1
| 0
| 0
| 1
| 1
| 0
| 0
| 0
| 0
| 1
| 1
|
Multi-modality therapeutics with potent anti-tumor effects: photochemical internalization enhances delivery of the fusion toxin scFvMEL/rGel.
|
BACKGROUND: There is a need for drug delivery systems (DDS) that can enhance cytosolic delivery of anti-cancer drugs trapped in the endo-lysosomal compartments. Exposure of cells to specific photosensitizers followed by light exposure (photochemical internalization, PCI) results in transfer of agents from the endocytic compartment into the cytosol.METHODOLOGY AND PRINCIPAL FINDINGS: The recombinant single-chain fusion construct scFvMEL/rGel is composed of an antibody targeting the progenitor marker HMW-MAA/NG2/MGP/gp240 and the highly effective toxin gelonin (rGel). Here we demonstrate enhanced tumor cell selectivity, cytosolic delivery and anti-tumor activity by applying PCI of scFvMEL/rGel. PCI performed by light activation of cells co-incubated with scFvMEL/rGel and the endo-lysosomal targeting photosensitizers AlPcS(2a) or TPPS(2a) resulted in enhanced cytotoxic effects against antigen-positive cell lines, while no differences in cytotoxicity between the scFvMEL/rGel and rGel were observed in antigen-negative cells. Mice bearing well-developed melanoma (A-375) xenografts (50-100 mm(3)) were treated with PCI of scFvMEL/rGel. By 30 days after injection, approximately 100% of mice in the control groups had tumors>800 mm(3). In contrast, by day 40, 50% of mice in the PCI of scFvMEL/rGel combination group had tumors<800 mm(3) with no increase in tumor size up to 110 days. PCI of scFvMEL/rGel resulted in a synergistic effect (p<0.05) and complete regression (CR) in 33% of tumor-bearing mice (n = 12).CONCLUSIONS/SIGNIFICANCE: This is a unique demonstration that a non-invasive multi-modality approach combining a recombinant, targeted therapeutic such as scFvMEL/rGel and PCI act in concert to provide potent in vivo efficacy without sacrificing selectivity or enhancing toxicity. The present DDS warrants further evaluation of its clinical potential.
|
['Animals', 'Antineoplastic Agents', 'Cell Line, Tumor', 'Drug Delivery Systems', 'Female', 'Humans', 'Immunoglobulin Fragments', 'Immunotoxins', 'Mice', 'Mice, Inbred BALB C', 'Photochemistry', 'Recombinant Fusion Proteins']
| 19,690,617
|
[['B01.050'], ['D27.505.954.248'], ['A11.251.210.190', 'A11.251.860.180'], ['E02.319.300'], ['B01.050.150.900.649.313.988.400.112.400.400'], ['D12.644.541.500', 'D12.776.124.486.485.680', 'D12.776.124.790.651.680', 'D12.776.377.715.548.680'], ['D12.776.124.790.651.114.580.450', 'D12.776.377.715.548.114.580.450', 'D27.888.569.257.500'], ['B01.050.150.900.649.313.992.635.505.500'], ['B01.050.050.199.520.520.338', 'B01.050.150.900.649.313.992.635.505.500.400.338'], ['H01.181.529.711'], ['D12.776.828.300']]
|
['Organisms [B]', 'Chemicals and Drugs [D]', 'Anatomy [A]', 'Analytical, Diagnostic and Therapeutic Techniques, and Equipment [E]', 'Disciplines and Occupations [H]']
| 1
| 1
| 0
| 1
| 1
| 0
| 0
| 1
| 0
| 0
| 0
| 0
| 0
| 0
|
Determination of viral capsid elastic properties from equilibrium thermal fluctuations.
|
We apply two-dimensional elasticity theory to viral capsids to develop a framework for calculating elastic properties of viruses from equilibrium thermal fluctuations of the capsid surface in molecular dynamics and elastic network model trajectories. We show that the magnitudes of the long wavelength modes of motion available in a simulation with all atomic degrees of freedom are recapitulated by an elastic network model. For the mode spectra to match, the elastic network model must be scaled appropriately by a factor which can be determined from an icosahedrally constrained all-atom simulation. With this method we calculate the two-dimensional Young's modulus Y, bending modulus ê, and F?ppl-von K?rm?n number ã, for the T=1 mutant of the Sesbania mosaic virus. The values determined are in the range of previous theoretical estimates.
|
['Algorithms', 'Capsid', 'Capsid Proteins', 'Computer Simulation', 'Elasticity', 'Molecular Dynamics Simulation', 'Motion', 'Temperature', 'Viruses']
| 21,635,128
|
[['G17.035', 'L01.224.050'], ['A21.249.500.250'], ['D12.776.964.970.600.550'], ['L01.224.160'], ['G01.374.590'], ['E05.599.595.500', 'G02.111.570.895', 'L01.224.160.500'], ['G01.482'], ['G01.906.595', 'G16.500.275.063.725.710', 'G16.500.750.775.710', 'N06.230.150.450', 'N06.230.300.100.725.710'], ['B04']]
|
['Phenomena and Processes [G]', 'Information Science [L]', 'Anatomy [A]', 'Chemicals and Drugs [D]', 'Analytical, Diagnostic and Therapeutic Techniques, and Equipment [E]', 'Health Care [N]', 'Organisms [B]']
| 1
| 1
| 0
| 1
| 1
| 0
| 1
| 0
| 0
| 0
| 1
| 0
| 1
| 0
|
Acute effects of endothelins on endogenous adrenomedullin system in the rat heart: Immunocytochemical and autoradiographic studies.
|
Many lines of evidence indicate that adrenomedullin (AM) through its coronary vasodilatory and inotropic effects, exerts a major cardiac protective action. Conversely, endothelins (ETs) exert a cardiac detrimental action, which seems to be mainly mediated by the ETA receptor, whose activation promotes coronary constriction and decreases cardiac blood flow. Hence, we have investigated by immunocytochemistry (ICC) and autoradiography the acute effects of ET-1 on endogenous AM system of adult rat heart. Isolated hearts were perfused for 20 min, according to the Langendorff technique, with 2x10(-9) M ET-1[1-21] or ET-1[1-31], which are mixed ETA/ETB and selective ETA receptor agonists, respectively. ICC demonstrated AM-immunoreactivity (IR) in cardiomyocytes, endocardium and especially in the wall of coronary vessels. Quantitative densitometry showed that ET-1[1-31], but not ET1[1-21], significantly decreased AM-IR in coronary vessels, thereby suggesting that ET-1 elicits AM release in the heart through the activation of ETA receptors. Autoradiography demonstrated [125I]AM-binding sites in cardiomyocytes and especially in the wall of coronary venules, and treatment with both ET-1s did not apparently affect them. This location af AM receptors suggests that AM raises cardiac blood flow by evoking coronary artery dilation indirectly, probably via its stimulating effect on NO production, and by decreasing postcapillary resistance via cardiac vein dilation. Collectively, our findings indicate that important functional interrelationships occur between ET and AM systems in the rat heart, where ETs may at least partly hamper their own ETA receptor-mediated decrease in blood flow by increasing the local release of endogenous AM.
|
['Adrenomedullin', 'Animals', 'Autoradiography', 'Coronary Vessels', 'Endothelins', 'Heart', 'Immunohistochemistry', 'Male', 'Myocardium', 'Peptides', 'Rats', 'Rats, Sprague-Dawley']
| 15,067,368
|
[['D06.472.699.077', 'D12.644.548.017'], ['B01.050'], ['E01.370.225.750.132', 'E05.200.750.132', 'E05.799.256'], ['A07.015.114.269', 'A07.015.908.194'], ['D12.644.276.400', 'D12.776.467.400', 'D23.529.400'], ['A07.541'], ['E01.370.225.500.607.512', 'E01.370.225.750.551.512', 'E05.200.500.607.512', 'E05.200.750.551.512', 'E05.478.583', 'H01.158.100.656.234.512', 'H01.158.201.344.512', 'H01.158.201.486.512', 'H01.181.122.573.512', 'H01.181.122.605.512'], ['A02.633.580', 'A07.541.704', 'A10.690.552.750'], ['D12.644'], ['B01.050.150.900.649.313.992.635.505.700'], ['B01.050.150.900.649.313.992.635.505.700.750']]
|
['Chemicals and Drugs [D]', 'Organisms [B]', 'Analytical, Diagnostic and Therapeutic Techniques, and Equipment [E]', 'Anatomy [A]', 'Disciplines and Occupations [H]']
| 1
| 1
| 0
| 1
| 1
| 0
| 0
| 1
| 0
| 0
| 0
| 0
| 0
| 0
|
Fellow eye comparison of corneal thickness and curvature in descemet membrane endothelial keratoplasty and descemet stripping automated endothelial keratoplasty.
|
PURPOSE: To compare posterior corneal curvature in the fellow eye of the same patients after Descemet membrane endothelial keratoplasty (DMEK) and Descemet stripping automated endothelial keratoplasty (DSAEK).METHODS: This retrospective, case series comparative study included consecutive patients who underwent DSAEK in one eye and DMEK in the fellow eye. Each eye underwent corneal evaluation with Pentacam HR (Oculus, Wetzlar, Germany). Postoperative corneal curvature, corneal thickness, and visual acuity were assessed.RESULTS: Twenty eyes of 10 patients (5 women and 5 men) aged 72.5 ± 13.5 (range, 42-87) years were included. No significant differences were observed between front flat K's (43.01 ± 1.6 vs. 43.5 ± 0.9, P = 0.27) and front steep K's (44.17 ± 1.5 vs. 44.52 ± 0.7, P = 0.39) in DMEK vs. DSAEK eyes, accordingly. Posterior curvature was statistically significantly flatter in DMEK compared with DSAEK eyes; back flat K's (-6.30 ± 0.2 vs. -6.84 ± 0.6, P = 0.012), back steep K's (-6.64 ± 0.1 vs. -7.2 ± 0.3, P = 0.03), and back Km (-6.45 ± 0.1 vs. -6.99 ± 0.4, P = 0.005), accordingly. Corneas in DMEK eyes were significantly thinner than in DSAEK eyes (541.0 ± 61 vs. 627.9 ± 70 ìm, P = 0.007).CONCLUSIONS: Eyes that underwent DSAEK surgery have thicker corneas with steeper posterior corneal curvature than fellow eyes that underwent DMEK. This difference may explain the hyperopic shift commonly observed after DSAEK and should be considered when choosing an intraocular lens for cataract surgery.
|
['Adult', 'Aged', 'Aged, 80 and over', 'Cornea', 'Descemet Membrane', 'Descemet Stripping Endothelial Keratoplasty', 'Endothelium, Corneal', 'Female', "Fuchs' Endothelial Dystrophy", 'Humans', 'Male', 'Middle Aged', 'Organ Preservation', 'Organ Size', 'Retrospective Studies', 'Tissue Donors', 'Visual Acuity']
| 24,699,562
|
[['M01.060.116'], ['M01.060.116.100'], ['M01.060.116.100.080'], ['A09.371.060.217'], ['A09.371.060.217.271', 'A10.615.179.437'], ['E02.095.147.725.262', 'E04.540.825.374.112', 'E04.936.580.262'], ['A09.371.060.067.318', 'A09.371.060.217.318', 'A10.272.491.318'], ['C11.204.236.438', 'C11.270.162.438', 'C16.320.290.162.410'], ['B01.050.150.900.649.313.988.400.112.400.400'], ['M01.060.116.630'], ['E02.792.833.660', 'E05.760.833.660'], ['E01.370.600.115.100.660', 'E05.041.124.715', 'G07.100.100.660', 'G07.345.249.690'], ['E05.318.372.500.500.500', 'E05.318.372.500.750.750', 'N05.715.360.330.500.500.500', 'N05.715.360.330.500.750.825', 'N06.850.520.450.500.500.500', 'N06.850.520.450.500.750.825'], ['M01.898'], ['E01.370.380.850.950', 'F02.463.593.932.901', 'G14.940']]
|
['Named Groups [M]', 'Anatomy [A]', 'Analytical, Diagnostic and Therapeutic Techniques, and Equipment [E]', 'Diseases [C]', 'Organisms [B]', 'Phenomena and Processes [G]', 'Health Care [N]', 'Psychiatry and Psychology [F]']
| 1
| 1
| 1
| 0
| 1
| 1
| 1
| 0
| 0
| 0
| 0
| 1
| 1
| 0
|
Bender scores and the horse as a distinct item on object assembly of the WISC.
|
This exploratory study investigated the relationship between two measures of perceptual-motor problems. Ratios derived from the Object Assembly subtest of the WISC with errors greater than 1 SD on the Bender test using Koppitz' scoring system were compared. The sample of 66 white middle-class children was 6 to 11 yr. old. The particular ratio studied was statistically significantly associated with the Bender, whereas ratios of other Object Assembly items were not. The Horse ratio was also significantly associated with the presence of learning problems shown in children's files.
|
['Bender-Gestalt Test', 'Brain Damage, Chronic', 'Child', 'Female', 'Humans', 'Learning Disabilities', 'Male', 'Neurocognitive Disorders', 'Psychomotor Performance', 'Wechsler Scales']
| 6,493,922
|
[['F04.711.513.180', 'F04.711.647.138'], ['C10.228.140.140'], ['M01.060.406'], ['B01.050.150.900.649.313.988.400.112.400.400'], ['C10.597.606.150.550', 'C23.888.592.604.150.550', 'F03.625.562'], ['F03.615'], ['F02.808', 'G11.427.700', 'G11.561.660'], ['F04.711.141.493.822']]
|
['Psychiatry and Psychology [F]', 'Diseases [C]', 'Named Groups [M]', 'Organisms [B]', 'Phenomena and Processes [G]']
| 0
| 1
| 1
| 0
| 0
| 1
| 1
| 0
| 0
| 0
| 0
| 1
| 0
| 0
|
Systematic Error Removal Using Random Forest for Normalizing Large-Scale Untargeted Lipidomics Data.
|
Large-scale untargeted lipidomics experiments involve the measurement of hundreds to thousands of samples. Such data sets are usually acquired on one instrument over days or weeks of analysis time. Such extensive data acquisition processes introduce a variety of systematic errors, including batch differences, longitudinal drifts, or even instrument-to-instrument variation. Technical data variance can obscure the true biological signal and hinder biological discoveries. To combat this issue, we present a novel normalization approach based on using quality control pool samples (QC). This method is called systematic error removal using random forest (SERRF) for eliminating the unwanted systematic variations in large sample sets. We compared SERRF with 15 other commonly used normalization methods using six lipidomics data sets from three large cohort studies (832, 1162, and 2696 samples). SERRF reduced the average technical errors for these data sets to 5% relative standard deviation. We conclude that SERRF outperforms other existing methods and can significantly reduce the unwanted systematic variation, revealing biological variance of interest.
|
['Datasets as Topic', 'Lipidomics', 'Quality Control', 'Scientific Experimental Error']
| 30,758,187
|
[['E05.318.308.056', 'L01.313.500.750.300.188.400.500', 'L01.399.250.224', 'L01.470.750.750.431', 'N05.715.360.300.224', 'N06.850.520.308.056'], ['H01.158.201.586.500', 'H01.158.273.180.599.500', 'H01.181.122.638.500'], ['J01.897.608'], ['E05.318.370.725.250.500', 'N05.715.360.300.202.500']]
|
['Analytical, Diagnostic and Therapeutic Techniques, and Equipment [E]', 'Information Science [L]', 'Health Care [N]', 'Disciplines and Occupations [H]', 'Technology, Industry, and Agriculture [J]']
| 0
| 0
| 0
| 0
| 1
| 0
| 0
| 1
| 0
| 1
| 1
| 0
| 1
| 0
|
Dephosphorylation of MnDPDP and related compounds by acid and alkaline phosphatase.
|
The enzymatic dephosphorylation of the magnetic resonance imaging contrast agent Teslascan was studied in in vitro experiments with acid phosphatase (prostatic, from human semen) and alkaline phosphatase (from human placenta). The active component, MnDPDP (manganese (II)-N,N'-dipyridoxylethylenediamine-N,N'-diacetate-5,5'-bis(phosphate), was dephosphorylated by both enzymes to the monophosphate MnDPMP and the totally dephosphorylated compound MnPLED. The corresponding zinc compound, ZnDPDP (which is a result of in vivo metabolism), was also dephosphorylated by both enzymes to ZnDPMP and ZnPLED. In separate experiments, both enzymes dephosphorylated MnDPMP and ZnDPMP. With the same amount of enzyme units, alkaline phosphatase was almost four times more active than acid phosphatase in dephosphorylating MnDPDP and ZnDPDP with only minor differences whether the substrate contained Mn or Zn. A similar difference in enzymatic activity was seen with the monophosphates, MnDPMP and ZnDPMP. This, taken together with the approximately 50 times higher activity of alkaline phosphatase than acid phosphatase in serum shows that alkaline phosphatase is responsible for most of the dephosphorylation of MnDPDP and its metabolites in vivo.
|
['Acid Phosphatase', 'Alkaline Phosphatase', 'Contrast Media', 'Edetic Acid', 'Phosphorylation', 'Pyridoxal Phosphate']
| 11,377,042
|
[['D08.811.277.352.650.025'], ['D08.811.277.352.650.035'], ['D27.505.259.500', 'D27.720.259'], ['D02.092.782.258.368.250', 'D02.241.081.018.253'], ['G02.111.665', 'G02.607.780', 'G03.796'], ['D03.383.725.676.925.500.500', 'D08.211.740']]
|
['Chemicals and Drugs [D]', 'Phenomena and Processes [G]']
| 0
| 0
| 0
| 1
| 0
| 0
| 1
| 0
| 0
| 0
| 0
| 0
| 0
| 0
|
Choice of level in lower extremity amputation--nationwide survey.
|
This survey analyses the levels of all major lower limb amputations in Denmark performed in 1980. During that year a total of 2,404 amputations were carried out on 2,177 patients.
|
['Adult', 'Aged', 'Amputation', 'Denmark', 'Diabetes Mellitus', 'Female', 'Humans', 'Knee', 'Leg', 'Male', 'Middle Aged', 'Venous Insufficiency']
| 6,622,232
|
[['M01.060.116'], ['M01.060.116.100'], ['E04.555.080'], ['Z01.542.816.124'], ['C18.452.394.750', 'C19.246'], ['B01.050.150.900.649.313.988.400.112.400.400'], ['A01.378.610.450'], ['A01.378.610.500'], ['M01.060.116.630'], ['C14.907.952']]
|
['Named Groups [M]', 'Analytical, Diagnostic and Therapeutic Techniques, and Equipment [E]', 'Geographicals [Z]', 'Diseases [C]', 'Organisms [B]', 'Anatomy [A]']
| 1
| 1
| 1
| 0
| 1
| 0
| 0
| 0
| 0
| 0
| 0
| 1
| 0
| 1
|
Familial osteosclerosis with abnormalities of the nervous system and meninges.
|
A mother and daughter with osteosclerotic dysplasia are described. The daughter had generalized osteosclerosis, flattening of the angles of the mandibles, high-arched palate, mandibular and facial bone hypoplasia, a large sella turcica, and spacious foramen magnum, platybasia, basilar impression, widened spinal cord with enlarged intervertebral foramina, and scalloping of the posterior surfaces of the vertebral bodies. Radiographic contrast studies and operative intervention revealed multiple thoracic and lumbar meningoceles and an "empty" sella, as well as evidence of maldevelopment of the spinal cord, cerebellum, and cerebral cortex. Many of these skeletal features were noted to a lesser degree in the asymptomatic mother.
|
['Abnormalities, Multiple', 'Adolescent', 'Bone and Bones', 'Diagnosis, Differential', 'Female', 'Humans', 'Mandibulofacial Dysostosis', 'Meninges', 'Nervous System Malformations', 'Osteosclerosis', 'Syndrome']
| 830,893
|
[['C16.131.077'], ['M01.060.057'], ['A02.835.232', 'A10.165.265'], ['E01.171'], ['B01.050.150.900.649.313.988.400.112.400.400'], ['C05.116.099.370.231.576', 'C05.660.207.231.576', 'C11.270.147.750', 'C16.131.621.207.231.576'], ['A08.186.566'], ['C10.500', 'C16.131.666'], ['C05.116.099.708.702'], ['C23.550.288.500']]
|
['Diseases [C]', 'Named Groups [M]', 'Anatomy [A]', 'Analytical, Diagnostic and Therapeutic Techniques, and Equipment [E]', 'Organisms [B]']
| 1
| 1
| 1
| 0
| 1
| 0
| 0
| 0
| 0
| 0
| 0
| 1
| 0
| 0
|
A randomized open-label study of gabapentin and lamotrigine in adults with learning disability and resistant epilepsy.
|
The aim of this study was to evaluate the efficacy and safety of gabapentin in patients with learning disabilities and resistant epilepsy, comparing the effects of gabapentin with lamotrigine on efficacy, behaviour and mood. An open-label, randomized, parallel group, multicentre add-on study comparing gabapentin with lamotrigine in 109 patients with drug-resistant localization-related epilepsy and learning disabilities was conducted: 39 patients were randomized to gabapentin and 44 to lamotrigine. The study population had a range of learning disabilities and severe partial epilepsy. The percentage of patients achieving a greater than or equal to 50% reduction in seizure frequency on gabapentin was 50%, (mean reduction in seizures was 51%). Compared to 48.6% of lamotrigine patients, no statistically significant treatment differences could be identified. The safety profile of both drugs was consistent with that seen in previous clinical trials. Carer-rated visual analogue scales detected significant improvements (P< 0.05) for the gabapentin-treated patients in seizure severity, attention, general health and sleeping pattern, while for lamotrigine seizure severity improved significantly. For learning disabled patients with resistant epilepsy, gabapentin and lamotrigine provide safe and effective treatment, with positive benefits on behaviour.
|
['Acetates', 'Adolescent', 'Adult', 'Amines', 'Anticonvulsants', 'Cyclohexanecarboxylic Acids', 'Drug Administration Schedule', 'Epilepsy', 'Female', 'Gabapentin', 'Humans', 'Intellectual Disability', 'Lamotrigine', 'Male', 'Middle Aged', 'Severity of Illness Index', 'Treatment Outcome', 'Triazines', 'gamma-Aminobutyric Acid']
| 11,407,953
|
[['D02.241.081.018', 'D10.251.400.045'], ['M01.060.057'], ['M01.060.116'], ['D02.092'], ['D27.505.954.427.080'], ['D02.241.223.268', 'D02.455.426.392.368.367.218'], ['E02.319.283'], ['C10.228.140.490'], ['D02.092.521', 'D02.241.081.114.500.350.300', 'D02.241.223.268.469', 'D02.455.426.392.368.367.218.500', 'D12.125.190.350.225'], ['B01.050.150.900.649.313.988.400.112.400.400'], ['C10.597.606.360', 'C23.888.592.604.646', 'F01.700.687', 'F03.625.539'], ['D03.383.931.480'], ['M01.060.116.630'], ['E05.318.308.980.438.475.456.500', 'N05.715.360.300.800.438.375.364.500', 'N06.850.520.308.980.438.475.364.500'], ['E01.789.800', 'N04.761.559.590.800', 'N05.715.360.575.575.800'], ['D03.383.931'], ['D02.241.081.114.500.350', 'D12.125.190.350']]
|
['Chemicals and Drugs [D]', 'Named Groups [M]', 'Analytical, Diagnostic and Therapeutic Techniques, and Equipment [E]', 'Diseases [C]', 'Organisms [B]', 'Psychiatry and Psychology [F]', 'Health Care [N]']
| 0
| 1
| 1
| 1
| 1
| 1
| 0
| 0
| 0
| 0
| 0
| 1
| 1
| 0
|
Removal of atrazine, lindane and diazinone from water by organo-zeolites.
|
Systematic adsorption tests were carried out to determine the efficiency of organo-zeolite (OZ) for removal of atrazine, lindane and diazinone from water. The hydrophobic character of OZ-pesticide interactions was confirmed by measuring the amount of pesticides sorbed on zeolite samples modified with 25, 50, 75 and 150 mmol of stearyldimethylbenzylammoniumchloride (SDBAC)/kg of zeolite. The effects of adsorbent particle size, solid content in the suspension and the initial pesticide concentration in the solutions were also investigated. For effective adsorption of diazinone onto an OZ, it is necessary for the SDBAC/diazinon ratio to be higher than 25. The adsorption capacities, calculated by fitting the experimental data to the Langmuir-Freundlich equation, were 2.0 micromol/g (atrazine), 4.4 micromol/g (diazinone) and 3.4 micromol/g (lindan). At lower initial concentrations of pesticide solution, a linear dependence existed between the amount adsorbed and the equilibrium concentration of pesticide. Column experiments showed that at volumetric flow of 6 cm3/ min, the breakthrough points (at C/C0 = 0.1) were 560 bed volume (BV) for lindane and 620 for diazinone.
|
['Adsorption', 'Atrazine', 'Diazinon', 'Herbicides', 'Hexachlorocyclohexane', 'Insecticides', 'Molecular Structure', 'Water Purification', 'Zeolites']
| 16,460,782
|
[['G01.030', 'G02.020'], ['D03.383.931.247'], ['D02.705.400.625.200', 'D02.705.539.345.200', 'D02.886.300.692.200'], ['D27.720.031.700.366', 'D27.888.723.366'], ['D02.455.526.439.600'], ['D27.720.031.700.491', 'D27.888.723.491'], ['G02.111.570', 'G02.466'], ['N06.850.780.200.800.800.900.900', 'N06.850.860.510.900.900'], ['D01.056.050.075.975', 'D01.578.725.025.975', 'D01.650.550.050.075.975', 'D01.837.725.700.760.050.950']]
|
['Phenomena and Processes [G]', 'Chemicals and Drugs [D]', 'Health Care [N]']
| 0
| 0
| 0
| 1
| 0
| 0
| 1
| 0
| 0
| 0
| 0
| 0
| 1
| 0
|
Specific association of the gene product of PKD2 with the TRPC1 channel.
|
The function(s) of the genes (PKD1 and PKD2) responsible for the majority of cases of autosomal dominant polycystic kidney disease is unknown. While PKD1 encodes a large integral membrane protein containing several structural motifs found in known proteins involved in cell-cell or cell-matrix interactions, PKD2 has homology to PKD1 and the major subunit of the voltage-activated Ca2+ channels. We now describe sequence homology between PKD2 and various members of the mammalian transient receptor potential channel (TRPC) proteins, thought to be activated by G protein-coupled receptor activation and/or depletion of internal Ca2+ stores. We show that PKD2 can directly associate with TRPC1 but not TRPC3 in transfected cells and in vitro. This association is mediated by two distinct domains in PKD2. One domain involves a minimal region of 73 amino acids in the C-terminal cytoplasmic tail of PKD2 shown previously to constitute an interacting domain with PKD1. However, distinct residues within this region mediate specific interactions with TRPC1 or PKD1. The C-terminal domain is sufficient but not necessary for the PKD2-TRPC1 association. A more N-terminal domain located within transmembrane segments S2 and S5, including a putative pore helical region between S5 and S6, is also responsible for the association. Given the ability of the TRPC to form functional homo- and heteromultimeric complexes, these data provide evidence that PKD2 may be functionally related to TRPC proteins and suggest a possible role of PKD2 in modulating Ca2+ entry in response to G protein-coupled receptor activation and/or store depletion.
|
['Amino Acid Sequence', 'Binding Sites', 'Calcium Channels', 'Cell Line', 'Humans', 'Ion Channels', 'Kidney', 'Membrane Proteins', 'Molecular Sequence Data', 'Polycystic Kidney, Autosomal Dominant', 'Proteins', 'Recombinant Fusion Proteins', 'Recombinant Proteins', 'Sequence Alignment', 'Sequence Homology, Amino Acid', 'TRPC Cation Channels', 'TRPP Cation Channels', 'Transfection']
| 10,097,141
|
[['G02.111.570.060', 'L01.453.245.667.060'], ['G02.111.570.120'], ['D12.776.157.530.400.150', 'D12.776.543.550.450.150', 'D12.776.543.585.400.150'], ['A11.251.210'], ['B01.050.150.900.649.313.988.400.112.400.400'], ['D12.776.157.530.400', 'D12.776.543.550.450', 'D12.776.543.585.400'], ['A05.810.453'], ['D12.776.543'], ['L01.453.245.667'], ['C12.777.419.403.875.500', 'C13.351.968.419.403.875.500', 'C16.131.077.717.500', 'C16.320.184.625.500'], ['D12.776'], ['D12.776.828.300'], ['D12.776.828'], ['E05.393.751'], ['G02.111.810.200', 'G05.810.200'], ['D12.776.157.530.400.901.500', 'D12.776.543.585.400.901.500'], ['D12.776.157.530.400.150.900', 'D12.776.157.530.400.901.777', 'D12.776.543.585.400.150.900', 'D12.776.543.585.400.901.777'], ['E05.393.350.810', 'G05.728.860']]
|
['Phenomena and Processes [G]', 'Information Science [L]', 'Chemicals and Drugs [D]', 'Anatomy [A]', 'Organisms [B]', 'Diseases [C]', 'Analytical, Diagnostic and Therapeutic Techniques, and Equipment [E]']
| 1
| 1
| 1
| 1
| 1
| 0
| 1
| 0
| 0
| 0
| 1
| 0
| 0
| 0
|
High symptom reporters are less interoceptively accurate in a symptom-related context.
|
OBJECTIVE: We investigated the role of a symptom interpretation frame on the accuracy of interoception and on retrospective symptom reporting in nonclinical high and low reporters of medically unexplained symptoms.METHODS: All participants (N=74) went through two subsequent trials of the Rebreathing Test, inducing altered respiration and other physical sensations as a result of a gradually increasing pCO(2) level in the blood. Each trial consisted of a baseline (60 s), a rebreathing phase (150 s), and a recovery phase (150 s). In one trial, the sensations were framed in a neutral way ("the gas mixture might alter breathing behavior and induce respiratory sensations"). In the other trial, a symptom frame was induced ("the gas mixture might alter breathing behavior and induce respiratory symptoms"). Breathing behavior was continuously monitored, subjective sensations were rated every 10 s, and after each trial, participants filled out a symptom checklist. Within-subject correlations between the subjective rating and its physiological referent were calculated for the rebreathing phase and recovery phase of each trial separately.RESULTS: High symptom reporters had more (retrospective) complaints than low symptom reporters, especially in the symptom trial. Only in the symptom frame were high symptom reporters less accurate than low symptom reporters. The reduction in interoceptive accuracy (IA) in high symptom reporters was most striking in the recovery phase of the symptom frame trial.CONCLUSION: A contextual cue, such as a reference to symptoms, reduced IA in high symptom reporters and this was more so during recovery from the symptom induction.
|
['Adolescent', 'Adult', 'Affect', 'Attention', 'Carbon Dioxide', 'Cues', 'Culture', 'Female', 'Humans', 'Hypercapnia', 'Illness Behavior', 'Lung Volume Measurements', 'Male', 'Mental Recall', 'Personality Inventory', 'Respiration', 'Sensation', 'Somatoform Disorders', 'Young Adult']
| 18,940,371
|
[['M01.060.057'], ['M01.060.116'], ['F01.470.047'], ['F02.830.104.214'], ['D01.200.200', 'D01.362.150', 'D01.650.550.200'], ['F02.463.425.234'], ['I01.076.201.450', 'I01.880.853.100'], ['B01.050.150.900.649.313.988.400.112.400.400'], ['C23.888.852.544'], ['F01.145.499'], ['E01.370.386.700.485'], ['F02.463.425.540.641'], ['F04.711.647.513'], ['G09.772.705'], ['F02.830.816', 'G11.561.790'], ['F03.875'], ['M01.060.116.815']]
|
['Named Groups [M]', 'Psychiatry and Psychology [F]', 'Chemicals and Drugs [D]', 'Anthropology, Education, Sociology, and Social Phenomena [I]', 'Organisms [B]', 'Diseases [C]', 'Analytical, Diagnostic and Therapeutic Techniques, and Equipment [E]', 'Phenomena and Processes [G]']
| 0
| 1
| 1
| 1
| 1
| 1
| 1
| 0
| 1
| 0
| 0
| 1
| 0
| 0
|
Structural adaptability in the ligand-binding pocket of the ecdysone hormone receptor.
|
The ecdysteroid hormones coordinate the major stages of insect development, notably moulting and metamorphosis, by binding to the ecdysone receptor (EcR); a ligand-inducible nuclear transcription factor. To bind either ligand or DNA, EcR must form a heterodimer with ultraspiracle (USP), the homologue of retinoid-X receptor. Here we report the crystal structures of the ligand-binding domains of the moth Heliothis virescens EcR-USP heterodimer in complex with the ecdysteroid ponasterone A and with a non-steroidal, lepidopteran-specific agonist BYI06830 used in agrochemical pest control. The two structures of EcR-USP emphasize the universality of heterodimerization as a general mechanism common to both vertebrates and invertebrates. Comparison of the EcR structures in complex with steroidal and non-steroidal ligands reveals radically different and only partially overlapping ligand-binding pockets that could not be predicted by molecular modelling and docking studies. These findings offer new perspectives for the design of insect-specific, environmentally safe insecticides. The concept of a ligand-dependent binding pocket in EcR provides an insight into the moulding of nuclear receptors to their ligand, and has potential applications for human nuclear receptors.
|
['Animals', 'Binding Sites', 'Crystallography, X-Ray', 'Dimerization', 'Dioxanes', 'Ecdysterone', 'Humans', 'Hydrazines', 'Ligands', 'Models, Molecular', 'Moths', 'Protein Conformation', 'Receptors, Steroid']
| 14,595,375
|
[['B01.050'], ['G02.111.570.120'], ['E05.196.309.742.225'], ['G02.206', 'G03.230'], ['D03.383.188'], ['D04.210.500.247.222.265.165.750', 'D06.472.445.573.271.750'], ['B01.050.150.900.649.313.988.400.112.400.400'], ['D02.442'], ['D27.720.470.480'], ['E05.599.595'], ['B01.050.500.131.617.720.500.500.937.650'], ['G02.111.570.820.709'], ['D12.776.826.750', 'D12.776.930.778']]
|
['Organisms [B]', 'Phenomena and Processes [G]', 'Analytical, Diagnostic and Therapeutic Techniques, and Equipment [E]', 'Chemicals and Drugs [D]']
| 0
| 1
| 0
| 1
| 1
| 0
| 1
| 0
| 0
| 0
| 0
| 0
| 0
| 0
|
Helicobacter pylori in dental plaque and gastric mucosa.
|
OBJECTIVE: The aim of this study was to investigate the presence of Helicobacter pylori in both dental plaque and gastric mucus.STUDY DESIGN: Dental scaling hand instruments were used to collect supragingival and subgingival dental plaque from 81 dentate participants. Denture plaque was obtained from the fitting surfaces of dentures from 41 edentulous patients. Gastric mucus from gastric mucosa of antrum and body of stomach were collected from all 122 participants (92% white) with soft gastroscopic brush. These samples were dispersed in modified urea broth and normal saline solution before being inoculated onto selective Skirrow's agar and incubated in a microaerophilic atmosphere for culturing H. pylori.RESULTS: Dental plaque from all dentate participants was negative for H. pylori culture. Only one 80-year-old edentulous patient had positive H. pylori culture in both gastric mucus and denture plaque.CONCLUSIONS: Although dental plaque has a mixed flora that may act as a reservoir for gastric reinfection, dental plaque could not be implicated as the major reservoir of H. pylori for gastric reinfection.
|
['Aged', 'Aged, 80 and over', 'Dental Plaque', 'Gastric Mucosa', 'Helicobacter pylori', 'Humans', 'Mouth, Edentulous']
| 8,705,587
|
[['M01.060.116.100'], ['M01.060.116.100.080'], ['C07.793.208.377'], ['A03.556.875.875.440', 'A10.615.550.291'], ['B03.440.500.550', 'B03.660.150.235.500.250.550'], ['B01.050.150.900.649.313.988.400.112.400.400'], ['C07.465.550', 'C07.793.597']]
|
['Named Groups [M]', 'Diseases [C]', 'Anatomy [A]', 'Organisms [B]']
| 1
| 1
| 1
| 0
| 0
| 0
| 0
| 0
| 0
| 0
| 0
| 1
| 0
| 0
|
Altered sensitivity to excitotoxic cell death and glutamate receptor expression between two commonly studied mouse strains.
|
Alterations in glutamatergic synapse function have been implicated in the pathogenesis of many different neurological disorders, including ischemia, epilepsy, Parkinson's disease, Alzheimer's disease, and Huntington's disease. While studying glutamate receptor function in juvenile Batten disease on the C57BL/6J and 129S6/S(v)E(v) mouse backgrounds, we noticed differences unlikely to be due to mutation difference alone. We report here that primary cerebellar granule cell cultures from C57BL/6J mice are more sensitive to N-methyl-D-aspartate (NMDA)-mediated cell death. Moreover, sensitivity to AMPA-mediated excitotoxicity is more variable and is dependent on the treatment conditions and age of the cultures. Glutamate receptor surface expression levels examined in vitro by in situ ELISA and in vivo by Western blot in surface cross-linked cerebellar samples indicated that these differences in sensitivity likely are due to strain-dependent differences in cell surface receptor expression levels. We propose that differences in glutamate receptor expression and in excitotoxic vulnerability should be taken into consideration in the context of characterizing disease models on the C57BL/6J and 129S6/S(v)E(v) mouse backgrounds.
|
['Alanine', 'Animals', 'Animals, Newborn', 'Cell Death', 'Cell Survival', 'Cells, Cultured', 'Cerebellar Cortex', 'Dose-Response Relationship, Drug', 'Drug Resistance', 'Excitatory Amino Acid Agonists', 'Male', 'Mice', 'Mice, Inbred C57BL', 'N-Methylaspartate', 'Nerve Degeneration', 'Neurotoxins', 'Organ Culture Techniques', 'Pyrimidinones', 'Receptors, Glutamate', 'Species Specificity', 'alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid']
| 20,544,821
|
[['D12.125.042'], ['B01.050'], ['B01.050.050.282'], ['G04.146'], ['G04.346'], ['A11.251'], ['A08.186.211.132.810.428.200.212'], ['G07.690.773.875', 'G07.690.936.500'], ['G07.690.773.984'], ['D27.505.519.625.190.200', 'D27.505.696.577.190.200'], ['B01.050.150.900.649.313.992.635.505.500'], ['B01.050.050.199.520.520.420', 'B01.050.150.900.649.313.992.635.505.500.400.420'], ['D12.125.067.500.400', 'D12.125.119.170.400'], ['C23.550.737'], ['D27.888.569.504'], ['E05.481.500.484'], ['D03.383.742.698'], ['D12.776.543.750.720.200.450'], ['G16.824'], ['D03.383.129.385.025']]
|
['Chemicals and Drugs [D]', 'Organisms [B]', 'Phenomena and Processes [G]', 'Anatomy [A]', 'Diseases [C]', 'Analytical, Diagnostic and Therapeutic Techniques, and Equipment [E]']
| 1
| 1
| 1
| 1
| 1
| 0
| 1
| 0
| 0
| 0
| 0
| 0
| 0
| 0
|
Properties of a modified cross-linked silicone for maxillofacial prostheses.
|
A dimethyl siloxane-triacetoxy terminated silane, Type A adhesive, can be modified with the base component of a medium grade polydimethyl siloxane with vinyl groups, MDX 4-4210, to produce more pliable maxillofacial prostheses. The mechanical properties of samples with various Type A adhesive/MDX 4-4210 ratios were determined. Addition of the MDX 4-4210 base decreased the hardness, modulus, and ultimate tensile strength, while the percentage elongation increased. The initial tear strength was relatively constant for the various ratios except for the 50/50 mix, where a 50% decrease was observed. The ability to obtain different mechanical properties by using various ratios of Type A adhesive and MDX 4-4210 could result in the production of maxillofacial prostheses which will more closely stimulate the properties of facial tissues.
|
['Adhesiveness', 'Adhesives', 'Biomechanical Phenomena', 'Dimethylpolysiloxanes', 'Hardness Tests', 'Materials Testing', 'Maxillofacial Prosthesis', 'Prosthesis Design', 'Silanes', 'Silicon', 'Silicone Elastomers', 'Silicones', 'Siloxanes', 'Surface Properties', 'Tensile Strength']
| 3,481,399
|
[['G02.860.139'], ['D27.720.013', 'J01.637.016'], ['G01.154.090', 'G01.374.089'], ['D02.756.650.700.150', 'D05.750.900.850.150', 'D25.720.900.850.150', 'J01.637.051.720.900.850.150'], ['E05.417', 'E05.570.500.500', 'G01.374.647.457', 'G01.374.687.500'], ['E05.570'], ['E07.695.510'], ['E05.320.550', 'E07.695.680'], ['D01.837.700'], ['D01.268.513.937'], ['D05.750.900.850.900', 'D25.720.327.900', 'D25.720.900.850.900', 'J01.637.051.720.327.900', 'J01.637.051.720.900.850.900', 'J01.637.412.900'], ['D02.756.650.700', 'D05.750.900.850', 'D25.720.900.850', 'J01.637.051.720.900.850'], ['D01.837.800', 'D02.756.650', 'D05.750.900', 'D25.720.900', 'J01.637.051.720.900'], ['G02.860'], ['G01.374.850']]
|
['Phenomena and Processes [G]', 'Chemicals and Drugs [D]', 'Technology, Industry, and Agriculture [J]', 'Analytical, Diagnostic and Therapeutic Techniques, and Equipment [E]']
| 0
| 0
| 0
| 1
| 1
| 0
| 1
| 0
| 0
| 1
| 0
| 0
| 0
| 0
|
Fracture experience of patients with coeliac disease: a population based survey.
|
BACKGROUND: While coeliac disease is now recognised as being associated with both osteoporosis and osteomalacia, the size of any increase in the risk of fracture in patients with coeliac disease compared with the general population has not been quantified.AIM: To examine the fracture experience of adults with coeliac disease compared with the general population.SUBJECTS: Patients with coeliac disease diagnosed in adulthood and born before 1950, selected from two large population based disease registers, and age and sex frequency matched controls identified from local general practitioner lists.METHODS: A four page lifestyle and general health questionnaire which included specific questions about fracture experience.RESULTS: Analysis was performed on 244 patients with coeliac disease and 161 controls, giving response rates of 89% and 72%, respectively. Eighty two (35%) coeliac patients and 53 (33%) controls reported ever having sustained one or more fractures, giving an age and sex adjusted odds ratio of 1.05 (95% confidence interval (CI) 0.68-1.62). The most common fracture site reported was the forearm or wrist, with an adjusted odds ratio of 1.21 (95% CI 0.66-2.25) for patients with coeliac disease having had a forearm or wrist fracture. Low trauma fractures were reported by 37 patients with coeliac disease (15.7%) and by 21 controls (13.8%), with an adjusted odds ratio of 1.16 (95% CI 0.65-2.10). The risk of low trauma fracture was slightly higher in coeliac men than women (odds ratio 1.28 compared with 1.12), but this difference was not statistically significant (p=0.84). After adjustment for age, sex, body mass index, and smoking status, patients with coeliac disease reported 13% more low trauma fractures than controls (odds ratio 1.13, 95% CI 0.60-2.12). There was no difference in low trauma fracture risk before and after diagnosis of coeliac disease.CONCLUSION: No overall increased fracture risk in patients with coeliac disease was observed. Although severe osteoporosis may develop in a subset of patients, as a whole patients with coeliac disease do not represent a population at particularly high risk of osteoporotic fracture and thus targeting them for osteoporosis screening and treatment is not justified.
|
['Adult', 'Age Distribution', 'Aged', 'Case-Control Studies', 'Celiac Disease', 'Female', 'Fractures, Bone', 'Health Surveys', 'Humans', 'Male', 'Middle Aged', 'Odds Ratio', 'Osteoporosis', 'Registries', 'Risk Assessment', 'Smoking']
| 12,631,662
|
[['M01.060.116'], ['I01.240.050', 'N01.224.033', 'N06.850.505.400.050'], ['M01.060.116.100'], ['E05.318.372.500.500', 'N05.715.360.330.500.500', 'N06.850.520.450.500.500'], ['C06.405.469.637.250', 'C18.452.603.250'], ['C26.404'], ['E05.318.308.980.438', 'N05.715.360.300.800.438', 'N06.850.520.308.980.438'], ['B01.050.150.900.649.313.988.400.112.400.400'], ['M01.060.116.630'], ['E05.318.740.600.600', 'G17.680.500', 'N05.715.360.750.625.590', 'N06.850.520.830.600.600'], ['C05.116.198.579', 'C18.452.104.579'], ['E05.318.308.970', 'N04.452.859.819', 'N05.715.360.300.715.700', 'N06.850.520.308.970'], ['E05.318.740.600.800.715', 'N04.452.871.715', 'N05.715.360.750.625.700.690', 'N06.850.505.715', 'N06.850.520.830.600.800.715'], ['F01.145.805']]
|
['Named Groups [M]', 'Anthropology, Education, Sociology, and Social Phenomena [I]', 'Health Care [N]', 'Analytical, Diagnostic and Therapeutic Techniques, and Equipment [E]', 'Diseases [C]', 'Organisms [B]', 'Phenomena and Processes [G]', 'Psychiatry and Psychology [F]']
| 0
| 1
| 1
| 0
| 1
| 1
| 1
| 0
| 1
| 0
| 0
| 1
| 1
| 0
|
Stretching position can affect levator scapular muscle activity, length, and cervical range of motion in people with a shortened levator scapulae.
|
OBJECTIVES: Levator scapulae (LS) muscle stretching exercises are a common method of lengthening a shortened muscle; however, the appropriate stretching position for lengthening the LS in people with a shortened LS remains unclear. The purpose of this study was to compare the effects of different stretching exercise positions on the LS and introduce effective stretching exercise methods to clinicians.PARTICIPANTS: Twenty-four university students (12 men, 12 women) with a shortened LS were recruited.METHODS: LS muscle activity, LS index (LSI), and cervical range of motion (ROM) were measured pre (baseline) and post three different stretching exercise positions (sitting, quadruped, and prone).RESULTS: The LSI and cervical ROM exceeded the minimal detectable change and had significant changes. The LSI was greater in the sitting position than at the baseline (p = 0.01), quadruped position (p < 0.01); the LSI in the prone position presented a higher increase than the quadruped position (p = 0.01). The cervical ROM increased in the sitting position when compared to the baseline (p < 0.01) and quadruped position (p < 0.01).CONCLUSIONS: Stretching the LS in the sitting position was the most effective exercise for improving LS muscle length and cervical ROM.
|
['Electromyography', 'Female', 'Humans', 'Male', 'Muscle Stretching Exercises', 'Neck', 'Posture', 'Prone Position', 'Range of Motion, Articular', 'Superficial Back Muscles', 'Young Adult']
| 28,578,252
|
[['E01.370.405.255', 'E01.370.530.255'], ['B01.050.150.900.649.313.988.400.112.400.400'], ['E02.760.169.063.500.387.750', 'E02.779.483.750', 'E02.831.535.483.750', 'G11.427.410.698.277.249', 'I03.350.249'], ['A01.598'], ['G11.427.695'], ['G11.427.695.525'], ['E01.370.600.700', 'G11.427.760'], ['A02.633.567.175.875'], ['M01.060.116.815']]
|
['Analytical, Diagnostic and Therapeutic Techniques, and Equipment [E]', 'Organisms [B]', 'Phenomena and Processes [G]', 'Anthropology, Education, Sociology, and Social Phenomena [I]', 'Anatomy [A]', 'Named Groups [M]']
| 1
| 1
| 0
| 0
| 1
| 0
| 1
| 0
| 1
| 0
| 0
| 1
| 0
| 0
|
Multicenter validation of a simplified score to predict massive transfusion in trauma.
|
BACKGROUND: Several studies have described predictive models to identify trauma patients who require massive transfusion (MT). Early identification of lethal exsanguination may improve survival in this patient population. The purpose of the current study was to validate a simplified score to predict MT at multiple Level I trauma centers.METHODS: All adult trauma patients treated at three Level I trauma centers from July 2006 to June 2007 who (1) were transported directly from the scene, (2) were trauma activations, and (3) received any blood transfusions during admission were included. Assessment of Blood Consumption (ABC) score developed using the same inclusion criteria for patients admitted to a single trauma center (Vanderbilt University Medical Center [VUMC]-1) between July 2005 and June 2006. ABC score calculated by assigning a value (0 or 1) to each of the four parameters: penetrating mechanism, positive focused assessment with sonography for trauma for fluid, arrival blood pressure <90 mm Hg, and arrival pulse >120 bpm. A score of 2 was used as "positive" to predict MT. Area under receiver-operating characteristic curve was calculated to compare the predictive ability of the score at each institution.RESULTS: There were 586 patients in the developmental (VUMC-1), 513 patients at trauma center 1 (VUMC-2), 372 at trauma center 2 (PMH), and 133 at trauma center 3 (Johns Hopkins Hospital). MT rate was similar between centers: 14% to 15%. Sensitivity and specificity for the ABC score predicting MT ranged from 75% to 90% and 67% to 88%, respectively. Correctly classified patients and area under receiver-operating characteristic curve, however, were 84% to 87% and 0.83 to 0.90, respectively.CONCLUSIONS: The ABC score is a valid instrument to predict MT early in the patient's care and across various demographically diverse trauma centers. Future research should focus on this score's ability to prospectively identify patients who will receive MT.
|
['Adult', 'Blood Transfusion', 'Female', 'Humans', 'Male', 'Middle Aged', 'Predictive Value of Tests', 'ROC Curve', 'Retrospective Studies', 'Risk Assessment', 'Trauma Centers', 'Trauma Severity Indices', 'Triage', 'Wounds and Injuries', 'Young Adult']
| 20,622,617
|
[['M01.060.116'], ['E02.095.135'], ['B01.050.150.900.649.313.988.400.112.400.400'], ['M01.060.116.630'], ['E05.318.370.800.650', 'N05.715.360.325.700.640', 'N06.850.520.445.800.650'], ['E05.318.370.800.750', 'E05.318.740.872.750', 'N05.715.360.325.700.680', 'N06.850.520.445.800.750'], ['E05.318.372.500.500.500', 'E05.318.372.500.750.750', 'N05.715.360.330.500.500.500', 'N05.715.360.330.500.750.825', 'N06.850.520.450.500.500.500', 'N06.850.520.450.500.750.825'], ['E05.318.740.600.800.715', 'N04.452.871.715', 'N05.715.360.750.625.700.690', 'N06.850.505.715', 'N06.850.520.830.600.800.715'], ['N02.278.216.500.968.336.500', 'N02.421.297.195.480', 'N04.452.442.452.422.336.400'], ['E05.318.308.940.968.875', 'E05.944', 'N04.452.859.564.800', 'N05.715.360.300.715.500.800', 'N06.850.520.308.940.968.875'], ['N02.421.297.900'], ['C26'], ['M01.060.116.815']]
|
['Named Groups [M]', 'Analytical, Diagnostic and Therapeutic Techniques, and Equipment [E]', 'Organisms [B]', 'Health Care [N]', 'Diseases [C]']
| 0
| 1
| 1
| 0
| 1
| 0
| 0
| 0
| 0
| 0
| 0
| 1
| 1
| 0
|
Cimetidine in duodenal ulcer. Controlled trial.
|
As part of a double-blind controlled clinical trial of cimetidine (1.6 g daily) in patients with endoscopically proven duodenal ulcer, repeat endoscopy has been carried out in 24 patients after two and/or six weeks' treatment. At six weeks, 9 out of 11 patients on cimetidine and 3 out of 12 patients on placebo had healed (P less than 0.025). A separate open pilot trial in 23 patients has shown no difference in ulcer healing at six weeks between patients taking 0.8 and 1.6 g daily. A total of 32 different patients received cimetidine in the two trials, and ulcer healing was observed in 21 (66%) at six weeks. No patients showed evidence of bone-marrow toxicity. A small but significant rise in mean S.G.O.T., S.G.P.T., and serum-creatinine occurred in 13 patients on cimetidine 1.6 g daily, but not in 13 patients on 0.8 g daily.
|
['Cimetidine', 'Clinical Trials as Topic', 'Double-Blind Method', 'Duodenal Ulcer', 'Guanidines', 'Humans', 'Placebos', 'Time Factors', 'Wound Healing']
| 73,797
|
[['D02.078.370.200', 'D03.383.129.308.130'], ['E05.318.372.250.250', 'N05.715.360.330.250.250', 'N06.850.520.450.250.250'], ['E05.318.370.300', 'E05.581.500.300', 'N05.715.360.325.320', 'N06.850.520.445.300'], ['C06.405.469.275.800.348', 'C06.405.748.586.349'], ['D02.078.370'], ['B01.050.150.900.649.313.988.400.112.400.400'], ['D26.660', 'E02.785'], ['G01.910.857'], ['G16.762.891']]
|
['Chemicals and Drugs [D]', 'Analytical, Diagnostic and Therapeutic Techniques, and Equipment [E]', 'Health Care [N]', 'Diseases [C]', 'Organisms [B]', 'Phenomena and Processes [G]']
| 0
| 1
| 1
| 1
| 1
| 0
| 1
| 0
| 0
| 0
| 0
| 0
| 1
| 0
|
Neuropathological changes in Down's syndrome hippocampal formation. Effect of age and apolipoprotein E genotype.
|
BACKGROUND: The neuropathological changes of Alzheimer's disease occur universally in individuals with Down's syndrome as they reach middle age and worsen with increasing age. Thus, evaluation of patients of various ages with Down's syndrome allows one to construct a life history of the development of neuropathological changes associated with Alzheimer's disease at various points in the disease process.METHODS: We have used semiquantitative scales and quantitative computerized image analysis techniques to analyze the characteristics of neurofibrillary tangle formation and A beta amyloid deposition in the hippocampal formation and inferior temporal gyrus in 36 individuals with Down's syndrome ranging in age from 4 to 73 years.RESULTS: Neurofibrillary tangles occur in a hierarchical distribution in a circumscribed set of neuronal fields, affecting the entorhinal cortex, area CA1/subiculum, then other hippocampal subfields. Although amyloid deposition occurs more evenly in a more widespread distribution, it also accumulates over the years 30 to 50. Surprisingly, examination of the patients available older than 50 years showed no trend toward continued increased deposition of amyloid. Within this group, however, individuals who had inherited the apolipoprotein E (Apo E) epsilon 4 genotype contained more than twice the amyloid burden of individuals who did not inherit the Apo E epsilon 4 genotype.COMMENT: This large series of cases confirms earlier observations that had suggested early vulnerability of entorhinal cortex and CA1/subiculum for neurofibrillary tangles and a more widespread but specific topography of A beta deposition. Moreover, it demonstrates quantitatively that the lesions increase to a certain level and then apparently reach a plateau. The level of amyloid deposition in Down's syndrome is higher than in sporadic Alzheimer's disease. Inheritance of the Apo E epsilon 4 genotype appears to be an additional (independent) risk factor for developing higher levels of amyloid accumulation.
|
['Adolescent', 'Adult', 'Aging', 'Alzheimer Disease', 'Apolipoprotein E4', 'Apolipoproteins E', 'Child', 'Child, Preschool', 'Dementia', 'Down Syndrome', 'Female', 'Genotype', 'Hippocampus', 'Humans', 'Male', 'Middle Aged', 'Neurofibrillary Tangles']
| 7,710,373
|
[['M01.060.057'], ['M01.060.116'], ['G07.345.124'], ['C10.228.140.380.100', 'C10.574.945.249', 'F03.615.400.100'], ['D10.532.091.500.750', 'D12.776.070.400.500.750', 'D12.776.521.120.500.750'], ['D10.532.091.500', 'D12.776.070.400.500', 'D12.776.521.120.500'], ['M01.060.406'], ['M01.060.406.448'], ['C10.228.140.380', 'F03.615.400'], ['C10.597.606.360.220', 'C16.131.077.327', 'C16.131.260.260', 'C16.320.180.260'], ['G05.380'], ['A08.186.211.180.405', 'A08.186.211.200.885.287.500.345'], ['B01.050.150.900.649.313.988.400.112.400.400'], ['M01.060.116.630'], ['A08.675.609.520', 'A11.284.430.214.190.750.640.520', 'A11.671.573.520']]
|
['Named Groups [M]', 'Phenomena and Processes [G]', 'Diseases [C]', 'Psychiatry and Psychology [F]', 'Chemicals and Drugs [D]', 'Anatomy [A]', 'Organisms [B]']
| 1
| 1
| 1
| 1
| 0
| 1
| 1
| 0
| 0
| 0
| 0
| 1
| 0
| 0
|
Semiautomated Surveillance of Deep Surgical Site Infections After Primary Total Hip or Knee Arthroplasty.
|
Manual surveillance of surgical site infections (SSIs) after total hip or knee arthroplasty is time-consuming and prone to error. Semiautomated surveillance based on routine care data extracted from electronic health records can retrospectively identify deep SSIs and substantially reduce workload while maintaining 100% sensitivity. Infect Control Hosp Epidemiol 2017;38:732-735.
|
['Aged', 'Arthroplasty, Replacement, Hip', 'Arthroplasty, Replacement, Knee', 'Electronic Health Records', 'Female', 'Humans', 'Male', 'Middle Aged', 'Models, Theoretical', 'Population Surveillance', 'Predictive Value of Tests', 'Retrospective Studies', 'Risk Assessment', 'Surgical Wound Infection']
| 28,366,180
|
[['M01.060.116.100'], ['E04.555.110.110.110', 'E04.650.110.110', 'E04.680.101.110.110'], ['E04.555.110.110.115', 'E04.650.110.115', 'E04.680.101.110.115'], ['E05.318.308.940.968.625.500', 'N04.452.859.564.650.125', 'N05.715.360.300.715.500.530.250', 'N06.850.520.308.940.968.625.250'], ['B01.050.150.900.649.313.988.400.112.400.400'], ['M01.060.116.630'], ['E05.599'], ['E05.318.308.980.438.700', 'N05.715.360.300.800.438.625', 'N06.850.520.308.980.438.700', 'N06.850.780.675'], ['E05.318.370.800.650', 'N05.715.360.325.700.640', 'N06.850.520.445.800.650'], ['E05.318.372.500.500.500', 'E05.318.372.500.750.750', 'N05.715.360.330.500.500.500', 'N05.715.360.330.500.750.825', 'N06.850.520.450.500.500.500', 'N06.850.520.450.500.750.825'], ['E05.318.740.600.800.715', 'N04.452.871.715', 'N05.715.360.750.625.700.690', 'N06.850.505.715', 'N06.850.520.830.600.800.715'], ['C01.947.692', 'C23.550.767.925']]
|
['Named Groups [M]', 'Analytical, Diagnostic and Therapeutic Techniques, and Equipment [E]', 'Health Care [N]', 'Organisms [B]', 'Diseases [C]']
| 0
| 1
| 1
| 0
| 1
| 0
| 0
| 0
| 0
| 0
| 0
| 1
| 1
| 0
|
Using malpractice claims to identify risk factors for neurological impairment among infants following non-reassuring fetal heart rate patterns during labour.
|
RATIONALE, AIMS AND OBJECTIVES: We sought to use a novel case-selection methodology to identify antenatal or intrapartum risk factors associated with neonatal neurological impairment following non-reassuring fetal heart rate patterns during labour.METHOD: We used a retrospective case-control design with bivariate and multivariate conditional logistic regression. Cases were births in which electronic fetal monitoring (EFM) showed non-reassuring patterns and the infant had neurological disability. Controls were births in which EFM was non-reassuring but the infant was born healthy. We identified 36 cases from among malpractice claims filed with a liability insurer in Massachusetts between 1985 and 2001 and randomly selected 70 controls, matching them to cases by hospital, birth date and gestational age.RESULTS: More cases had maternal antenatal vaginal bleeding (P = 0.004), a prolonged latent phase or protracted dilation during the first stage of labour (P = 0.03), and protracted descent or prolonged second stage (P = 0.01). More cases also had minimal variability on EFM on admission (P = 0.02) and during the second stage (P = 0.02). Multivariate analysis highlighted three significant predictors of neurological injury following complicated labour: antenatal vaginal bleeding (OR = 27.1), prolonged latent phase or protracted dilation in the first stage (OR = 4.0) and EFM showing minimal variability in the first stage (OR = 4.3).CONCLUSION: These promising initial findings suggest that future research into outcomes from complicated labour with non-reassuring heart rate patterns should focus on maternal history of vaginal bleeding, slow labour and minimal variability on EFM.
|
['Adolescent', 'Adult', 'Female', 'Fetal Monitoring', 'Heart Rate, Fetal', 'Humans', 'Infant, Newborn', 'Insurance Claim Review', 'Malpractice', 'Massachusetts', 'Nervous System Diseases', 'Pregnancy', 'Pregnancy Complications', 'Retrospective Studies', 'Risk Factors', 'Young Adult']
| 20,482,746
|
[['M01.060.057'], ['M01.060.116'], ['E01.370.378.230', 'E01.370.520.230'], ['G09.330.380.500.430'], ['B01.050.150.900.649.313.988.400.112.400.400'], ['M01.060.703.520'], ['N03.219.521.576.215'], ['I01.880.604.583.524', 'N03.706.535.606'], ['Z01.107.567.875.550.510'], ['C10'], ['G08.686.784.769'], ['C13.703'], ['E05.318.372.500.500.500', 'E05.318.372.500.750.750', 'N05.715.360.330.500.500.500', 'N05.715.360.330.500.750.825', 'N06.850.520.450.500.500.500', 'N06.850.520.450.500.750.825'], ['E05.318.740.600.800.725', 'N05.715.350.200.700', 'N05.715.360.750.625.700.700', 'N06.850.490.625.750', 'N06.850.520.830.600.800.725'], ['M01.060.116.815']]
|
['Named Groups [M]', 'Analytical, Diagnostic and Therapeutic Techniques, and Equipment [E]', 'Phenomena and Processes [G]', 'Organisms [B]', 'Health Care [N]', 'Anthropology, Education, Sociology, and Social Phenomena [I]', 'Geographicals [Z]', 'Diseases [C]']
| 0
| 1
| 1
| 0
| 1
| 0
| 1
| 0
| 1
| 0
| 0
| 1
| 1
| 1
|
Preparation and X-ray crystallographic analysis of recombinant obelin crystals diffracting to beyond 1.1 A.
|
Crystals of recombinant obelin, the Ca(2+)-regulated photoprotein from the marine hydroid Obelia longissima, have been grown from a solution containing PEG 8000 and potassium phosphate. Hexaminecobalt trichloride was used as an additive to increase the chance of crystallization. The crystals grow in a light yellow cubic form (0.5 x 0.5 x 0.45 mm) which diffracts to beyond 1.1 A resolution. The crystals belong to the space group C2, with unit-cell parameters a = 83.43, b = 54.92, c = 52.99 A, beta = 112.00 degrees. The asymmetric unit contains one molecule. Crystals exposed to calcium ion before and after X-ray irradiation emit light, confirming that the crystals consist of an active photoprotein.
|
['Animals', 'Cnidaria', 'Crystallization', 'Crystallography, X-Ray', 'Luminescent Proteins', 'Protein Conformation', 'Recombinant Proteins']
| 11,717,517
|
[['B01.050'], ['B01.050.500.308'], ['E05.196.300', 'G02.171'], ['E05.196.309.742.225'], ['D12.776.532'], ['G02.111.570.820.709'], ['D12.776.828']]
|
['Organisms [B]', 'Analytical, Diagnostic and Therapeutic Techniques, and Equipment [E]', 'Phenomena and Processes [G]', 'Chemicals and Drugs [D]']
| 0
| 1
| 0
| 1
| 1
| 0
| 1
| 0
| 0
| 0
| 0
| 0
| 0
| 0
|
Multispectral real-time fluorescence imaging for intraoperative detection of the sentinel lymph node in gynecologic oncology.
|
The prognosis in virtually all solid tumors depends on the presence or absence of lymph node metastases. Surgical treatment most often combines radical excision of the tumor with a full lymphadenectomy in the drainage area of the tumor. However, removal of lymph nodes is associated with increased morbidity due to infection, wound breakdown and lymphedema. As an alternative, the sentinel lymph node procedure (SLN) was developed several decades ago to detect the first draining lymph node from the tumor. In case of lymphogenic dissemination, the SLN is the first lymph node that is affected (Figure 1). Hence, if the SLN does not contain metastases, downstream lymph nodes will also be free from tumor metastases and need not to be removed. The SLN procedure is part of the treatment for many tumor types, like breast cancer and melanoma, but also for cancer of the vulva and cervix. The current standard methodology for SLN-detection is by peritumoral injection of radiocolloid one day prior to surgery, and a colored dye intraoperatively. Disadvantages of the procedure in cervical and vulvar cancer are multiple injections in the genital area, leading to increased psychological distress for the patient, and the use of radioactive colloid. Multispectral fluorescence imaging is an emerging imaging modality that can be applied intraoperatively without the need for injection of radiocolloid. For intraoperative fluorescence imaging, two components are needed: a fluorescent agent and a quantitative optical system for intraoperative imaging. As a fluorophore we have used indocyanine green (ICG). ICG has been used for many decades to assess cardiac function, cerebral perfusion and liver perfusion. It is an inert drug with a safe pharmaco-biological profile. When excited at around 750 nm, it emits light in the near-infrared spectrum around 800 nm. A custom-made multispectral fluorescence imaging camera system was used. The aim of this video article is to demonstrate the detection of the SLN using intraoperative fluorescence imaging in patients with cervical and vulvar cancer. Fluorescence imaging is used in conjunction with the standard procedure, consisting of radiocolloid and a blue dye. In the future, intraoperative fluorescence imaging might replace the current method and is also easily transferable to other indications like breast cancer and melanoma.
|
['Female', 'Fluorescent Dyes', 'Humans', 'Indocyanine Green', 'Lymph Nodes', 'Sentinel Lymph Node Biopsy', 'Spectrometry, Fluorescence', 'Uterine Cervical Neoplasms', 'Vulvar Neoplasms']
| 21,048,667
|
[['D27.720.233.348', 'D27.720.470.410.505.500'], ['B01.050.150.900.649.313.988.400.112.400.400'], ['D03.633.100.473.400'], ['A10.549.400', 'A15.382.520.604.412'], ['E01.370.225.500.384.100.580', 'E01.370.225.998.054.580', 'E01.370.388.100.580', 'E04.074.580', 'E04.446.819', 'E05.200.500.384.100.580', 'E05.200.998.054.580', 'E05.242.384.100.580'], ['E05.196.712.516.600.676', 'E05.196.867.726'], ['C04.588.945.418.948.850', 'C13.351.500.852.593.131', 'C13.351.500.852.762.850', 'C13.351.937.418.875.850'], ['C04.588.945.418.968', 'C13.351.500.944.819', 'C13.351.937.418.968']]
|
['Chemicals and Drugs [D]', 'Organisms [B]', 'Anatomy [A]', 'Analytical, Diagnostic and Therapeutic Techniques, and Equipment [E]', 'Diseases [C]']
| 1
| 1
| 1
| 1
| 1
| 0
| 0
| 0
| 0
| 0
| 0
| 0
| 0
| 0
|
Upper airway lesions in children after accidental ingestion of caustic substances.
|
Of 33 children admitted within 24 hours after accidental ingestion of a caustic substance, 14 (42.5%) had evidence of upper airway lesions on direct laryngoscopy. Three patients, 10 to 12 months old, needed endotracheal intubation for acute respiratory obstruction; four patients younger than 2 years had severe dyspnea without obstruction; seven patients had mild or no respiratory symptoms. All were discharged without respiratory sequelae, although esophageal stenosis developed in six patients. Nine of 13 patients younger than 2 years, compared to five of 20 patients older than 2 years, had upper airway lesions (P less than 0.01). The frequency of respiratory tract lesions was higher in patients with severe esophagitis. Eleven of 17 patients with severe esophagitis, compared to three of 16 with mild inflammation, had respiratory tract lesions (P less than 0.025). No specific caustic substance predisposed to upper airway lesions.
|
['Ampicillin', 'Burns, Chemical', 'Caustics', 'Child', 'Child, Preschool', 'Epiglottis', 'Esophagoscopy', 'Fiber Optic Technology', 'Gastric Mucosa', 'Glottis', 'Humans', 'Infant', 'Intubation, Intratracheal', 'Laryngoscopy', 'Larynx', 'Prednisone', 'Radiography', 'Respiratory Insufficiency']
| 3,973,778
|
[['D02.065.589.099.750.750.050', 'D02.886.108.750.750.050', 'D03.633.100.300.750.750.050'], ['C26.200.156'], ['D27.720.185', 'D27.888.569.185'], ['M01.060.406'], ['M01.060.406.448'], ['A02.165.257.625.411', 'A02.165.407.500.411', 'A04.329.591.411'], ['E01.370.372.250.250.275', 'E01.370.388.250.250.250.260', 'E04.210.240.250.260', 'E04.502.250.250.250.260'], ['H01.671.617.249'], ['A03.556.875.875.440', 'A10.615.550.291'], ['A04.329.364'], ['B01.050.150.900.649.313.988.400.112.400.400'], ['M01.060.703'], ['E02.041.500', 'E02.585.578', 'E05.497.578'], ['E01.370.386.460', 'E01.370.388.250.525', 'E04.502.250.525', 'E04.580.373'], ['A04.329'], ['D04.210.500.745.432.719.702'], ['E01.370.350.700'], ['C08.618.846']]
|
['Chemicals and Drugs [D]', 'Diseases [C]', 'Named Groups [M]', 'Anatomy [A]', 'Analytical, Diagnostic and Therapeutic Techniques, and Equipment [E]', 'Disciplines and Occupations [H]', 'Organisms [B]']
| 1
| 1
| 1
| 1
| 1
| 0
| 0
| 1
| 0
| 0
| 0
| 1
| 0
| 0
|
Association of elevated GRP78 expression with increased astrocytoma malignancy via Akt and ERK pathways.
|
Unlike other members of HSP70 family, GRP78 manifests multifaceted subcellular distribution and forms complex with different signals, resulting in its close correlation with various tumors. However, its expression profile and function in glioma remain less well defined. In this study, normal brain tissue and astrocytic tumor specimens were evaluated for GRP78 expression, which was shown to be up-regulated in astrocytoma compared with normal tissue, increased markedly as astrocytoma pathologic grade escalates, and can still be enhanced for disease recurrence. By employing Cox regression analyses, high GRP78 expression was correlated with a poorer outcome for recurrent glioblastoma patients. In addition, immunofluorescence microscopy detected cell surface positioning of GRP78 on human glioma cells. After transfection with siRNA or antibody ligation of surface GRP78, phosphorylation of Akt and ERK was attenuated. These findings indicate that GRP78 plays an important role in astrocytoma malignancy, whereas its cell surface localization may be attractive for clinical utilization.
|
['Antibodies, Neutralizing', 'Astrocytoma', 'Brain Neoplasms', 'Cell Division', 'Chromones', 'Gene Expression Regulation, Neoplastic', 'Gene Knockdown Techniques', 'Glioblastoma', 'Heat-Shock Proteins', 'Humans', 'Membrane Proteins', 'Mitogen-Activated Protein Kinase 1', 'Mitogen-Activated Protein Kinase 3', 'Morpholines', 'Neoplasm Invasiveness', 'Neoplasm Proteins', 'Neoplasm Recurrence, Local', 'Nerve Tissue Proteins', 'Prognosis', 'Proto-Oncogene Proteins c-akt', 'RNA, Small Interfering', 'Signal Transduction']
| 21,112,319
|
[['D12.776.124.486.485.114.244', 'D12.776.124.790.651.114.244', 'D12.776.377.715.548.114.244'], ['C04.557.465.625.600.380.080', 'C04.557.470.670.380.080', 'C04.557.580.625.600.380.080'], ['C04.588.614.250.195', 'C10.228.140.211', 'C10.551.240.250'], ['G04.144.220', 'G04.161.750.500', 'G05.113', 'G07.345.249.410.750.500'], ['D03.383.663.283.266', 'D03.633.100.150.266'], ['G05.308.370'], ['E05.393.335.500'], ['C04.557.465.625.600.380.080.335', 'C04.557.470.670.380.080.335', 'C04.557.580.625.600.380.080.335'], ['D12.776.580.216'], ['B01.050.150.900.649.313.988.400.112.400.400'], ['D12.776.543'], ['D08.811.913.696.620.682.700.567.249.500', 'D12.644.360.450.169.500', 'D12.776.476.450.169.500'], ['D08.811.913.696.620.682.700.567.249.750', 'D12.644.360.450.169.750', 'D12.776.476.450.169.750'], ['D03.383.533.640'], ['C04.697.645', 'C23.550.727.645'], ['D12.776.624'], ['C04.697.655', 'C23.550.727.655'], ['D12.776.631'], ['E01.789'], ['D08.811.913.696.620.682.700.755', 'D12.776.476.565', 'D12.776.624.664.700.168'], ['D13.150.650.700', 'D13.444.735.150.700', 'D13.444.735.790.552.875'], ['G02.111.820', 'G04.835']]
|
['Chemicals and Drugs [D]', 'Diseases [C]', 'Phenomena and Processes [G]', 'Analytical, Diagnostic and Therapeutic Techniques, and Equipment [E]', 'Organisms [B]']
| 0
| 1
| 1
| 1
| 1
| 0
| 1
| 0
| 0
| 0
| 0
| 0
| 0
| 0
|
[Reduction of atherogenesis in an arterialized venous graft by using an external sleeve].
|
The parietal thickening of a vein under hemodynamical conditions in the arterial system can be reduced when supporting the vein with a rigid external sleeve. To assess the role of thickness reduction in atherogenesis of an arterialized vein graft, a 4 mm thick external sleeve was implemented around the proximal half of a carotid-carotid vein graft in 16 New Zealand rabbits. Eleven rabbits were submitted to a hypercholesterolemic diet (HC group), while five others were submitted to a normal cholesterol diet (NC group). After eight weeks, a statistically significant difference in thickness was observed between free and sleeved segments, in the NC group with 105 +/- 9 microns versus 65 +/- 6 microns (p < 10.0001) respectively as well as in the HC group with 180 +/- 37 microns versus 99 +/- 35 microns (p < 10.0001) respectively. Studying the extent of soudanophilic lesions showed a statistically significant difference according to the use or not of an external sleeve where average extent is 68 +/- 17% in free segments versus 31 +/- 26% (p < 10.0001) is sleeved segments. The reduction in vein overfullness using an external constrictive sleeve prevents structural parietal changes in the vein and allows reducing atherogenesis of the arterialized vein graft.
|
['Animals', 'Arteriosclerosis', 'Carotid Arteries', 'Clinical Protocols', 'Endothelium, Vascular', 'Hypercholesterolemia', 'Rabbits', 'Transplantation, Autologous', 'Veins']
| 1,345,700
|
[['B01.050'], ['C14.907.137.126'], ['A07.015.114.186'], ['E02.183', 'N05.715.360.330.125'], ['A07.015.700.500', 'A10.272.491.355'], ['C18.452.584.500.500.396'], ['B01.050.150.900.649.313.968.700'], ['E04.936.664'], ['A07.015.908']]
|
['Organisms [B]', 'Diseases [C]', 'Anatomy [A]', 'Analytical, Diagnostic and Therapeutic Techniques, and Equipment [E]', 'Health Care [N]']
| 1
| 1
| 1
| 0
| 1
| 0
| 0
| 0
| 0
| 0
| 0
| 0
| 1
| 0
|
Copy Number Variations in Tilapia Genomes.
|
Discovering the nature and pattern of genome variation is fundamental in understanding phenotypic diversity among populations. Although several millions of single nucleotide polymorphisms (SNPs) have been discovered in tilapia, the genome-wide characterization of larger structural variants, such as copy number variation (CNV) regions has not been carried out yet. We conducted a genome-wide scan for CNVs in 47 individuals from three tilapia populations. Based on 254 Gb of high-quality paired-end sequencing reads, we identified 4642 distinct high-confidence CNVs. These CNVs account for 1.9% (12.411 Mb) of the used Nile tilapia reference genome. A total of 1100 predicted CNVs were found overlapping with exon regions of protein genes. Further association analysis based on linear model regression found 85 CNVs ranging between 300 and 27,000 base pairs significantly associated to population types (R 2 > 0.9 and P > 0.001). Our study sheds first insights on genome-wide CNVs in tilapia. These CNVs among and within tilapia populations may have functional effects on phenotypes and specific adaptation to particular environments.
|
['Adaptation, Physiological', 'Animals', 'Chromosome Mapping', 'DNA Copy Number Variations', 'Gene Ontology', 'Genetics, Population', 'Genome', 'Genome-Wide Association Study', 'High-Throughput Nucleotide Sequencing', 'Molecular Sequence Annotation', 'Tilapia']
| 28,168,542
|
[['G07.025', 'G16.012.500'], ['B01.050'], ['E05.393.183'], ['G05.365.795.297.500'], ['H01.158.273.343.249.099', 'H01.770.644.145.350.124', 'L01.224.050.375.480.500.500', 'L01.313.500.750.300.550.500.500', 'L01.453.245.945.079.500'], ['H01.158.273.343.335'], ['G05.360.340'], ['E05.318.370.392', 'E05.318.416.249', 'E05.393.385.500', 'E05.393.522.500', 'E05.393.760.640.500', 'N06.850.520.445.392', 'N06.850.520.470.500'], ['E05.393.760.319'], ['E05.393.760.479', 'L01.453.245.667.580'], ['B01.050.150.900.493.602.200.800']]
|
['Phenomena and Processes [G]', 'Organisms [B]', 'Analytical, Diagnostic and Therapeutic Techniques, and Equipment [E]', 'Disciplines and Occupations [H]', 'Information Science [L]', 'Health Care [N]']
| 0
| 1
| 0
| 0
| 1
| 0
| 1
| 1
| 0
| 0
| 1
| 0
| 1
| 0
|
TRAIL-induced apoptosis of hepatocellular carcinoma cells is augmented by targeted therapies.
|
AIM: To analyze the effect of chemotherapeutic drugs and specific kinase inhibitors, in combination with the death receptor ligand tumor necrosis factor-related apoptosis inducing ligand (TRAIL), on overcoming TRAIL resistance in hepatocellular carcinoma (HCC) and to study the efficacy of agonistic TRAIL antibodies, as well as the commitment of antiapoptotic BCL-2 proteins, in TRAIL-induced apoptosis.METHODS: Surface expression of TRAIL receptors (TRAIL-R1-4) and expression levels of the antiapoptotic BCL-2 proteins MCL-1 and BCL-x(L) were analyzed by flow cytometry and Western blotting, respectively. Knock-down of MCL-1 and BCL-x(L) was performed by transfecting specific small interfering RNAs. HCC cells were treated with kinase inhibitors and chemotherapeutic drugs. Apoptosis induction and cell viability were analyzed via flow cytometry and 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay.RESULTS: TRAIL-R1 and -R2 were profoundly expressed on the HCC cell lines Huh7 and Hep-G2. However, treatment of Huh7 and Hep-G2 with TRAIL and agonistic antibodies only induced minor apoptosis rates. Apoptosis resistance towards TRAIL could be considerably reduced by adding the chemotherapeutic drugs 5-fluorouracil and doxorubicin as well as the kinase inhibitors LY294002 [inhibition of phosphoinositol-3-kinase (PI3K)], AG1478 (epidermal growth factor receptor kinase), PD98059 (MEK1), rapamycin (mammalian target of rapamycin) and the multi-kinase inhibitor Sorafenib. Furthermore, the antiapoptotic BCL-2 proteins MCL-1 and BCL-x(L) play a major role in TRAIL resistance: knock-down by RNA interference increased TRAIL-induced apoptosis of HCC cells. Additionally, knock-down of MCL-1 and BCL-x(L) led to a significant sensitization of HCC cells towards inhibition of both c-Jun N-terminal kinase and PI3K.CONCLUSION: Our data identify the blockage of survival kinases, combination with chemotherapeutic drugs and targeting of antiapoptotic BCL-2 proteins as promising ways to overcome TRAIL resistance in HCC.
|
['Animals', 'Antineoplastic Agents', 'Apoptosis', 'Carcinoma, Hepatocellular', 'Cell Line, Tumor', 'Doxorubicin', 'Enzyme Inhibitors', 'Fluorouracil', 'Humans', 'Liver Neoplasms', 'Myeloid Cell Leukemia Sequence 1 Protein', 'Proto-Oncogene Proteins c-bcl-2', 'Receptors, TNF-Related Apoptosis-Inducing Ligand', 'TNF-Related Apoptosis-Inducing Ligand', 'bcl-X Protein']
| 20,014,456
|
[['B01.050'], ['D27.505.954.248'], ['G04.146.954.035'], ['C04.557.470.200.025.255', 'C04.588.274.623.160', 'C06.301.623.160', 'C06.552.697.160'], ['A11.251.210.190', 'A11.251.860.180'], ['D02.455.426.559.847.562.050.200.175', 'D04.615.562.050.200.175', 'D09.408.051.059.200.175'], ['D27.505.519.389'], ['D03.383.742.698.875.404'], ['B01.050.150.900.649.313.988.400.112.400.400'], ['C04.588.274.623', 'C06.301.623', 'C06.552.697'], ['D12.644.360.075.718.984', 'D12.776.476.075.718.968', 'D12.776.624.664.700.169.500'], ['D12.644.360.075.718', 'D12.776.476.075.718', 'D12.776.624.664.700.169'], ['D12.776.543.750.690.600', 'D12.776.543.750.705.852.760.396'], ['D12.644.276.374.750.625', 'D12.776.467.374.750.625', 'D23.529.374.750.625'], ['D12.644.360.075.718.937', 'D12.776.476.075.718.875']]
|
['Organisms [B]', 'Chemicals and Drugs [D]', 'Phenomena and Processes [G]', 'Diseases [C]', 'Anatomy [A]']
| 1
| 1
| 1
| 1
| 0
| 0
| 1
| 0
| 0
| 0
| 0
| 0
| 0
| 0
|
Mapping of nuclease-sensitive sites in native reticulocyte ribosomes--an analysis of the accessibility of ribosomal RNA to enzymatic cleavage.
|
Treatment of ribosomes in reticulocyte lysates with low concentrations of the calcium-dependent nuclease from Staphylococcus aureus resulted in cleavage of rRNA. The positions of the cleaved phosphodiester bonds were localised by primer extension and polyacrylamide gel electrophoresis. S. aureus nuclease-induced strand scissions were found in the 5'-domain of 18S rRNA and in domains II, IV and VI of 28S rRNA. The majority of the cleavage sites were located in eukaryote-specific expansion segments and only one cleavage site was found in a region suggested to be directly involved in ribosomal function. Treatment of the reticulocyte lysate with increasing amounts of S. aureus nuclease resulted in the introduction of new cleavage sites. However, even at the highest nuclease concentration used, large parts of the rRNAs were protected from nuclease digestion. Removal of translational components, by salt wash of isolated reticulocyte polysomes, exposed additional rRNA sequences to S. aureus nuclease cleavage. These sequences were found in the 3'-major domain of 18S rRNA and in domains II, IV, and V of 28S rRNA. These sites are located at the putative translational surface of the ribosome. The translational activity of the S. aureus nuclease-treated ribosomes, determined after addition of exogenous mRNA, was directly correlated to the extent of nuclease digestion of the ribosomes. However, the decrease in translational activity observed in lysates treated with low amounts of S. aureus nuclease was not due to a preferential exclusion of damaged ribosomes from polysome formation. This suggests that the induced cleavages were not detrimental to ribosomal function but could influence the rate of ribosomal movement along the mRNA.
|
['Animals', 'Protein Biosynthesis', 'RNA, Ribosomal', 'Rabbits', 'Reticulocytes', 'Ribonucleases', 'Ribosomes', 'Staphylococcus aureus']
| 9,249,022
|
[['B01.050'], ['G02.111.660.871', 'G03.734.871', 'G05.297.670'], ['D13.444.735.686'], ['B01.050.150.900.649.313.968.700'], ['A11.118.290.760', 'A11.148.790', 'A11.443.240.665', 'A15.145.229.334.760', 'A15.378.316.790'], ['D08.811.277.352.700'], ['A11.284.430.214.190.875.811'], ['B03.300.390.400.800.750.100', 'B03.353.500.750.750.100', 'B03.510.100.750.750.100', 'B03.510.400.790.750.100']]
|
['Organisms [B]', 'Phenomena and Processes [G]', 'Chemicals and Drugs [D]', 'Anatomy [A]']
| 1
| 1
| 0
| 1
| 0
| 0
| 1
| 0
| 0
| 0
| 0
| 0
| 0
| 0
|
The YggX protein of Salmonella enterica is involved in Fe(II) trafficking and minimizes the DNA damage caused by hydroxyl radicals: residue CYS-7 is essential for YggX function.
|
Previous work from our laboratory identified YggX as a protein whose accumulation increased the resistance of Salmonella enterica to superoxide stress, reversed defects attributed to oxidized [Fe-S] clusters, and decreased the spontaneous mutation frequency of the cells. Here we present work aimed at determining why the accumulation of YggX correlates with reduced mutation frequency. Genetic and biochemical data showed that accumulation of YggX reduced the damage to DNA by hydroxyl radicals. The ability of purified YggX to protect DNA from Fenton chemistry mediated damage in vitro and to decrease the concentration of Fe(II) ions in solution available for chelation provided a framework for the interpretation of data obtained from in vivo experiments. The interpretation of in vitro assay results, within the context of the in vivo phenotypes, was validated by a mutant variant of YggX (C7S) that was unable to function in vivo or in vitro. We propose a model, based on data presented here and reported earlier, that suggests YggX is a player in Fe(II) trafficking in bacteria.
|
['Bacterial Proteins', 'DNA Damage', 'DNA Glycosylases', 'Gene Expression Regulation, Bacterial', 'Hydroxyl Radical', 'In Vitro Techniques', 'Iron', 'Mutagenesis', 'N-Glycosyl Hydrolases', 'Salmonella enterica', 'Species Specificity']
| 12,670,952
|
[['D12.776.097'], ['G05.200'], ['D08.811.074.249', 'D08.811.277.450.430.099'], ['G05.308.300'], ['D01.045.250.357', 'D01.248.497.158.459.300', 'D01.339.431.249'], ['E05.481'], ['D01.268.556.412', 'D01.268.956.287', 'D01.552.544.412'], ['G05.558'], ['D08.811.277.450.430'], ['B03.440.450.425.800.200', 'B03.660.250.150.710.160'], ['G16.824']]
|
['Chemicals and Drugs [D]', 'Phenomena and Processes [G]', 'Analytical, Diagnostic and Therapeutic Techniques, and Equipment [E]', 'Organisms [B]']
| 0
| 1
| 0
| 1
| 1
| 0
| 1
| 0
| 0
| 0
| 0
| 0
| 0
| 0
|
Synthesis and pharmacological examination of 1-(3-methoxy-4-methylphenyl)-2-aminopropane and 5-methoxy-6-methyl-2-aminoindan: similarities to 3,4-(methylenedioxy)methamphetamine (MDMA).
|
The racemate and the enantiomers of 1-(3-methoxy-4-methyphenyl)-2- aminopropane (6) and racemic 5-methoxy-6-methyl-2-aminoindan (11) were tested for stimulus generalization in the two-lever drug-discrimination paradigm. Both 6 and 11 were found to substitute with high potency in 3,4-(methylenedioxy)methamphetamine (1) and (S)-1-(1,3-benzodioxol-5-yl)-2-(methylamino)butane (2) trained rats. In the latter assay, both enantiomers of 6 had identical potencies, but their dose-response curves were not parallel. Racemic 6, but not 11, partially substituted for LSD. Racemic 6 and 11 did not substitute in (S)-amphetamine-trained rats. All of the test compounds were potent inhibitors of [3H]-5-HT uptake into synaptosomes in vitro, with the S enantiomer of 6 being most active. Rat brain monoamine levels were unaltered 1 week following a single high dose (10 or 20 mg/kg, sc) of 6 or 11, or two weeks following a subacute dosing regimen (20 mg/kg, sc, twice a day for 4 days). In addition, radioligand-binding parameters in rat brain homogenate with the 5-HT uptake inhibitor [3H]paroxetine were unchanged after subacute dosing with either racemic 6 or 11. The results indicate that compounds 6 and 11 have animal behavioral pharmacology similar to the methylenedioxy compounds 1 and 2, but that they do not induce the serotonin neurotoxicity that has been observed for the latter two drugs.
|
['3,4-Methylenedioxyamphetamine', 'Animals', 'Behavior, Animal', 'Brain', 'Chemical Phenomena', 'Chemistry', 'Dose-Response Relationship, Drug', 'Indans', 'Male', 'N-Methyl-3,4-methylenedioxyamphetamine', 'Phenethylamines', 'Rats', 'Rats, Inbred Strains', 'Serotonin Antagonists', 'Stereoisomerism', 'Structure-Activity Relationship']
| 1,674,539
|
[['D02.092.471.683.152.660'], ['B01.050'], ['F01.145.113'], ['A08.186.211'], ['G02'], ['H01.181'], ['G07.690.773.875', 'G07.690.936.500'], ['D02.455.426.559.847.486.487', 'D04.615.486.487'], ['D02.092.471.683.152.670'], ['D02.092.471.683'], ['B01.050.150.900.649.313.992.635.505.700'], ['B01.050.050.199.520.760', 'B01.050.150.900.649.313.992.635.505.700.400'], ['D27.505.519.625.850.850', 'D27.505.696.577.850.850'], ['G02.607.445.682'], ['G02.111.830', 'G07.690.773.997']]
|
['Chemicals and Drugs [D]', 'Organisms [B]', 'Psychiatry and Psychology [F]', 'Anatomy [A]', 'Phenomena and Processes [G]', 'Disciplines and Occupations [H]']
| 1
| 1
| 0
| 1
| 0
| 1
| 1
| 1
| 0
| 0
| 0
| 0
| 0
| 0
|
Triplet chemotherapy for malignant pericardial mesothelioma: a case report.
|
Malignant pericardial mesothelioma (MPM) is a relatively rare neoplasm in Japan, and no standard treatment regimens have been established for this disease. A 47-year-old woman with MPM presenting with cardiac tamponade was treated using four cycles of chemotherapy consisting of cisplatin (CDDP) 40 mg/m2, gemcitabine (GEM) 800 mg/m2 and vinorelbine (VNR) 20 mg/m2 on days 1 and 8 every 4 weeks after pericardial drainage alone. The diagnosis of MPM was confirmed by an immunohistochemical procedure using either positive or negative markers of malignant mesothelioma in addition to conventional cytological examinations using pericardial effusion. The patient experienced no severe non-hematological or hematological toxicities except for grade 3 neutropenia. The patient has returned to her usual activities and has remained well for 24 months after the last chemotherapy without any evidence of disease progression.
|
['Antineoplastic Combined Chemotherapy Protocols', 'Cisplatin', 'Deoxycytidine', 'Drainage', 'Drug Administration Schedule', 'Female', 'Heart Neoplasms', 'Humans', 'Mesothelioma', 'Middle Aged', 'Neutropenia', 'Pericardial Effusion', 'Remission Induction', 'Survivors', 'Vinblastine', 'Vinorelbine']
| 16,533,802
|
[['E02.183.750.500', 'E02.319.077.500', 'E02.319.310.037'], ['D01.210.375', 'D01.625.125', 'D01.710.100'], ['D03.383.742.680.245.500', 'D13.570.230.329', 'D13.570.685.245.500'], ['E02.309', 'E04.237'], ['E02.319.283'], ['C04.588.894.309', 'C14.280.459'], ['B01.050.150.900.649.313.988.400.112.400.400'], ['C04.557.470.035.510', 'C04.557.470.660.510'], ['M01.060.116.630'], ['C15.378.553.546.184.564'], ['C14.280.695'], ['E02.860'], ['M01.860'], ['D03.132.436.681.827.650', 'D03.633.100.473.402.681.827.650', 'D03.633.100.496.500.500.681.827.650'], ['D03.132.436.681.827.915', 'D03.633.100.473.402.681.827.915', 'D03.633.100.496.500.500.681.827.915']]
|
['Analytical, Diagnostic and Therapeutic Techniques, and Equipment [E]', 'Chemicals and Drugs [D]', 'Diseases [C]', 'Organisms [B]', 'Named Groups [M]']
| 0
| 1
| 1
| 1
| 1
| 0
| 0
| 0
| 0
| 0
| 0
| 1
| 0
| 0
|
Expression of serum survivin protein in diagnosis and prognosis of gallbladder cancer: a comparative study.
|
The role of survivin in gallbladder cancer (GBC) has not been evaluated. We investigated survivin protein expression in serum of patients with gallbladder diseases (cholelithiasis, n = 30; GBC, n = 39) and compared with healthy controls (n = 25). Clinicopathological parameters, diagnosis and prognosis of patients with GBC were correlated with the expression of serum survivin by enzyme-linked immunosorbent assay. Significantly higher (P < 0.0001) expression of survivin protein was observed in GBC as compared to cholelithiasis and control. Increased survivin expression was significantly associated with higher tumor stage (stage III vs. stage II; P < 0.0001) and cellular differentiation (poor and moderate vs. well differentiated; P < 0.0001) in GBC. No significant correlation was observed with any of the other clinico-pathological parameters studied. The cutoff value of survivin protein of 79 pg/ml with sensitivity of 81.16 % and specificity of 80 % differentiated the diseased group (cholelithiasis or GBC) from control group were as the cutoff value of 109 pg/ml differentiated GBC from cholelithiasis with a sensitivity of 82.05 % and specificity of 93.33 %. Though not significant, increased expression of survivin was associated with median overall survival (12 vs. 18 months; P = 0.05) in GBC patients. Our study suggests that survivin protein in serum could be both a useful diagnostic marker and an important prognostic factor for GBC.
|
['Adult', 'Biomarkers, Tumor', 'Case-Control Studies', 'Cholelithiasis', 'Female', 'Gallbladder Neoplasms', 'Humans', 'Inhibitor of Apoptosis Proteins', 'Kaplan-Meier Estimate', 'Male', 'Middle Aged', 'Prognosis', 'ROC Curve', 'Survivin']
| 25,129,311
|
[['M01.060.116'], ['D23.101.140'], ['E05.318.372.500.500', 'N05.715.360.330.500.500', 'N06.850.520.450.500.500'], ['C06.130.409'], ['C04.588.274.120.401', 'C06.130.320.401', 'C06.130.564.401', 'C06.301.120.401'], ['B01.050.150.900.649.313.988.400.112.400.400'], ['D08.811.464.938.750.210', 'D12.644.360.075.437', 'D12.776.476.075.437'], ['E05.318.740.998.650', 'N05.715.360.750.795.650', 'N06.850.520.830.998.650'], ['M01.060.116.630'], ['E01.789'], ['E05.318.370.800.750', 'E05.318.740.872.750', 'N05.715.360.325.700.680', 'N06.850.520.445.800.750'], ['D12.644.360.075.437.625', 'D12.776.167.576', 'D12.776.220.600.450.495', 'D12.776.476.075.437.625']]
|
['Named Groups [M]', 'Chemicals and Drugs [D]', 'Analytical, Diagnostic and Therapeutic Techniques, and Equipment [E]', 'Health Care [N]', 'Diseases [C]', 'Organisms [B]']
| 0
| 1
| 1
| 1
| 1
| 0
| 0
| 0
| 0
| 0
| 0
| 1
| 1
| 0
|
1,25-dihydroxyvitamin D3 induces LL-37 and HBD-2 production in keratinocytes from diabetic foot ulcers promoting wound healing: an in vitro model.
|
Diabetic foot ulcers (DFU) are one of the most common diabetes-related cause of hospitalization and often lead to severe infections and poor healing. It has been recently reported that patients with DFU have lower levels of antimicrobial peptides (AMPs) at the lesion area, which contributes with the impairment of wound healing. The aim of this study was to determine whether 1,25-dihydroxyvitamin D3 (1,25 (OH)2 D3) and L-isoleucine induced HBD-2 and LL-37 in primary cultures from DFU. We developed primary cell cultures from skin biopsies from 15 patients with DFU and 15 from healthy donors. Cultures were treated with 1,25 (OH)2D3 or L-isoleucine for 18 h. Keratinocytes phenotype was identified by western blot and flow cytometry. Real time qPCR for DEFB4, CAMP and VDR gene expression was performed as well as an ELISA to measure HBD-2 and LL-37 in supernatant. Antimicrobial activity, in vitro, wound healing and proliferation assays were performed with conditioned supernatant. The results show that primary culture from DFU treated with 1,25(OH)2D3, increased DEFB4 and CAMP gene expression and increased the production of HBD-2 and LL-37 in the culture supernatant. These supernatants had antimicrobial activity over E. coli and induced remarkable keratinocyte migration. In conclusion the 1,25(OH)2D3 restored the production of AMPs in primary cell from DFU which were capable to improve the in vitro wound healing assays, suggesting their potential therapeutic use on the treatment of DFU.
|
['Adult', 'Aged', 'Aged, 80 and over', 'Antimicrobial Cationic Peptides', 'Biopsy', 'Case-Control Studies', 'Cathelicidins', 'Cell Movement', 'Cell Proliferation', 'Cells, Cultured', 'Culture Media, Conditioned', 'Diabetic Foot', 'Female', 'Gene Expression Regulation', 'Humans', 'Keratinocytes', 'Male', 'Middle Aged', 'Phenotype', 'Receptors, Calcitriol', 'Vitamin D', 'Wound Healing', 'beta-Defensins']
| 25,337,708
|
[['M01.060.116'], ['M01.060.116.100'], ['M01.060.116.100.080'], ['D12.644.050', 'D12.776.543.695.054'], ['E01.370.225.500.384.100', 'E01.370.225.998.054', 'E01.370.388.100', 'E04.074', 'E05.200.500.384.100', 'E05.200.998.054', 'E05.242.384.100'], ['E05.318.372.500.500', 'N05.715.360.330.500.500', 'N06.850.520.450.500.500'], ['D12.644.050.099', 'D12.776.543.695.054.099'], ['G04.198', 'G07.568.500.180'], ['G04.161.750', 'G07.345.249.410.750'], ['A11.251'], ['D27.720.470.305.250', 'E07.206.250'], ['C14.907.320.191', 'C17.800.893.592.450.200', 'C19.246.099.500.191', 'C19.246.099.937.250'], ['G05.308'], ['B01.050.150.900.649.313.988.400.112.400.400'], ['A11.409.500', 'A11.436.397'], ['M01.060.116.630'], ['G05.695'], ['D12.776.826.535'], ['D04.210.500.812.768'], ['G16.762.891'], ['D12.644.050.200.075', 'D12.776.543.695.054.200.075']]
|
['Named Groups [M]', 'Chemicals and Drugs [D]', 'Analytical, Diagnostic and Therapeutic Techniques, and Equipment [E]', 'Health Care [N]', 'Phenomena and Processes [G]', 'Anatomy [A]', 'Diseases [C]', 'Organisms [B]']
| 1
| 1
| 1
| 1
| 1
| 0
| 1
| 0
| 0
| 0
| 0
| 1
| 1
| 0
|
Wound healing in tadpole tailfin pieces in vitro.
|
Explants of tail fins from R. catesbeiana tadpoles undergo reepithelialization of their cut surfaces (healing) when cultured in vitro in Hanks' balanced salt solution at 22 degrees C. Healing is initiated early and closure of the wound is complete by 12 to 24 hours. Morphogenesis continues for several days as further reorganization and migration of epidermal cells from the regions adjacent to the wound margins take place. The addition of serum to the culture media improves the general appearance of these tissues and promotes healing. The rate of healing is affected by temperature. Tail fins maintained at 10 degrees C do not heal while fins maintained at 30 degrees and 37 degrees, although healing more rapidly than at 22 degrees, undergo progressive degeneration in culture. Epidermal cell movements were also studied in explants consisting of a combination of intact tail fin plus tail fin deprived of its epithelium. Rapid and extensive migration of epidermal cells from the intact tail fin across the collagen lamella of the stripped fin is observed.
|
['Animals', 'Anura', 'Culture Media', 'Culture Techniques', 'Larva', 'Rana catesbeiana', 'Skin Physiological Phenomena', 'Temperature', 'Wound Healing']
| 308,094
|
[['B01.050'], ['B01.050.150.900.090.180'], ['D27.720.470.305', 'E07.206'], ['E05.481.500'], ['B05.500.500', 'G07.345.500.550.500.500'], ['B01.050.150.900.090.180.708.180'], ['G13.750'], ['G01.906.595', 'G16.500.275.063.725.710', 'G16.500.750.775.710', 'N06.230.150.450', 'N06.230.300.100.725.710'], ['G16.762.891']]
|
['Organisms [B]', 'Chemicals and Drugs [D]', 'Analytical, Diagnostic and Therapeutic Techniques, and Equipment [E]', 'Phenomena and Processes [G]', 'Health Care [N]']
| 0
| 1
| 0
| 1
| 1
| 0
| 1
| 0
| 0
| 0
| 0
| 0
| 1
| 0
|
Use of a Vero cell-based fluorescent assay to assess relative toxicities of Shiga toxin 2 subtypes from Escherichia coli.
|
Shiga toxin-producing Escherichia coli is a leading cause of human gastroenteritis from food and waterborne sources worldwide. Shiga toxins 1 and 2 are important virulence factors linked to severe human illness. In particular, Shiga toxin 2 is composed of a diverse and heterogeneous group of subtypes with differential cytotoxicities in mammalian cells. In this chapter, we describe the use of the Vero-d2EGFP fluorescent assay to examine the relative toxicities of Stx2 and Stx2 subtypes expressed by strains of Shiga toxin-producing E. coli.
|
['Animals', 'Chlorocebus aethiops', 'Food Contamination', 'Green Fluorescent Proteins', 'Microscopy, Fluorescence', 'Shiga Toxin 1', 'Shiga Toxin 2', 'Shiga-Toxigenic Escherichia coli', 'Toxicity Tests', 'Vero Cells', 'Virulence Factors']
| 21,567,318
|
[['B01.050'], ['B01.050.150.900.649.313.988.400.112.199.120.126.110'], ['J01.576.423.850.730.500.249', 'N06.850.460.400', 'N06.850.601.500.249'], ['D12.776.532.265'], ['E01.370.350.515.458', 'E05.595.458'], ['D08.811.277.450.430.700.750.750.120', 'D12.776.097.275.877', 'D23.946.123.794.100', 'D23.946.330.575.120'], ['D08.811.277.450.430.700.750.750.124', 'D12.776.097.275.879', 'D23.946.123.794.124', 'D23.946.330.575.124'], ['B03.440.450.425.325.300.800', 'B03.660.250.150.180.100.800'], ['E05.940'], ['A11.251.210.955', 'A11.436.955'], ['D23.946.896']]
|
['Organisms [B]', 'Technology, Industry, and Agriculture [J]', 'Health Care [N]', 'Chemicals and Drugs [D]', 'Analytical, Diagnostic and Therapeutic Techniques, and Equipment [E]', 'Anatomy [A]']
| 1
| 1
| 0
| 1
| 1
| 0
| 0
| 0
| 0
| 1
| 0
| 0
| 1
| 0
|
Understanding the role of sex differences in work injuries: implications for primary care practice.
|
PURPOSE: Primary care physicians care for work-injured women and men, yet there is little information on sex differences in outcomes and factors contributing to post-injury outcomes to guide their evaluation and recommendations.METHODS: Two self-administered questionnaires were sent to a large sample of women and men with work injuries reported to the New Hampshire (USA) Department of Labour between November 2000 and March 2002. Factors associated with the work injury and outcomes were assessed.RESULTS: A total of 3001 persons (1448 women and 1553 men) completed the first questionnaire and 67% completed the second questionnaire. Work-injured women were significantly younger, more educated, more likely to be single, had more pre-injury comorbidities, and worked in less physically demanding occupations as compared to work-injured men. Women's injuries were more often a result of routine job tasks and of gradual onset. Women had worse long-term outcomes including job stability and post-injury income. In multivariate analyses, being female was independently associated with a negative employer response and greater future work concerns.CONCLUSIONS: Women and men differ in terms of work injury circumstances and factors contributing to post-injury outcomes. Primary care providers should consider sex when evaluating and treating work-injured adults.
|
['Accidents, Occupational', 'Adult', 'Age Factors', 'Cross-Sectional Studies', 'Data Collection', 'Female', 'Humans', 'Job Description', 'Male', 'Middle Aged', 'Multivariate Analysis', 'New Hampshire', 'Primary Health Care', 'Prognosis', 'Sex Factors', 'Socioeconomic Factors', 'Wounds and Injuries']
| 17,852,283
|
[['N06.850.135.240'], ['M01.060.116'], ['N05.715.350.075', 'N06.850.490.250'], ['E05.318.372.500.875', 'N05.715.360.330.500.875', 'N06.850.520.450.500.875'], ['E05.318.308', 'L01.399.250', 'N05.715.360.300', 'N06.850.520.308'], ['B01.050.150.900.649.313.988.400.112.400.400'], ['N04.452.677.410'], ['M01.060.116.630'], ['E05.318.740.150.500', 'N05.715.360.750.125.500', 'N06.850.520.830.150.500'], ['Z01.107.567.875.550.580'], ['N04.590.233.727'], ['E01.789'], ['N05.715.350.675', 'N06.850.490.875'], ['I01.880.853.996', 'N01.824'], ['C26']]
|
['Health Care [N]', 'Named Groups [M]', 'Analytical, Diagnostic and Therapeutic Techniques, and Equipment [E]', 'Information Science [L]', 'Organisms [B]', 'Geographicals [Z]', 'Anthropology, Education, Sociology, and Social Phenomena [I]', 'Diseases [C]']
| 0
| 1
| 1
| 0
| 1
| 0
| 0
| 0
| 1
| 0
| 1
| 1
| 1
| 1
|
Using connected objects in clinical research.
|
Connected objects (CO), whether medical devices or not, are used in clinical research for data collection, a specific activity (communication, diagnosis, effector, etc.), or several functions combined. Their validation should be based on three approaches: technical and clinical reliability, data protection and cybersecurity. Consequently, the round table recommends that the typology of COs, their uses and limitations, be known and shared by all, particularly for implementing precise specifications. COs are used in clinical research during observational studies (assessment of the device itself or data collection), randomized studies, where only one group has a CO (assessment of its impact on patient follow-up or management), or randomized studies where both groups have a CO, which is then used as a tool to help with assessment. The benefits of using COs in clinical research includes: improved collection and quality of data, compliance of patients and pharmacovigilance, easier implementation of e-cohorts and a better representative balance of patients. The societal limits and risks identified relate to the sometimes intrusive nature of certain collected parameters and the possible misuse of data. The round table recommends the following on this last point: anticipation, by securing transmission methods, the qualification of data hosts, and assessment of the object's vulnerability. For this, a risk analysis appears necessary for each project. It is also necessary to accurately document the data flow, in order to inform both patients and healthcare professionals and to ensure adequate security. Anticipating regulatory changes and involving users starting from the study design stage are also recommended.
|
['Biomedical Research', 'Computer Communication Networks', 'Computer Security', 'Data Collection', 'Europe', 'Humans', 'Telemetry']
| 29,478,706
|
[['H01.770.644.145'], ['L01.224.230.110'], ['L01.224.134', 'N04.452.910.200'], ['E05.318.308', 'L01.399.250', 'N05.715.360.300', 'N06.850.520.308'], ['Z01.542'], ['B01.050.150.900.649.313.988.400.112.400.400'], ['E01.370.520.750', 'E05.925', 'L01.178.847.675']]
|
['Disciplines and Occupations [H]', 'Information Science [L]', 'Health Care [N]', 'Analytical, Diagnostic and Therapeutic Techniques, and Equipment [E]', 'Geographicals [Z]', 'Organisms [B]']
| 0
| 1
| 0
| 0
| 1
| 0
| 0
| 1
| 0
| 0
| 1
| 0
| 1
| 1
|
The dependency of bioactive follicle-stimulating hormone secretion on gonadotropin-releasing hormone in hypogonadal and cycling women.
|
An antagonist analog of GnRH, (Ac-delta 3-Pro1,p-F-D-Phe2,D-Trp3,6)GnRH (4F-antagonist), was administered to normal women and women with hypergonadotropic hypogonadism. Serum FSH levels were determined by both the granulosa cell aromatase bioassay and RIA. The constant infusion of 4F-antagonist (30 micrograms/kg.h) to the four hypogonadal women resulted in a more pronounced decline in bioactive FSH (62%) than in immunoreactive FSH levels (30%), and the FSH bioactive to immunoreactive ratio decreased significantly (P less than 0.05). Infusion of 4F-antagonist in normal women in the midfollicular phase revealed a similar pattern of suppression of bioactive (64%) and immunoreactive FSH (29%). When 4F-antagonist was administered sc at a dose of 80 micrograms/kg twice daily for 3 days to normal women in the midfollicular phase of their cycles, the bioactive FSH response was biphasic, with the maximal decrease on the second day, followed by return to basal levels on the third day. Correspondingly, there was a precipitous decline in serum estradiol (apparent demise of the dominant follicle), followed by a progressive rise in estradiol levels. Thus, in contrast to immunoreactive FSH levels, bioactive FSH more clearly reflects the biological action of FSH on the follicle in response to GnRH antagonist administration in women. The disparity in the quantitative decline between serum bioactive and immunoreactive FSH levels after presumed blockade of the GnRH receptor may reflect the microheterogeneity of the FSH molecule and suggests that alterations in the biological activity of secreted FSH may be GnRH dependent.
|
['Adult', 'Biological Assay', 'Estradiol', 'Female', 'Follicle Stimulating Hormone', 'Follicular Phase', 'Gonadotropin-Releasing Hormone', 'Humans', 'Hypogonadism', 'Menstrual Cycle', 'Middle Aged', 'Radioimmunoassay']
| 3,123,512
|
[['M01.060.116'], ['E05.091'], ['D04.210.500.365.415.248', 'D06.472.334.851.437.500'], ['D06.472.699.322.576.288', 'D06.472.699.631.525.343.288', 'D12.644.548.691.525.343.288'], ['G08.686.605.310'], ['D06.472.699.327.740.320', 'D12.644.400.400.740.320', 'D12.644.456.460', 'D12.644.548.365.740.320', 'D12.776.631.650.405.740.320'], ['B01.050.150.900.649.313.988.400.112.400.400'], ['C19.391.482'], ['G08.686.605'], ['M01.060.116.630'], ['E01.370.384.700', 'E05.478.566.639', 'E05.601.470.639']]
|
['Named Groups [M]', 'Analytical, Diagnostic and Therapeutic Techniques, and Equipment [E]', 'Chemicals and Drugs [D]', 'Phenomena and Processes [G]', 'Organisms [B]', 'Diseases [C]']
| 0
| 1
| 1
| 1
| 1
| 0
| 1
| 0
| 0
| 0
| 0
| 1
| 0
| 0
|
Isoelectric focusing of phosphorylated cattle rhodopsin.
|
32P-rhodopsin was partially separated by isoelectric focusing into several fractions of different phosphorylation extent. It was found that the incorporated phosphate is not uniformly distributed in a population of rhodopsin molecules. In a preparation with an average phosphorylation extent of 2.4 moles of phosphate per mole of rhodopsin, most of the 32P-phosphate was found in fractions where 4-5 phosphates are bound per rhodopsin, whereas a large fraction of the total rhodopsin was not phosphorylated at all. The maximum number os phosphate binding sites in rhodopsin appears to be at least five.
|
['Animals', 'Cattle', 'Isoelectric Focusing', 'Phosphates', 'Photoreceptor Cells', 'Protein Binding', 'Retinal Pigments', 'Rhodopsin']
| 890,058
|
[['B01.050'], ['B01.050.150.900.649.313.500.380.271'], ['E05.196.401.663', 'E05.301.300.663'], ['D01.029.260.700.675.374', 'D01.248.497.158.730', 'D01.695.625.675.650'], ['A08.675.650.850.625', 'A08.675.650.915.937', 'A08.800.950.937', 'A09.371.729.831.625', 'A11.671.650.850.625', 'A11.671.650.915.937'], ['G02.111.679', 'G03.808'], ['D23.767.930'], ['D12.776.543.750.695.955', 'D23.767.930.750.500.500']]
|
['Organisms [B]', 'Analytical, Diagnostic and Therapeutic Techniques, and Equipment [E]', 'Chemicals and Drugs [D]', 'Anatomy [A]', 'Phenomena and Processes [G]']
| 1
| 1
| 0
| 1
| 1
| 0
| 1
| 0
| 0
| 0
| 0
| 0
| 0
| 0
|
Acquired slow-channel syndrome.
|
We report the case of a 37-year-old man with clinical and electrophysiological features of hereditary slow-channel syndrome (SCS) and antibodies against acetylcholine receptors (AChR-Abs). He presented with weakness of shoulder and hand muscles. A supramaximal single stimulus to the motor nerves disclosed a double compound muscle action potential (CMAP). Repetitive stimulation of ulnar, suprascapular, and median nerves showed a CMAP decrement greater than 10%. The patient responded to pyridostigmine. This report confirms the importance of AChR-Ab titers in suspected cases of hereditary SCS because patients with positive AChR-Abs may have a better response to available treatments.
|
['Adult', 'Humans', 'Male', 'Muscles', 'Myasthenic Syndromes, Congenital', 'Neural Conduction']
| 11,003,795
|
[['M01.060.116'], ['B01.050.150.900.649.313.988.400.112.400.400'], ['A02.633', 'A10.690'], ['C10.668.758.800', 'C16.320.590'], ['G07.265.753', 'G11.561.601']]
|
['Named Groups [M]', 'Organisms [B]', 'Anatomy [A]', 'Diseases [C]', 'Phenomena and Processes [G]']
| 1
| 1
| 1
| 0
| 0
| 0
| 1
| 0
| 0
| 0
| 0
| 1
| 0
| 0
|
Pharmacokinetics and pharmacodynamics of slow-release theophylline during treatment with nimesulide.
|
The pharmacodynamic and pharmacokinetic interactions were studied between nimesulide, a recently introduced non-steroidal anti-inflammatory drug, and theophylline, another highly protein-bound drug, in patients who were receiving slow-release theophylline for a chronic airflow-obstruction and who also needed anti-inflammatory treatment. A good tolerability was demonstrated of the two drugs association and there was an absence of pharmacodynamic interaction, as shown by lung function parameters, assayed before and after the coinciding nimesulide association. The pharmacokinetics of nimesulide and 4-hydroxy-nimesulide (its active metabolite) were not modified, in agreement with data shown by other authors. On the contrary, there was a slight alteration of theophylline pharmacokinetics, yet neither clinically nor biologically significant, probably due to an enzymatic induction.
|
['Adolescent', 'Adult', 'Aged', 'Delayed-Action Preparations', 'Drug Interactions', 'Female', 'Humans', 'Male', 'Middle Aged', 'Sulfonamides', 'Theophylline']
| 1,814,842
|
[['M01.060.057'], ['M01.060.116'], ['M01.060.116.100'], ['D26.255.210', 'E02.319.300.253'], ['G07.690.773.968'], ['B01.050.150.900.649.313.988.400.112.400.400'], ['M01.060.116.630'], ['D02.065.884', 'D02.886.590.700'], ['D03.132.960.751', 'D03.633.100.759.758.824.751']]
|
['Named Groups [M]', 'Chemicals and Drugs [D]', 'Analytical, Diagnostic and Therapeutic Techniques, and Equipment [E]', 'Phenomena and Processes [G]', 'Organisms [B]']
| 0
| 1
| 0
| 1
| 1
| 0
| 1
| 0
| 0
| 0
| 0
| 1
| 0
| 0
|
Prevalence and Risk Factors of Cytopenia in HIV-Infected Patients before and after the Initiation of HAART.
|
Background: Cytopenia is a frequent hematological disorder in patients with human immunodeficiency virus (HIV) infection. However, the distribution and risk factors of cytopenia in patients starting highly active anti-retrovirus treatment (HAART) and the effect of HAART on cytopenia were not fully investigated.Methods: From November 2004 to August 2016, a retrospective study was conducted to evaluate the prevalence of cytopenia in 4325 HAART-na?ve patients. Risk factors of cytopenia at baseline and on recovery from cytopenia were analyzed using logistic regression analysis after 24 months of HAART in Beijing Ditan Hospital.Results: The prevalence of cytopenia was 19.1% in HIV-na?ve patients. Risk factors for cytopenia in HAART-na?ve patients were a CD4 cell count<200 cells/ìL, femaleness, WHO stage IV, coinfection with hepatitis B virus (HBV), BMI <18.5 kg/m2, a viral load ?100,000 copies/ml, and age ?40 years. In total, 70.2% and 76.4% of patients with cytopenia recovered after 6 and 24 months of HAART, respectively. The predictors of patients without normal blood cells after 24 months HAART were a CD4 cell count of <200 cells/ìL, femaleness, WHO stage IV, coinfection with hepatitis B virus (HBV), BMI <18.5 kg/m2, a viral load ?100,000 copies/ml, and age ?40 years. In total, 70.2% and 76.4% of patients with cytopenia recovered after 6 and 24 months of HAART, respectively. The predictors of patients without normal blood cells after 24 months HAART were a CD4 cell count of <200 cells/.Conclusion: Early detection could decrease the prevalence of HIV-related cytopenia, while starting HAART as early as possible seems to be effective for normalization of the blood cells in HIV-infected patients.
|
['Adult', 'Antiretroviral Therapy, Highly Active', 'Female', 'HIV Infections', 'Hematologic Diseases', 'Humans', 'Logistic Models', 'Male', 'Prevalence', 'Risk Factors']
| 32,090,076
|
[['M01.060.116'], ['E02.319.310.075'], ['C01.221.250.875', 'C01.221.812.640.400', 'C01.778.640.400', 'C01.925.782.815.616.400', 'C01.925.813.400', 'C20.673.480'], ['C15.378'], ['B01.050.150.900.649.313.988.400.112.400.400'], ['E05.318.740.500.525', 'E05.318.740.600.800.450', 'E05.318.740.750.450', 'E05.599.835.875', 'N05.715.360.750.530.480', 'N05.715.360.750.625.700.450', 'N05.715.360.750.695.470', 'N06.850.520.830.500.525', 'N06.850.520.830.600.800.450', 'N06.850.520.830.750.450'], ['E05.318.308.985.525.750', 'N01.224.935.597.750', 'N06.850.505.400.975.525.750', 'N06.850.520.308.985.525.750'], ['E05.318.740.600.800.725', 'N05.715.350.200.700', 'N05.715.360.750.625.700.700', 'N06.850.490.625.750', 'N06.850.520.830.600.800.725']]
|
['Named Groups [M]', 'Analytical, Diagnostic and Therapeutic Techniques, and Equipment [E]', 'Diseases [C]', 'Organisms [B]', 'Health Care [N]']
| 0
| 1
| 1
| 0
| 1
| 0
| 0
| 0
| 0
| 0
| 0
| 1
| 1
| 0
|
Beta-cell expression of 65-kDa heat-shock protein mRNA is function- and age-dependent.
|
This study examined the expression of mRNA coding for the 65-kDa heat-shock protein (HSP) in rat islet cells of different functional states and different ages. In addition, beta cells and non-beta cells purified by fluorescence-activated cell sorting were studied. Total RNA from islet cells and insulin-producing RINm5F cells was isolated and analyzed by Northern blotting using a cDNA probe coding for the human homologue to the mycobacterial 65-kDa HSP, after which blots were quantified by densitometric scanning. Isolated beta cells were found to express 65-kDa HSP mRNA. The expression was increased in Lewis islet cells exposed to heat shock or high glucose concentration, four- and three-fold, respectively (p < 0.01). In isolated beta cells cultured at high glucose concentration a doubling in the content of 65-kDa HSP mRNA was seen compared with islets cultured at low glucose concentration (p < 0.05). In islets from Lewis rats fasted for 24 h, the content of 65-kDa HSP mRNA was 42% lower than in islets isolated from normally fed Lewis rats (p < 0.01). Both in BB rats and Wistar Furth rats the content of 65-kDa HSP mRNA was found to be higher in the 30- and the 60-day-old rats compared with the neonatal animals (p < 0.01). The expression of 65-kDa HSP mRNA was increased in RINm5F cells following heat shock, while no induction was seen after stimulation with glucose, TPA or IBMX. It is concluded that the 65-kDa heat-shock protein belongs to the family of inducible functional antigens in beta cells, which strengthens the interest in 65-kDa HSP as an antigen possibly involved in the initiation of autoimmune beta-cell destruction.
|
['Age Factors', 'Animals', 'Heat-Shock Proteins', 'Islets of Langerhans', 'Male', 'RNA, Messenger', 'Rats', 'Rats, Inbred Lew']
| 1,389,096
|
[['N05.715.350.075', 'N06.850.490.250'], ['B01.050'], ['D12.776.580.216'], ['A03.734.414', 'A06.300.414'], ['D13.444.735.544'], ['B01.050.150.900.649.313.992.635.505.700'], ['B01.050.050.199.520.760.280', 'B01.050.150.900.649.313.992.635.505.700.400.280']]
|
['Health Care [N]', 'Organisms [B]', 'Chemicals and Drugs [D]', 'Anatomy [A]']
| 1
| 1
| 0
| 1
| 0
| 0
| 0
| 0
| 0
| 0
| 0
| 0
| 1
| 0
|
Overdentures on implants placed in bone augmented with fresh frozen bone.
|
AIM: In the last decade several studies have been performed to evaluate the clinical outcome of one or two stage loaded implants supporting overdentures. Since fresh frozen bone (FFB) has an ever-increasing number of clinical applications and few reports are available on implants inserted into FFB, we performed a retrospective study on fixtures inserted in FFB and bearing overdentures.METHODS: In the period between December 2003 and December 2006, 17 patients (14 females and 3 males with a median age of about 56 years) were grafted and 60 implants inserted thereafter. A total of 17 overdentures were delivered: 8 in the mandible and 9 in the maxilla. Multiple implant systems were used: 22 Double etched, 7 SLA, 9 Anodic oxidized, and 22 CaPo4 ceramic-blasted. Implant diameter ranged from 3.25 to 4.3 mm and length from 11.5 to 16.0 mm. Implants were inserted to replace 23 incisors, 9 cuspids, 20 premolars and 8 molars.RESULTS: No implants were lost (i.e., survival rate=100%) and no differences were detected among the studied variables. Kaplan Meier algorithm and Cox regression did not reveal any statistical differences among the studied variables also as regards the success rate.CONCLUSION: Implants inserted FFB and bearing overdentures have a high survival rate and success rates, which are comparable to those of implants inserted in non-grafted bone. FFB bone is a reliable material for alveolar ridge augmentation. No difference was detected among removable prostheses supported by two or more implants.
|
['Alveolar Ridge Augmentation', 'Bone Transplantation', 'Cryopreservation', 'Dental Implantation, Endosseous', 'Dental Implants, Single-Tooth', 'Denture, Overlay', 'Equipment Design', 'Female', 'Humans', 'Jaw, Edentulous', 'Jaw, Edentulous, Partially', 'Kaplan-Meier Estimate', 'Male', 'Mandible', 'Maxilla', 'Middle Aged', 'Proportional Hazards Models', 'Retrospective Studies', 'Tissue Preservation', 'Treatment Outcome']
| 21,252,845
|
[['E04.545.550.100', 'E06.645.550.100'], ['E02.095.147.725.052', 'E04.555.130', 'E04.936.580.052'], ['E01.370.225.500.620.760.160', 'E01.370.225.750.600.760.160', 'E02.792.156', 'E05.200.500.620.760.160', 'E05.200.750.600.760.160', 'E05.760.156'], ['E04.545.550.280.280', 'E04.650.230.500', 'E06.645.550.280.280', 'E06.780.314.310'], ['E06.780.346.593.185', 'E07.695.185.185'], ['E06.780.346.760.887', 'E07.695.190.200.215'], ['E05.320'], ['B01.050.150.900.649.313.988.400.112.400.400'], ['C05.500.480', 'C07.320.550', 'C07.465.550.425', 'C07.793.597.425'], ['C05.500.480.450', 'C07.320.550.450', 'C07.465.550.425.450', 'C07.793.597.425.450'], ['E05.318.740.998.650', 'N05.715.360.750.795.650', 'N06.850.520.830.998.650'], ['A02.835.232.781.324.502.632', 'A14.521.632'], ['A02.835.232.781.324.502.645', 'A14.521.645'], ['M01.060.116.630'], ['E05.318.740.500.700', 'E05.318.740.600.700', 'E05.318.740.750.725', 'E05.318.740.998.825', 'E05.599.835.900', 'N05.715.360.750.530.650', 'N05.715.360.750.625.650', 'N05.715.360.750.695.650', 'N05.715.360.750.795.825', 'N06.850.520.830.500.700', 'N06.850.520.830.600.700', 'N06.850.520.830.750.725', 'N06.850.520.830.998.912'], ['E05.318.372.500.500.500', 'E05.318.372.500.750.750', 'N05.715.360.330.500.500.500', 'N05.715.360.330.500.750.825', 'N06.850.520.450.500.500.500', 'N06.850.520.450.500.750.825'], ['E01.370.225.500.620.760', 'E01.370.225.750.600.760', 'E02.792.833', 'E05.200.500.620.760', 'E05.200.750.600.760', 'E05.760.833'], ['E01.789.800', 'N04.761.559.590.800', 'N05.715.360.575.575.800']]
|
['Analytical, Diagnostic and Therapeutic Techniques, and Equipment [E]', 'Organisms [B]', 'Diseases [C]', 'Health Care [N]', 'Anatomy [A]', 'Named Groups [M]']
| 1
| 1
| 1
| 0
| 1
| 0
| 0
| 0
| 0
| 0
| 0
| 1
| 1
| 0
|
HIV/hepatitis coinfection in eastern Europe and new pan-European approaches to hepatitis prevention and management.
|
ISSUES: HIV/hepatitis coinfection in Europe; WHO European clinical protocols on the management of people coinfected with HIV/AIDS and hepatitis B or C (HBV or HCV); stakeholder recommendations for better HCV services.INTRODUCTION: The increasing availability of highly active antiretroviral therapy throughout Europe and central Asia has changed comorbidity and mortality patterns among people living with HIV/AIDS (PLWHA) as liver disease has increasingly replaced AIDS as the cause of death in PLWHA in western European countries. The average prevalence of HCV among PLWHA is 40 per cent, and much higher in countries where the HIV epidemic is driven by injecting drug use. Access to hepatitis treatment for PLWHA and IDUs is still very limited in Europe due to a lack of clear clinical management guidelines for HIV/hepatitis coinfections, high costs and a national failure to recognise hepatitis as a critical health issue.DESCRIPTION: In October 2006, the WHO Regional Office for Europe issued protocols for the clinical management of HIV/HCV and HIV/HBV coinfections. They include diagnostic algorithms adjusted for resource availability, and guidelines for the management of patients who do not yet need treatment, those who need only hepatitis or only HIV/AIDS treatment, and those who need both. Though the protocols should provide practical guidelines for physicians and assist in the development of national treatment standards, there is still a need for targeted prevention, treatment and care interventions. To expand access to hepatitis prevention and treatment, public awareness needs to be raised and national political leaders need to address hepatitis as a public health issue. Effective public health measures include price reductions for anti-hepatitis drugs; targeted testing, counselling and prevention activities; increased access to hepatitis B and C treatment and to HBV vaccination for the populations most at risk.
|
['Antiviral Agents', 'Europe, Eastern', 'HIV Infections', 'Harm Reduction', 'Health Knowledge, Attitudes, Practice', 'Health Policy', 'Health Services Accessibility', 'Hepatitis B', 'Hepatitis C', 'Humans', 'Needle-Exchange Programs', 'Patient Education as Topic', 'Practice Guidelines as Topic', 'Prevalence', 'Substance Abuse, Intravenous', 'Viral Hepatitis Vaccines', 'World Health Organization']
| 17,854,732
|
[['D27.505.954.122.388'], ['Z01.542.248'], ['C01.221.250.875', 'C01.221.812.640.400', 'C01.778.640.400', 'C01.925.782.815.616.400', 'C01.925.813.400', 'C20.673.480'], ['F01.145.477'], ['F01.100.150.500', 'N05.300.150.410'], ['I01.655.500.608.400', 'I01.880.604.825.608.400', 'N03.623.500.608.428'], ['N04.590.374.350', 'N05.300.430'], ['C01.221.250.500', 'C01.925.256.430.400', 'C01.925.440.435', 'C06.552.380.705.437'], ['C01.221.250.750', 'C01.925.440.440', 'C01.925.782.350.350', 'C06.552.380.705.440'], ['B01.050.150.900.649.313.988.400.112.400.400'], ['N02.421.726.708'], ['I02.233.332.500', 'N02.421.726.407.680'], ['N04.761.700.350.650', 'N05.700.350.650'], ['E05.318.308.985.525.750', 'N01.224.935.597.750', 'N06.850.505.400.975.525.750', 'N06.850.520.308.985.525.750'], ['C25.775.793', 'F03.900.793'], ['D20.215.894.899.955'], ['N03.540.514.718.800']]
|
['Chemicals and Drugs [D]', 'Geographicals [Z]', 'Diseases [C]', 'Psychiatry and Psychology [F]', 'Health Care [N]', 'Anthropology, Education, Sociology, and Social Phenomena [I]', 'Organisms [B]', 'Analytical, Diagnostic and Therapeutic Techniques, and Equipment [E]']
| 0
| 1
| 1
| 1
| 1
| 1
| 0
| 0
| 1
| 0
| 0
| 0
| 1
| 1
|
Movement sequencing abilities and basal ganglia morphology in first-episode schizophrenia.
|
INTRODUCTION: Studies of brain morphology suggest a link between movement sequencing ability and basal ganglia dysfunction. Unfortunately, relevant studies have provided inconsistent data, which may be the result of differences in the methods of brain morphology assessment, statistical analysis or heterogeneity of the populations studied.AIM: To test the hypothesis of a link between the dysfunction of movement sequencing and basal ganglia morphology in a homogenous sample of first-episode schizophrenia patients.METHOD: Thirty-seven first-episode schizophrenia patients underwent an assessment of movement sequencing abilities using the NES scale and basal ganglia morphology from MR images. The data were compared with a group of 19 age- and sex-matched healthy controls.RESULTS: The group of first-episode patients had a higher concentration of gray matter than healthy controls in the putamen and pallidum in both hemispheres. Patients with abnormal sequencing of movements had lower gray matter concentration than patients without such abnormalities in the left putamen, and no differences were found between the symptomatic group and healthy controls.SUMMARY AND CONCLUSION: Our study suggests the involvement of the left putamen in the movement sequencing abnormalities in schizophrenia. Because of the potential confounding effect of medication, the lack of support from external evidence and the low power to perform the whole-brain analysis the results should be considered as preliminary. Further studies, especially with antipsychotic-naive first-episode schizophrenia patients are needed to solve these issues.
|
['Acute Disease', 'Basal Ganglia', 'Female', 'Humans', 'Magnetic Resonance Imaging', 'Male', 'Movement Disorders', 'Schizophrenia', 'Severity of Illness Index', 'Young Adult']
| 18,609,414
|
[['C23.550.291.125'], ['A08.186.211.200.885.287.249'], ['B01.050.150.900.649.313.988.400.112.400.400'], ['E01.370.350.825.500'], ['C10.228.662'], ['F03.700.750'], ['E05.318.308.980.438.475.456.500', 'N05.715.360.300.800.438.375.364.500', 'N06.850.520.308.980.438.475.364.500'], ['M01.060.116.815']]
|
['Diseases [C]', 'Anatomy [A]', 'Organisms [B]', 'Analytical, Diagnostic and Therapeutic Techniques, and Equipment [E]', 'Psychiatry and Psychology [F]', 'Health Care [N]', 'Named Groups [M]']
| 1
| 1
| 1
| 0
| 1
| 1
| 0
| 0
| 0
| 0
| 0
| 1
| 1
| 0
|
The association between red cell distribution width, erythropoietin levels, and coronary artery disease.
|
BACKGROUND: Red cell distribution width (RDW) is a cardiac marker for risk stratification and prognostic evaluation of coronary artery disease (CAD); however, the underlying mechanism remains unclear. Erythropoietin (EPO), a crucial factor affecting erythropoiesis, has been reported to be a protective molecule regulating the process of myocardial ischemia and relevant damage. No study has as yet reported the relationship between RDW and endogenous EPO in CAD patients. This cross-sectional study aimed to establish the association between endogenous EPO levels and increases in RDW in CAD patients.PATIENTS AND METHODS: Two hundred participants who underwent coronary arteriography were recruited from July 2015 to October 2015. The participants were divided into CAD and non-CAD groups on the basis of angiography diagnosis. Demographic data were obtained through personal interviews and general clinical methods.RESULTS: RDW and EPO levels in the CAD group were higher than those in the non-CAD group. The correlation between RDW and EPO levels was statistically significant among CAD patients (r=0.411, P<0.001). The increases in EPO and RDW were related to the prevalence of CAD. The levels of RDW were correlated to endogenous EPO levels in CAD patients.CONCLUSION: Increased EPO and RDW might be risk factors for CAD. Endogenous EPO levels are associated with increases in RDW in CAD patients.
|
['Aged', 'Case-Control Studies', 'Coronary Angiography', 'Coronary Artery Disease', 'Cross-Sectional Studies', 'Erythrocyte Indices', 'Erythropoietin', 'Female', 'Humans', 'Linear Models', 'Logistic Models', 'Male', 'Middle Aged', 'Risk Factors']
| 28,885,393
|
[['M01.060.116.100'], ['E05.318.372.500.500', 'N05.715.360.330.500.500', 'N06.850.520.450.500.500'], ['E01.370.350.130.625', 'E01.370.350.700.060.200', 'E01.370.370.050.200', 'E01.370.370.380.200'], ['C14.280.647.250.260', 'C14.907.137.126.339', 'C14.907.585.250.260'], ['E05.318.372.500.875', 'N05.715.360.330.500.875', 'N06.850.520.450.500.875'], ['E01.370.225.625.230', 'E05.200.625.230', 'G09.188.260'], ['D12.644.276.374.410.240.150', 'D12.776.395.240.150', 'D12.776.467.374.410.240.150', 'D23.529.374.410.240.150'], ['B01.050.150.900.649.313.988.400.112.400.400'], ['E05.318.740.500.500', 'E05.318.740.750.425', 'E05.599.835.750', 'N05.715.360.750.530.460', 'N05.715.360.750.695.460', 'N06.850.520.830.500.500', 'N06.850.520.830.750.425'], ['E05.318.740.500.525', 'E05.318.740.600.800.450', 'E05.318.740.750.450', 'E05.599.835.875', 'N05.715.360.750.530.480', 'N05.715.360.750.625.700.450', 'N05.715.360.750.695.470', 'N06.850.520.830.500.525', 'N06.850.520.830.600.800.450', 'N06.850.520.830.750.450'], ['M01.060.116.630'], ['E05.318.740.600.800.725', 'N05.715.350.200.700', 'N05.715.360.750.625.700.700', 'N06.850.490.625.750', 'N06.850.520.830.600.800.725']]
|
['Named Groups [M]', 'Analytical, Diagnostic and Therapeutic Techniques, and Equipment [E]', 'Health Care [N]', 'Diseases [C]', 'Phenomena and Processes [G]', 'Chemicals and Drugs [D]', 'Organisms [B]']
| 0
| 1
| 1
| 1
| 1
| 0
| 1
| 0
| 0
| 0
| 0
| 1
| 1
| 0
|
[Heat exchange between human body and environment (theoretical bases of physiological measurement and evaluation)].
|
In the first part of this report the theory of the heat exchange between human body and external environment is developed. In particular, the problems concerning energy expenditure and heat production [metabolic heat] during physical activity, the heat exchange between internal organs and body surface, and its elimination are considered. Proposal of heat exchange equations (in case of conduction, convection, evaporation, radiation transport) are made, and the involved parameters and constants are indicated. Some pages are devoted to heat exchange through the lung and to "perspiratio insensibilis". In the second part the problems concerning the wellbeing and the thermal discomfort are discussed. A description of some widely employed indices of thermal stress, strain and comfort concludes the report [P4SR index, HSI index, ITS index, TTL index, HR index, WBGT index, TE indices]. In the end, the Fanger equations of thermal comfort are presented and discussed.
|
['Body Temperature Regulation', 'Convection', 'Energy Metabolism', 'Hot Temperature', 'Humans', 'Lung', 'Models, Biological', 'Respiration', 'Stress, Physiological', 'Thermodynamics', 'Water Loss, Insensible']
| 10,771,731
|
[['G07.110.232', 'G07.410.421', 'G16.012.500.535'], ['G01.906.230'], ['G03.295'], ['G01.906.595.543', 'G16.500.275.063.725.710.380', 'G16.500.750.775.710.380', 'N06.230.300.100.725.232', 'N06.230.300.100.725.710.380'], ['B01.050.150.900.649.313.988.400.112.400.400'], ['A04.411'], ['E05.599.395'], ['G09.772.705'], ['G07.775'], ['G01.906'], ['G02.111.635.500.750', 'G03.615.500.750', 'G07.410.810.500.750']]
|
['Phenomena and Processes [G]', 'Health Care [N]', 'Organisms [B]', 'Anatomy [A]', 'Analytical, Diagnostic and Therapeutic Techniques, and Equipment [E]']
| 1
| 1
| 0
| 0
| 1
| 0
| 1
| 0
| 0
| 0
| 0
| 0
| 1
| 0
|
Psychological Symptoms and Well-Being After Treatment for Primary Aldosteronism.
|
Primary aldosteronism (PA) is an increasingly identified cause of secondary hypertension. PA can be caused by an aldosterone-producing adenoma or by bilateral adrenal hyperplasia, generally treated by adrenalectomy or mineralocorticoid receptor antagonists, respectively. Recent studies suggest that PA is associated with more psychological symptoms and lower levels of well-being. The purpose of this study was to investigate the associations between subtype of PA and psychological symptoms and well-being after specific treatment. We analyzed the outcomes of the Mental Health Continuum-Short Form and the Symptom Checklist in 160 patients (mean age 57 years; 74.3% males) with PA, comparing the scores for psychological symptoms and well-being between both subtypes of PA. Additionally, we performed subgroup analyses based on gender, age, time since initiation of treatment, and co-morbidity. Moreover, we compared the results with published norm scores. Mean follow-up after adrenalectomy or start of medication was four years and two months. Depressive symptoms, anxiety and obsessive-compulsive thoughts and well-being did not differ between subtypes of PA. Subgroup analysis did not reveal any differences, except for women with bilateral adrenal hyperplasia who scored higher on the anxiety subscale than women after adrenalectomy. Compared to the general population, patients with treated PA reported more psychological symptoms. In contrast, well-being did not differ significantly from norm scores. Subtype and treatment of PA were no important determinants of psychological symptoms and well-being on the long-term. We suggest that physicians should be alert for psychological symptoms, as these were more frequently present in patients with PA.
|
['Adrenalectomy', 'Adult', 'Aged', 'Aldosterone', 'Cross-Sectional Studies', 'Female', 'Follow-Up Studies', 'Humans', 'Hyperaldosteronism', 'Male', 'Middle Aged']
| 29,895,075
|
[['E04.270.115'], ['M01.060.116'], ['M01.060.116.100'], ['D04.210.500.745.745.654.062', 'D06.472.040.585.353.118'], ['E05.318.372.500.875', 'N05.715.360.330.500.875', 'N06.850.520.450.500.875'], ['E05.318.372.500.750.249', 'N05.715.360.330.500.750.350', 'N06.850.520.450.500.750.350'], ['B01.050.150.900.649.313.988.400.112.400.400'], ['C19.053.800.604'], ['M01.060.116.630']]
|
['Analytical, Diagnostic and Therapeutic Techniques, and Equipment [E]', 'Named Groups [M]', 'Chemicals and Drugs [D]', 'Health Care [N]', 'Organisms [B]', 'Diseases [C]']
| 0
| 1
| 1
| 1
| 1
| 0
| 0
| 0
| 0
| 0
| 0
| 1
| 1
| 0
|
Efficacy of different selective media for the isolation of salmonellae from faeces.
|
Comparative results obtained in isolating salmonellae from faeces by the use of tetrathionate broth, MS, and MM enrichment medium are given. The best results were obtained by tetrathionate broth prepared from infusion broth. The MS as well as the MM medium increased the total number of positive results.
|
['Culture Media', 'In Vitro Techniques', 'Salmonella', 'Salmonella Infections']
| 5,844,202
|
[['D27.720.470.305', 'E07.206'], ['E05.481'], ['B03.440.450.425.800', 'B03.660.250.150.710'], ['C01.150.252.400.310.821']]
|
['Chemicals and Drugs [D]', 'Analytical, Diagnostic and Therapeutic Techniques, and Equipment [E]', 'Organisms [B]', 'Diseases [C]']
| 0
| 1
| 1
| 1
| 1
| 0
| 0
| 0
| 0
| 0
| 0
| 0
| 0
| 0
|
A comprehensive study of ovine haemostasis to assess suitability to model human coagulation.
|
INTRODUCTION: Similarities in size, anatomy and physiology have supported the use of sheep to model a wide range of human diseases, including coagulopathy. However, coagulation studies involving sheep are limited by the absence of high quality data defining normal ovine coagulation and fibrinolysis.MATERIALS AND METHODS: Full blood examination, routine and specialised coagulation tests, rotational thromboelastometry and whole blood platelet aggregometry was performed on 50 healthy Samm & Border Leicester Cross ewes and compared to corresponding human ranges. Intraspecies breed and gender variability was investigated by comparison to a smaller population of 13 healthy Merino wethers.RESULTS: Ovine coagulation was similar to human according to routine coagulation methods (PT, aPTT, TCT, Fib(C)) and some specialised coagulation tests (vWF, AT, Plasmin Inh). Despite these similarities, ovine secondary haemostasis demonstrated substantial differences to that of human. Rapid initiation of the contact activation pathway, high levels of FVIII, low Protein C, greater overall clot firmness and a reduced capacity for clot lysis was documented in sheep. In addition, ADP and collagen agonists precipitated a reduced primary haemostatic response in sheep relative to human. Intraspecies differences in whole blood platelet aggregometry between the cohorts of sheep indicate the need for breed-specific normal ranges.CONCLUSIONS: The application of a board spectrum of coagulation assays has enabled elucidation of the similarities as well as differences between ovine and human coagulation. The new knowledge generated from this study will guide the design of future translational coagulation studies in ovine models.
|
['Animals', 'Blood Coagulation Tests', 'Female', 'Hemostasis', 'Humans', 'Male', 'Models, Animal', 'Sheep']
| 24,929,837
|
[['B01.050'], ['E01.370.225.625.115', 'E05.200.625.115'], ['G09.188.390'], ['B01.050.150.900.649.313.988.400.112.400.400'], ['E05.598'], ['B01.050.150.900.649.313.500.380.791']]
|
['Organisms [B]', 'Analytical, Diagnostic and Therapeutic Techniques, and Equipment [E]', 'Phenomena and Processes [G]']
| 0
| 1
| 0
| 0
| 1
| 0
| 1
| 0
| 0
| 0
| 0
| 0
| 0
| 0
|
Expression and display of UreA of Helicobacter acinonychis on the surface of Bacillus subtilis spores.
|
BACKGROUND: The bacterial endospore (spore) has recently been proposed as a new surface display system. Antigens and enzymes have been successfully exposed on the surface layers of the Bacillus subtilis spore, but only in a few cases the efficiency of expression and the effective surface display and have been determined. We used this heterologous expression system to produce the A subunit of the urease of the animal pathogen Helicobater acinonychis. Ureases are multi-subunit enzymes with a central role in the virulence of various bacterial pathogens and necessary for colonization of the gastric mucosa by the human pathogen H. pylori. The urease subunit UreA has been recognized as a major antigen, able to induce high levels of protection against challenge infections.RESULTS: We expressed UreA from H. acinonychis on the B. subtilis spore coat by using three different spore coat proteins as carriers and compared the efficiency of surface expression and surface display obtained with the three carriers. A combination of western-, dot-blot and immunofluorescence microscopy allowed us to conclude that, when fused to CotB, UreA is displayed on the spore surface (ca. 1 x 10(3) recombinant molecules per spore), whereas when fused to CotC, although most efficiently expressed (7-15 x 10(3) recombinant molecules per spore) and located in the coat layer, it is not displayed on the surface. Experiments with CotG gave results similar to those with CotC, but the CotG-UreA recombinant protein appeared to be partially processed.CONCLUSION: UreA was efficiently expressed on the spore coat of B. subtilis when fused to CotB, CotC or CotG. Of these three coat proteins CotC allows the highest efficiency of expression, whereas CotB is the most appropriate for the display of heterologous proteins on the spore surface.
|
['Bacillus subtilis', 'Bacterial Proteins', 'Gene Expression', 'Helicobacter', 'Recombinant Fusion Proteins', 'Spores, Bacterial', 'Urease']
| 20,082,702
|
[['B03.300.390.400.158.218.725', 'B03.353.500.100.218.725', 'B03.510.100.100.218.725', 'B03.510.415.400.158.218.725', 'B03.510.460.410.158.218.725'], ['D12.776.097'], ['G05.297'], ['B03.440.500', 'B03.660.150.235.500.250'], ['D12.776.828.300'], ['A11.870.700', 'B05.775.700'], ['D08.811.277.087.902']]
|
['Organisms [B]', 'Chemicals and Drugs [D]', 'Phenomena and Processes [G]', 'Anatomy [A]']
| 1
| 1
| 0
| 1
| 0
| 0
| 1
| 0
| 0
| 0
| 0
| 0
| 0
| 0
|
Maintenance Electroconvulsive Therapy in Severe Bipolar Disorder: A Retrospective Chart Review.
|
OBJECTIVE: The aim of this study was to evaluate the effectiveness of continuation and maintenance electroconvulsive therapy (C/M-ECT) in patients with bipolar or schizoaffective disorder.METHODS: We reviewed the charts of all patients diagnosed with a bipolar or schizoaffective disorder treated with C/M-ECT from August 2009 until December 2013. We gathered demographic data and treatment variables (electrode placement, stimulus dose, and concomitant use of medication; number of C/M-ECT sessions; and number of new ECT courses). Primary outcome measure was the number of hospitalization days during C/M-ECT as compared with an equal period before starting the index course.RESULTS: Twenty women (64.5%) and 11 men (35.5%) with a Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition bipolar disorder (n = 22, 71%) or schizoaffective disorder (n = 9, 29%) received C/M-ECT. The mean (SD) age was 51.23 (14.86; range, 28-74) years. Before the start of the index ECT, patients had a mean of 290 hospitalization days (248.4 days, full hospitalization; 41.6 days, partial hospitalization), whereas during C/M-ECT, they had a mean of 214.7 hospitalization days (85.4 days, full hospitalization; 129.3 days, partial hospitalization). The number of readmissions before ECT was 2.13, whereas during C/M-ECT, it decreased to 1.48. Only the decrease in number of full hospitalization days was significant. Most patients (n = 23, 74.19%) needed an acute course of ECT during M-ECT.CONCLUSIONS: Maintenance ECT seems to significantly reduce the number of full hospitalization days in patients with severe bipolar or schizoaffective disorder.
|
['Adult', 'Aged', 'Anesthesia', 'Bipolar Disorder', 'Diagnostic and Statistical Manual of Mental Disorders', 'Electroconvulsive Therapy', 'Female', 'Hospitalization', 'Humans', 'Length of Stay', 'Male', 'Middle Aged', 'Psychotic Disorders', 'Retrospective Studies', 'Treatment Outcome']
| 26,172,058
|
[['M01.060.116'], ['M01.060.116.100'], ['E03.155'], ['F03.084.500'], ['L01.453.245.945.200'], ['F04.570.200.583', 'F04.669.224.300'], ['E02.760.400', 'N02.421.585.400'], ['B01.050.150.900.649.313.988.400.112.400.400'], ['E02.760.400.480', 'N02.421.585.400.480'], ['M01.060.116.630'], ['F03.700.675'], ['E05.318.372.500.500.500', 'E05.318.372.500.750.750', 'N05.715.360.330.500.500.500', 'N05.715.360.330.500.750.825', 'N06.850.520.450.500.500.500', 'N06.850.520.450.500.750.825'], ['E01.789.800', 'N04.761.559.590.800', 'N05.715.360.575.575.800']]
|
['Named Groups [M]', 'Analytical, Diagnostic and Therapeutic Techniques, and Equipment [E]', 'Psychiatry and Psychology [F]', 'Information Science [L]', 'Health Care [N]', 'Organisms [B]']
| 0
| 1
| 0
| 0
| 1
| 1
| 0
| 0
| 0
| 0
| 1
| 1
| 1
| 0
|
Tetralogy of fallot and absence of left pulmonary artery.
|
Unilateral absence of the pulmonary artery is a rare congenital lesion usually caused by backward displacement of the conical artery of the truncus arteriosus. The purpose of this report is to describe and discuss the treatment of an 8-year-old patient who presented with cyanosis and was diagnosed with tetralogy of Fallot together with an absence of the left pulmonary artery and major aortopulmonary collateral arteries.
|
['Abnormalities, Multiple', 'Cardiac Surgical Procedures', 'Child', 'Collateral Circulation', 'Cyanosis', 'Humans', 'Male', 'Pulmonary Artery', 'Radiography', 'Tetralogy of Fallot', 'Treatment Outcome', 'Vascular Surgical Procedures']
| 18,810,704
|
[['C16.131.077'], ['E04.100.376', 'E04.928.220'], ['M01.060.406'], ['G09.330.100.248'], ['C23.888.248'], ['B01.050.150.900.649.313.988.400.112.400.400'], ['A07.015.114.715'], ['E01.370.350.700'], ['C14.240.400.849', 'C14.280.400.849', 'C16.131.240.400.849'], ['E01.789.800', 'N04.761.559.590.800', 'N05.715.360.575.575.800'], ['E04.100.814']]
|
['Diseases [C]', 'Analytical, Diagnostic and Therapeutic Techniques, and Equipment [E]', 'Named Groups [M]', 'Phenomena and Processes [G]', 'Organisms [B]', 'Anatomy [A]', 'Health Care [N]']
| 1
| 1
| 1
| 0
| 1
| 0
| 1
| 0
| 0
| 0
| 0
| 1
| 1
| 0
|
Role of antidiuretic activity in the inhibition of renin secretion by vasopressin in anesthetized dogs.
|
The nature of the activity of vasopressin which is responsible for the inhibition of renin secretion was studied by comparing the effects of vasopressin (AVP) and analogs of AVP in anesthetized water-loaded dogs. Infusion of AVP (1.0 ng/kg/min) increased mean arterial pressure (MAP) and decreased heart rate (HR) and free water clearance (CH2O). Plasma renin activity (PRA) decreased from 11.9 +/- 4.7 to 3.8 +/- 1.7 ng/ml/3 hr (p less than 0.05). A selective antidiuretic agonist, 1-deamino-8-D-arginine vasopressin (1.0 ng/kg/min), which had no effect on MAP or HR but was effective as AVP in decreasing CH2O, decreased PRA from 13.5 +/- 4.6 to 7.0 +/- 2.9 ng/ml/3 hr (p less than 0.05). Infusion of a selective vasoconstrictor agonist, 2-phenylalanine-8-ornithine oxytocin (1.0 ng/kg/min), increased MAP and decreased HR but did not decrease CH2O or PRA. A vasoconstrictor antagonist, d(CH2)5Tyr(Me)AVP (10 micrograms/kg), completely blocked the MAP and HR responses to AVP but did not block the decrease in CH2O or PRA (5.9 +/- 1.8 to 2.9 +/- 1.6 ng/ml/3 hr) (p less than 0.001). Infusion of the 0.45% saline vehicle had no significant effect on MAP, HR, CH2O or PRA. These results indicate that the inhibition of renin secretion by vasopressin in anesthetized water-loaded dogs is due to its antidiuretic activity.
|
['Animals', 'Arginine Vasopressin', 'Blood Pressure', 'Deamino Arginine Vasopressin', 'Diuresis', 'Dogs', 'Female', 'Heart Rate', 'Kinetics', 'Male', 'Natriuresis', 'Oxytocin', 'Renin', 'Time Factors']
| 3,520,511
|
[['B01.050'], ['D06.472.699.631.692.781.100', 'D12.644.400.900.100', 'D12.644.456.925.100', 'D12.644.548.691.692.781.100', 'D12.776.631.650.937.100'], ['E01.370.600.875.249', 'G09.330.380.076'], ['D06.472.699.631.692.781.100.250', 'D12.644.400.900.100.250', 'D12.644.456.925.100.250', 'D12.644.548.691.692.781.100.250', 'D12.776.631.650.937.100.250'], ['G08.852.179'], ['B01.050.150.900.649.313.750.250.216.200'], ['E01.370.600.875.500', 'G09.330.380.500'], ['G01.374.661', 'G02.111.490'], ['G08.852.179.557'], ['D06.472.699.631.692.433', 'D12.644.548.691.692.433'], ['D08.811.277.656.074.500.780', 'D08.811.277.656.300.048.780', 'D08.811.277.656.837.750'], ['G01.910.857']]
|
['Organisms [B]', 'Chemicals and Drugs [D]', 'Analytical, Diagnostic and Therapeutic Techniques, and Equipment [E]', 'Phenomena and Processes [G]']
| 0
| 1
| 0
| 1
| 1
| 0
| 1
| 0
| 0
| 0
| 0
| 0
| 0
| 0
|
Tuning the mechanism of DNA cleavage photosensitized by ruthenium dipyridophenazine complexes by varying the structure of the two non intercalating ligands.
|
The influence of the nature of ligands on the efficiency of ruthenium complexes for photosensitizing DNA cleavage was investigated. Ru(bipy)2dppz2+ and Ru(bpz)2dppz2+ were selected as DNA breakers on the basis of their high affinity for DNA due to the presence of a dppz ligand which can partially intercalate in the major groove of DNA. Their photosensitizing properties were compared to those of Ru(bipy)3(2+), a complex which binds to DNA with a far lower constant. Upon irradiation, these complexes promoted the formation of single strand breaks in supercoiled phi X 174 DNA. Unexpectedly, Ru(bipy)2dppz2+ was found to be less efficient than Ru(bipy)3(2+) whatever the dye concentration or the [base pair]/[Ru] molar ratio r. Scavenging experiments have shown that the oxidative DNA cleavage induced by Ru(bipy)2dppz2+ mainly results from a Type II mechanism. The behavior of Ru(bipy)2dppz2+ was different: this compound was clearly more efficient than Ru(bipy)3(2+) as DNA breaker and its efficiency was not modified by the presence of oxygen or by addition of scavengers of reactive oxygen species. In this case, a mechanism involving electron transfer between the excited state of the ruthenium complex and the guanine residue was proposed in agreement emission lifetime measurements. The change in mechanism observed between Ru(bipy)2dppz2+ and Ru (bipy)2dppz2+ results from an increase of the reduction potential of the ruthenium complexes in the excited state, which appears to be the main factor controlling the efficiency.
|
['Bacteriophage phi X 174', 'DNA Damage', 'DNA, Superhelical', 'DNA, Viral', 'Intercalating Agents', 'Ligands', 'Light', 'Magnetic Resonance Spectroscopy', 'Molecular Structure', 'Organometallic Compounds', 'Phenazines', 'Photosensitizing Agents', 'Pyridines', 'Ruthenium', 'Structure-Activity Relationship']
| 7,815,190
|
[['B04.123.205.320', 'B04.123.470.500.320', 'B04.280.470.500.320'], ['G05.200'], ['D13.444.308.283.250', 'G02.111.570.820.486.212.250', 'G05.360.580.156.250'], ['D13.444.308.568'], ['D27.720.470.410.360'], ['D27.720.470.480'], ['G01.358.500.505.650', 'G01.590.540', 'G01.750.250.650', 'G01.750.770.578'], ['E05.196.867.519'], ['G02.111.570', 'G02.466'], ['D02.691'], ['D03.633.300.704'], ['D27.505.954.444.600', 'D27.505.954.600.710'], ['D03.383.725'], ['D01.268.556.805', 'D01.268.956.812', 'D01.552.544.805'], ['G02.111.830', 'G07.690.773.997']]
|
['Organisms [B]', 'Phenomena and Processes [G]', 'Chemicals and Drugs [D]', 'Analytical, Diagnostic and Therapeutic Techniques, and Equipment [E]']
| 0
| 1
| 0
| 1
| 1
| 0
| 1
| 0
| 0
| 0
| 0
| 0
| 0
| 0
|
Blockade of adrenaline-induced hyperglycaemia in the anaesthetized cat by continuous infusion of phentolamine and propranolol.
|
1 The effects of adrenoceptor blocking drugs on the metabolic responses to adrenaline infusion (1 microgram kg-1 min-1) have been studied in the anaesthetized, fasted cat. 2 Propranolol, in doses (0.25 or 1 mg/kg) which prevented completely adrenaline-induced tachycardia, reduced but did not abolish adrenaline-induced hyperglycaemia. 3 Phentolamine infusion, at a rate (15 micrograms kg-1 min-1 after a priming dose of 2.5 mg/kg) which reversed the pressor effect of adrenaline, reduced but did not abolish adrenaline-induced hyperglycaemia. 4 The continuous infusion of a combination of phentolamine (15 micrograms kg-1 min-1 after a priming dose of 2.5 mg/kg) and propranolol (5 micrograms kg-1 min-1 after a priming dose of 0.25 mg/kg) prevented completely the hyperglycaemia response to adrenaline infusion over a 6 h period. 5 The increase in blood lactate concentration produced by adrenaline was prevented completely by the combined infusion of propranolol and phentolamine but was not modified by phentolamine alone.
|
['Anesthesia', 'Animals', 'Blood Glucose', 'Blood Pressure', 'Cats', 'Epinephrine', 'Female', 'Heart Rate', 'Male', 'Phentolamine', 'Propranolol', 'Receptors, Adrenergic']
| 7,052,338
|
[['E03.155'], ['B01.050'], ['D09.947.875.359.448.500'], ['E01.370.600.875.249', 'G09.330.380.076'], ['B01.050.150.900.649.313.750.377.750.250.125'], ['D02.033.100.291.310', 'D02.092.063.291.310', 'D02.092.211.215.454', 'D02.092.311.461', 'D02.455.426.559.389.657.166.175.461'], ['E01.370.600.875.500', 'G09.330.380.500'], ['D03.383.129.308.754'], ['D02.033.100.624.698.711', 'D02.033.755.624.698.711', 'D02.092.063.624.698.711', 'D02.455.426.559.847.638.945', 'D04.615.638.945'], ['D12.776.543.750.670.300.300', 'D12.776.543.750.695.150.300', 'D12.776.543.750.720.330.300']]
|
['Analytical, Diagnostic and Therapeutic Techniques, and Equipment [E]', 'Organisms [B]', 'Chemicals and Drugs [D]', 'Phenomena and Processes [G]']
| 0
| 1
| 0
| 1
| 1
| 0
| 1
| 0
| 0
| 0
| 0
| 0
| 0
| 0
|
Prostaglandin E2-induced release of luteinizing hormone-releasing factor (LRF).
|
Prostaglandin E2 (PGE2) injected into the third ventricle (3rd V) of conscious ovariectomized rats bearing a permanent jugular cannula increased the percentage of plasma samples showing detectable immunoassayable LRF levels at 1, 3 and 5 min after injection. This percentage was small at 2 and 4 min. When plasma LRF and LH titers were measured in animals injected intraventicularly with PGE2 and decapitated 5 min later, both LRF and LH were significantly higher than control values of diluent-injected animals. These results indicate that PGE2 is acting on the hypothalamus to induce release of LRF sufficient in mangitude to be detected by measuring this neurohormone directly in peripheral plasma.
|
['Animals', 'Castration', 'Female', 'Gonadotropin-Releasing Hormone', 'Hypothalamus', 'Luteinizing Hormone', 'Ovary', 'Prostaglandins E', 'Radioimmunoassay', 'Rats', 'Time Factors']
| 1,095,952
|
[['B01.050'], ['E04.270.282', 'E04.950.165'], ['D06.472.699.327.740.320', 'D12.644.400.400.740.320', 'D12.644.456.460', 'D12.644.548.365.740.320', 'D12.776.631.650.405.740.320'], ['A08.186.211.180.497', 'A08.186.211.200.317.357'], ['D06.472.699.322.576.463', 'D06.472.699.631.525.343.463', 'D12.644.548.691.525.343.463'], ['A05.360.319.114.630', 'A05.360.576.497', 'A06.300.312.497'], ['D10.251.355.255.550.250', 'D23.469.050.175.725.250'], ['E01.370.384.700', 'E05.478.566.639', 'E05.601.470.639'], ['B01.050.150.900.649.313.992.635.505.700'], ['G01.910.857']]
|
['Organisms [B]', 'Analytical, Diagnostic and Therapeutic Techniques, and Equipment [E]', 'Chemicals and Drugs [D]', 'Anatomy [A]', 'Phenomena and Processes [G]']
| 1
| 1
| 0
| 1
| 1
| 0
| 1
| 0
| 0
| 0
| 0
| 0
| 0
| 0
|
The Australian government's review of positron emission tomography: evidence-based policy-making in action.
|
The Commonwealth Government constituted the Medicare Services Advisory Committee (MSAC) to implement its commitment to entrench the principles of evidence-based medicine in Australian clinical practice. With its recent review of positron emission tomography (PETReview), the Commonwealth intervened in an established MSAC process, and sanctioned the stated objective to restrict expenditure on the technology. In our opinion: The evaluation of evidence by PETReview was fundamentally compromised by a failure to meet the terms of reference, poor science, poor process and unique decision-making benchmarks. By accepting the recommendations of PETReview, the Commonwealth is propagating information which is not of the highest quality. The use of inferior-quality information for decision-making by doctors, patients and policy-makers is likely to harm rather than enhance healthcare outcomes.
|
['Australia', 'Benchmarking', 'Data Interpretation, Statistical', 'Evidence-Based Medicine', 'Humans', 'Policy Making', 'Reproducibility of Results', 'Research Design', 'Technology Assessment, Biomedical', 'Tomography, Emission-Computed']
| 15,200,360
|
[['Z01.639.100', 'Z01.678.100.373'], ['N04.452.500.150', 'N04.761.685.150', 'N04.761.700.150', 'N05.700.150', 'N05.715.360.650.150'], ['E05.245.380', 'E05.318.740.300', 'L01.313.500.750.190.380', 'N05.715.360.750.300', 'N06.850.520.830.300'], ['H02.249.750', 'H02.403.200.400'], ['B01.050.150.900.649.313.988.400.112.400.400'], ['N03.706.742'], ['E05.318.370.725', 'E05.337.851', 'N05.715.360.325.685', 'N06.850.520.445.725'], ['E05.581.500', 'H01.770.644.728'], ['N03.880', 'N05.715.360.825'], ['E01.370.350.350.800', 'E01.370.350.600.350.800', 'E01.370.350.710.800', 'E01.370.350.825.800', 'E01.370.384.730.800']]
|
['Geographicals [Z]', 'Health Care [N]', 'Analytical, Diagnostic and Therapeutic Techniques, and Equipment [E]', 'Information Science [L]', 'Disciplines and Occupations [H]', 'Organisms [B]']
| 0
| 1
| 0
| 0
| 1
| 0
| 0
| 1
| 0
| 0
| 1
| 0
| 1
| 1
|
Expression of a decorin-like moleculein human melanoma.
|
Decorin, a member of the family of small leucin-rich proteoglycans, has originally been described as a secreted proteoglycan component of the connective tissues, and has been implicated in the negative regulation of cell proliferation directly or via interactions with TGF-beta. It was reported to be generally absent from tumor cells. Here we show that human melanoma cell lines express a decorin-like molecule. We detected decorin mRNA by RT-PCR in 7 out 7 human melanoma lines characterized by various metastatic potential. Using polyclonal antiserum against the core protein of decorin, the typical 80-120 kD glycanated form as well as a high molecular weight aberrant version (200-210 kD) of decorin were demonstrated by Western blot technique in the culture supernatants as well as in lysates of human melanoma cells. Finally, decorin epitope was also demonstrated immunohistochemically in human melanoma xenografts, as well as in tumor cells of surgically resected melanomas but not in melanocytes of nevi. The expression of this aberrant decorin did not inhibit the in vitroor in vivogrowth of human melanoma cells, and it was independent of their metastatic potential. Human melanoma cell lines expressing aberrant decorin retained sensitivity to the antiproliferative and gelatinase-stimulatory effects of exogenous TGF-beta.
|
['Animals', 'Blotting, Southern', 'Cell Division', 'Cell Transformation, Neoplastic', 'Collagenases', 'DNA Primers', 'Decorin', 'Extracellular Matrix Proteins', 'Flow Cytometry', 'Immunoenzyme Techniques', 'Melanoma', 'Mice', 'Mice, SCID', 'Neoplasm Metastasis', 'Polymerase Chain Reaction', 'Proteoglycans', 'RNA, Messenger', 'Skin Neoplasms', 'Transforming Growth Factor beta', 'Tumor Cells, Cultured']
| 11,882,905
|
[['B01.050'], ['E05.196.401.114', 'E05.301.300.087', 'E05.601.150'], ['G04.144.220', 'G04.161.750.500', 'G05.113', 'G07.345.249.410.750.500'], ['C04.697.098.500', 'C23.550.727.098.500'], ['D08.811.277.656.300.480.205', 'D08.811.277.656.675.374.205'], ['D13.695.578.424.450.275', 'D27.720.470.530.600.223.600'], ['D09.698.735.700.750', 'D12.776.395.650.750.625', 'D12.776.395.650.875.500', 'D12.776.860.300.806.750'], ['D12.776.860.300'], ['E01.370.225.500.363.342', 'E01.370.225.500.386.350', 'E05.196.712.516.600.240.350', 'E05.200.500.363.342', 'E05.200.500.386.350', 'E05.242.363.342', 'E05.242.386.350'], ['E05.478.566.350', 'E05.478.583.400', 'E05.601.470.350'], ['C04.557.465.625.650.510', 'C04.557.580.625.650.510', 'C04.557.665.510'], ['B01.050.150.900.649.313.992.635.505.500'], ['B01.050.150.900.649.313.992.635.505.500.550.780'], ['C04.697.650', 'C23.550.727.650'], ['E05.393.620.500'], ['D09.698.735', 'D12.776.395.650'], ['D13.444.735.544'], ['C04.588.805', 'C17.800.882'], ['D12.644.276.374.687', 'D12.644.276.954.775', 'D12.776.467.374.687', 'D12.776.467.942.775', 'D23.529.374.687', 'D23.529.942.775'], ['A11.251.860']]
|
['Organisms [B]', 'Analytical, Diagnostic and Therapeutic Techniques, and Equipment [E]', 'Phenomena and Processes [G]', 'Diseases [C]', 'Chemicals and Drugs [D]', 'Anatomy [A]']
| 1
| 1
| 1
| 1
| 1
| 0
| 1
| 0
| 0
| 0
| 0
| 0
| 0
| 0
|
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.